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ABSTRACT 
Cesar Augusto Lopez: Zika virus pathogenesis at sites of vector-independent 
transmission and a foray into applied seroprevalence  
(Under the direction of Helen M. Lazear) 
 
Zika virus (ZIKV) recently emerged in 2016 spread by mosquito-borne, sexual, 
and congenital transmission. During the course of this work, severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) also emerged and has been one of the most 
significant causes of mortality in 2020 as a result of the disease it causes, coronavirus 
disease 2019 (COVID-19).  
Because ZIKV causes placental damage, I set out to establish in collaboration 
with Tulika Singh in Dr. Sallie Permar’s laboratory whether antibody transfer is 
preserved during gestational ZIKV infection. I found that approximately half of our small 
20-person cohort had serologic evidence of ZIKV infection during gestation and that 
ZIKV infection does not impair transfer of ZIKV and DENV-neutralizing antibodies. One 
individual had prolonged infection during gestation, and I showed that an IgM isolated 
from this individual potently neutralizes ZIKV and can protect mice from severe disease.  
I also investigated ZIKV replication in the vagina of wild-type (WT) mice. 
Typically, ZIKV infections in the laboratory are performed in mice deficient in IFN-αβ 
signaling because these mice are permissive to disseminated infection following 
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inoculation by footpad. I found that ZIKV infection in the vagina is regulated by 
progesterone but not IFN-αβ signaling. I also found that progesterone-induced 
susceptibility to ZIKV is unlikely to be due to decreased epithelial integrity, changes in 
leukocyte numbers in vaginal tissue, or dampened antiviral signaling in the vagina.  
Finally, I coordinated a multi-site effort to measure SARS-CoV-2 seroprevalence 
over a 6-month time frame. We found that Latinx and underinsured individuals were at 
greatest risk of infection. Also, SARS-CoV-2 neutralizing antibody titers for individuals 
without respiratory symptoms were lower than for those with symptoms or COVID-19 
diagnosis, supporting that asymptomatic infections may result in lower neutralizing 
titers. 
My results support that transplacental antibody transfer is not solely a result of 
placental damage. They also support that progesterone regulates some aspect of viral 
susceptibility independent of the interferon response. My results also emphasize that 
those at risk of systemic racism also may be at greatest risk of infection of emerging 
viruses that are driven by transmission in close quarters.
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Flaviviruses are significant causes of human disease. Most recently, Zika virus 
(ZIKV) has emerged in areas that were already endemic for the related flavivirus 
dengue virus (DENV). Uniquely among flaviviruses, ZIKV can be transmitted sexually 
and congenitally in addition to the more typical arthropod-borne transmission. During 
the course of this work, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) also emerged and has been one of the most significant causes of mortality in 2020 
despite having only emerged a little over a year ago.  
1.2 Zika virus emergence 
Prior to 2014, ZIKV was one of many arboviruses poised for broader emergence 
known only to cause little more than mild febrile illness1–5. ZIKV had previously only 
caused sporadic infections within the geographic range of the Aedes aegypti mosquito 
vector it shares with related flaviviruses such as DENV and Spondweni virus (SPOV). 
But in 2013-2014 ZIKV began to emerge as a cause of serious human disease when it 
caused an increase in acute ascending paralysis cases that were consistent with 
Guillain-Barre syndrome observed in an outbreak in French Polynesia6,7.  
ZIKV emerged within the next two years in a massive outbreak across the 
Americas with almost 600,000 clinically suspected cases although it has been estimated 
that millions were infected8–10. The Latin American ZIKV pandemic revealed that ZIKV 
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infection during pregnancy could cause microcephaly, arthrogryposis, intrauterine 
growth restriction and other congenital defects now established to be caused by 
congenital ZIKV infection11–13. ZIKV also caused increased rates of Guillain-Barre 
syndrome in Latin America during this outbreak14. This outbreak also confirmed the 
ability of ZIKV to spread via sexual transmission in addition to mosquito-borne 
transmission, although one case of ZIKV sexual transmission had been reported 
previously following infection in Africa indicating that sexual transmission was not a new 
property of ZIKV15–19.  
1.3 ZIKV Antibody response 
Myeloid cells are an important target for flavivirus infection20–22. Flavivirus 
proteins are first translated as a single polyprotein in replication centers on the 
endoplasmic reticulum (ER)23,24. This polyprotein contains multiple transmembrane 
regions, and is cleaved into different proteins by both host and viral proteases25. The 
envelope protein (E) is cleaved from the membrane protein (M) by host signal peptidase 
but remains membrane-anchored. The E protein forms the surface of the virus once 
viral RNA protected by capsid proteins bud into the ER. Most enveloped viruses do not 
have regular icosahedral symmetry, as proteins embedded in the envelope are usually 
fewer in number and able to diffuse laterally within the membrane. However, the surface 
of flaviviruses consists of 180 interlocking E proteins forming 90 dimers in a herringbone 
pattern embedded in the membrane derived from the ER24,26. The flavivirus precursor 
membrane (prM) protein protects the fusion loop present on the E protein, preventing its 
insertion into membranes during virion assembly. The pr peptide is cleaved from M by 
host furin enzymes during virion maturation but this cleavage process is thought to be 
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inefficient in cell culture, leaving a mixture of particles that are mostly mature with E 
proteins ready to rearrange and expose the fusion loop following a low pH trigger, and 
particles that are only partially mature and have the fusion loop protected by pr. 
However, recent evidence from DENV isolated from patient sera suggests that though 
DENV grown in the laboratory is a mix of mature and immature particles, DENV 
particles in humans are mostly mature27. The presence of the pr peptide affects 
antibody binding and therefore can affect neutralization, antibody dependent 
enhancement of infection (ADE), and protection from disease. 
Flavivirus infections, including ZIKV, induce a potent neutralizing antibody 
response targeting the E protein. The E protein is divided into Domains I, II, and III (DI, 
DII, DIII). The fusion loop on one E protein is located at the tip of DII near DIII of its 
paired E protein (Figure 1.1). The lateral ridge of DIII is thought to be important for 
cellular attachment28,29. Antibodies to the fusion loop are commonly isolated after 
infection, and the high degree of conservation in the fusion loop region between 
flaviviruses means that these antibodies are likely to cross-react among viruses30–34. 
Some of the most potently neutralizing human antibodies against ZIKV target either the 
lateral ridge of DIII34–37 or across E proteins within or between 2-3 dimers38,39. No 
human antibodies targeting the pr peptide on the surface of the ZIKV particle have been 
reported. 
1.4 Flavivirus antibody cross-reactivity & enhancement of infection 
Flaviviruses have historically been classified into serogroups, such that if immune 
sera raised against one virus neutralizes another virus they were placed into the same 
serogroup40–42. This cross-neutralization is due to extensive antigenic cross-reactivity 
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between flaviviruses. One of the greatest diagnostic challenges during the 2015-2016 
ZIKV pandemic was the high degree of antibody cross-reactivity between the newly 
introduced ZIKV and DENV, which was already endemic to the Americas. In some 
regions, by age 18 over 95% of individuals had serologic evidence of prior DENV 
infection43. ZIKV and mild DENV infections are difficult to distinguish clinically, and the 
antibody response to the two is highly cross-reactive due in large part to conserved 
regions near the flavivirus fusion loop. ZIKV is in the same serogroup as Spondweni 
virus (SPOV) separate from DENV so these cross-reactive antibodies have only limited 
cross-neutralizing activity in cell culture and do not appear to provide long-term 
protection against the other virus. Similarly, prior infection with one of the four viruses 
within the DENV serogroup does not confer protective immunity to the other three, but 
does generate cross-reactive non-neutralizing antibodies. These cross-reactive 
antibodies bind to virions from another DENV serotype and facilitate DENV infection of 
myeloid cells via Fcγ receptors, a process termed antibody-dependent enhancement 
(ADE). ADE results in higher viremia and increased risk of severe dengue, including 
hemorrhagic fever and shock. Antibodies can worsen disease caused by various 
viruses due to immunopathology44–46, but in the case of DENV, the worsened disease is 
thought to result from increased viral replication. It is possible to demonstrate ADE in 
cell culture with a wide variety of viruses from different families47–52, but in humans, only 
with DENV is enhancement of viral infection demonstrated to be directly associated with 
worsened disease53. 
Given the established role of cross-reactive non-neutralizing antibodies 
exacerbating DENV disease via ADE, at the beginning of the ZIKV pandemic it was a 
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reasonable hypothesis that ZIKV infection might be enhanced by cross-reactive DENV 
antibodies. Other flaviviruses are easily enhanced in cell culture54–56 and in mice57 by 
cross-reactive antibodies from heterologous flaviviruses, or even by neutralizing 
antibodies that are sufficiently diluted. Thus it is no surprise that ZIKV infection also can 
be enhanced by sera and antibodies from heterologous flaviviruses in laboratory 
assays58. Likewise, heterologous cross-reactive antibodies worsen ZIKV-induced fetal 
pathology in mice59. There however remains no evidence to date that any flavivirus 
besides DENV undergoes ADE of infection in primates. If anything, cross-reactive 
antibodies may offer transient cross-protection soon after infection60 though despite the 
high seroprevalence of DENV in communities affected in the 2015-2016 ZIKV 
epidemic43,61, this cross-protection was clearly not sufficient to prevent the high force of 
ZIKV infection. Consistent with the hypothesis that DENV is uniquely capable of 
antibody-enhanced infection in primates, prior ZIKV exposure elevates risk of severe 
DENV62. 
1.5 ZIKV placental pathology 
The 2015-2016 Latin American ZIKV outbreak was large enough to observe rare 
outcomes including congenital infection. The types of pathogens capable of causing 
congenital disease in humans varies widely (viruses, bacteria, and parasites), but only a 
select few pathogens are able to do so. The types of congenital disease they can cause 
and the mechanism by which they cause disease can be the result of direct infection of 
the fetus, as is the case with Toxoplasma gondii, which can cause brain calcifications in 
the developing fetus. Others, like Plasmodium falciparum, cause intrauterine growth 
restriction by causing placental insufficiency.  
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Though ZIKV is the first arbovirus demonstrated to cause significant congenital 
disease in humans, it is not the only one capable of congenital infection in mammals. 
Among bunyaviruses, the mosquito-borne Rift Valley fever virus and midge-borne 
Schmallenberg virus cause spontaneous abortions in ruminants63,64, and the flavivirus 
Japanese encephalitis virus (JEV) can cause abortions in swine65. In humans, there 
have been isolated cases of spontaneous abortion following JEV infection66 and 
congenital defects following West Nile virus (WNV) infection67 but these do not appear 
to be common outcomes of JEV or WNV infection. 
Gestational DENV infection may also be associated with elevated maternal 
mortality, pregnancy complications, premature birth, and low infant birth weight 68–72, but 
these adverse outcomes may result from the severity of DENV infection on the mother, 
such as inflammatory responses and cytokine storm. ZIKV not only causes intrauterine 
growth restriction, but also is neurotropic within the developing fetus even if the mother 
only has mild or no symptoms. ZIKV infection of neural progenitor cells can result in 
microcephaly, lissencephaly, arthrogryposis, cortical atrophy, sensorineural hearing 
loss, and ocular defects13,73–79. In the years that come, we may also come to find that 
congenital ZIKV infection affects development after gestation resulting in other long 
term cognitive deficits that have not been characterized. ZIKV infection in pregnancy 
can result in prolonged viremia, suggesting that the placenta may be an active site of 
viral replication and seeding virus back into circulation within the infected gestational 
parent78,80–82. The placenta is an organ that develops during pregnancy from fetal cells 
and anchors into the uterine wall with cytotrophoblast cells extending from placental villi. 
These villi are bathed in blood originating from endometrial arteries. It is across these 
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villi that oxygen and macromolecule exchange such as transplacental IgG transfer 
occurs, providing the fetus with passive immune protection that persists for a few 
months after delivery83–87. These villi consist of cytotrophoblasts and a multinucleated 
syncytiotrophoblast layer that is resistant to infection by all pathogens tested88–90. The 
syncytiotrophoblasts are also the site of transplacental IgG transfer via the neonatal Fc 
receptor (FcRn)91. This transfer occurs after binding of IgG to FcRn in acidified 
endosomes, where it is rerouted from degradative pathways and released at the 
basolateral membrane. Hofbauer cells, specialized placental macrophages, also are 
present within the villi and aid the development of vasculature as well as serving as a 
second line of immune surveillance past the syncytiotrophoblasts92–95.  
ZIKV infects cells within the placenta such as Hofbauer macrophages and villous 
trophoblasts and thus infects the placenta itself 74,96–98. Placental damage such as 
necrosis, calcifications, fibrosis, and Hofbauer cell hyperplasia have been observed 
after gestational ZIKV infection in humans74,97,98. It seems likely that the placental 
damage observed during ZIKV infection results from infected placental cell types as well 
as inflammatory immunopathology mediated by antiviral interferon (IFN) signaling99,100. 
Damage to the likely derives from  multiple factors such as ZIKV infection of fetal 
neurons, virus-induced immunopathology, and placental insufficiency resulting from 
ZIKV damage to the placenta101,102.  
The placental pathology associated with congenial ZIKV infection (e.g. 
calcification, inflammation, and hypoxia) also is associated with gestational malaria103–
106. Vascular changes to the placenta during gestational malaria are thought to result in 
hypoxia, and also result in hampered transplacental transfer of IgG from mother to fetus 
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during gestation107–109. Human immunodeficiency virus 1 (HIV-1) is also thought to 
impair transplacental IgG transfer, though the mechanism is poorly understood110,111. 
IgG transferred to the fetus during gestation are critical for neonatal health, and thus it 
was important to determine whether ZIKV similarly decreases transplacental IgG 
transfer like malaria or if like DENV it does not affect IgG transfer112,113. This serious 
knowledge gap was something I sought to tackle in my research. 
1.7 ZIKV infection in reproductive tracts 
Most sexually transmitted ZIKV cases appear to be unidirectional following penis-
in-vagina (PIV) sex, presumably after exposure to infectious seminal fluids from a 
penetrative partner who recently returned from a region with an active outbreak. 
However, there are isolated cases implicating oral sex114, anal sex115, or where the 
source of infectious virus was vaginal mucus or menstrual blood116. Mouse models have 
also demonstrated that an infected male can infect a female, but the opposite did not 
occur117. The testes are the site of spermatogenesis and can become productively 
infected by ZIKV in animal models and human explants118–123, and sperm cells 
themselves may contain ZIKV antigens124. However, viral shedding in semen and 
sexual transmission have also been reported from vasectomized individuals16,125,126 and 
has been confirmed in animal models117, indicating that the testes are not the sole 
source of ZIKV in semen. Accessory glands in the male reproductive tract potentially 
could be other sources of ZIKV in semen and ZIKV infection of the prostate been 
observed in animal models and human explants122,127.  
Following ejaculation, ZIKV is thought to infect a variety of cells in the vagina 
including epithelial and immune cells128,129. From here, the virus is able to disseminate 
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and cause viremia, producing similar symptoms as mosquito-borne transmission130, 
including congenital Zika syndrome131. In non-human primates, vaginal infection can 
also result in viremia and fetal transmission132,133. 
In mice deficient in type I interferon (IFN-αβ) signaling, ZIKV inoculated into the 
vagina disseminates through the entire mouse similar to infection via footpad 
inoculation129,134,135. This infection can then result in fetal pathology in pregnant 
mice99,135,136, though there is strong evidence that fetal pathology is also driven by 
immunopathology99,137,138. There is also a report of fetal pathology and possible viral 
transmission to fetuses in wild-type mice resulting from vaginal inoculation, despite the 
lack of systemic infection135. This suggests the possibility for ascending infection that 
bypasses the placenta entirely. The related flavivirus SPOV can only be found rarely in 
the semen of infected mice, and can also cause fetal pathology139,140. Nonetheless, 
surveillance of SPOV should consider the possibility that it could also be sexually 
transmitted in humans 
Of note, studies evaluating ZIKV pathogenesis are typically performed in mice 
deficient in IFN-αβ signaling because these mice are permissive to disseminated 
infection following inoculation by footpad134. In wild-type mice, ZIKV inoculated via 
footpad does not cause disease or more than a very transient viremia. This is because 
ZIKV is able to inhibit and target STAT2 in humans but not murine STAT2141, preventing 
IFN-αβ signaling in infected cells. These same mice are the ones typically used in 
vaginal infection models. 
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1.8 Antiviral mechanisms in the vagina 
The vagina is a unique tissue that has to respond to sexually transmitted 
pathogens while also maintaining a degree of immune homeostasis so as to not mount 
a pathologic immune response against its own microbiome, microabrasions resulting 
from sexual intercourse, or foreign antigens in the form of sperm and semen.  
The mucosal environment of the vagina contains specialized immune 
mechanisms not typically encountered by mosquito-borne viruses. One example of this 
is interactions with mucins, which are large molecular weight proteins covered in 
glycosylations 142,143. IgG is secreted into vaginal mucus from the systemic circulation 
and is the predominant immunoglobulin in the vagina144–147. Individual IgG molecules 
bind to mucins only transiently and with low affinity148–151. However, IgG-opsonized 
particles can be immobilized by the additive effects of multiple IgG-mucin 
interactions152. This immobilizing activity of IgG is independent of virus neutralization, 
meaning that the particles can remain infectious but are physically trapped in mucus 
and prevented from accessing host cells. By this mechanism, non-neutralizing 
antibodies can contribute to protection against viruses in the vagina153.  
Innate immune cells present in the vagina that contribute to defense against 
pathogens include dendritic cells, natural killer (NK) cells, and neutrophils154. 
Neutrophils and NK cells in particular have been highlighted for their roles in responding 
to herpes simplex virus (HSV) infections155–157. T cells outnumber B cells as the 
adaptive immune cells in the vagina158, but ZIKV-specific IgG are thought to be the 
predominant adaptive immune mechanism by which the vagina is protected from a 
second ZIKV infection in mice159. Prior to the emergence of ZIKV there was little reason 
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to study the immune cells that respond to arbovirus infections in the vagina, so little is 
known about the role they play on the first ZIKV infection.   
Like at many other barrier sites, antiviral signaling in the vagina includes a role 
for type III interferons (IFN-λ) in addition to IFN-αβ and type II IFN (IFN-γ) involved in 
systemic antiviral responses160. IFN-λ signals through different receptors on the cell 
surface but activates many of the same signaling pathways and transcriptional 
programs as IFN-αβ. Despite the similarities, IFN-λ can also perform unique restriction 
of viruses independent of other IFN signaling pathways161. IFN-λ restricts HSV infection 
in the vagina162 and may also play a role in restricting ZIKV infection in the vagina of 
ovariectomized mice, a model where the hormonal state is tightly controlled by hormone 
replacement129. 
1.9 Hormonal control of antiviral state in the vagina 
Antiviral mechanisms within the vagina are under control of hormones such as 
sex hormones. In place of the 4-week-long menstrual cycle in humans, mice instead 
have an estrous cycle that lasts 4-5 days. In mice the longest phase of the estrous cycle 
is diestrus, characterized by high levels of progesterone and low levels of estrogen163–
165. Estrogen rises thereafter, resulting in ovulation and bringing mice from proestrus to 
estrus where estrogen levels decline while progesterone remains low. The estrus phase 
is also when mice are sexually receptive. Estrus gives way to metestrus as 
progesterone begins to rise, and estrogen continues to trend downwards. Diestrus 
occurs once estrogen is again at its lowest. 
The quality of vaginal mucus changes throughout different stages of the human 
menstrual cycle and murine estrous cycle or following treatment with sex hormones. 
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These changes include the concentration of secreted antibodies166–170. Vaginal 
epithelium is thicker at hormonal stages where progesterone is low 128,171–173. 
Neutrophils are increased in the vagina when estrogen signaling is low as in diestrus in 
mice, or when estrogen signaling is disrupted172. Likewise, the vaginal epithelium also 
becomes more permeable to immune cells and microbiota following administration of 
exogenous progesterone172, though the relative numbers of immune cells in the vagina 
might not change in the absence of disease or infection. 
Regardless, exogenous progesterone may induce local changes to leukocytes 
already present in the vagina which may increase HIV infection risk by increasing 
expression of HIV coreceptors, CXCR4 and CCR5174–176. Exogenous progesterone 
treatment is also a required component of HSV and Chlamydia murine infection models 
and is required for the inflammation observed in response to these pathogens177,178. The 
precise mechanism by which progesterone is required for these infection models 
remains unknown but it may be due to a combination of thinned epithelium, increased 
permeability, and increased inflammatory infiltrate. Systemically, progesterone may also 
skew the immune response away from a Th1 type response and towards a Th2 
response179–181.  
Non-pregnant mouse models for vaginal ZIKV infection tend to all treat with 
progesterone, following in the footsteps of HSV and Chlamydia infection 
models128,135,159,170,177,178,182,183. Tang et al. showed that after treatment with exogenous 
hormones, ZIKV preferentially infects mice in diestrus-like phase compared to an 
estrus-like phase128. Similarly, Caine et al. demonstrated that exogenous estradiol in 
ovariectomized mice is sufficient to protect even Ifnar1-/- mice from vaginal infection129. 
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Khan et al. have speculated that as with HSV, the susceptibility of progesterone-treated 
mice to vaginal ZIKV infection may be the result of thinned epithelium183. They also find 
potentially small decreases in RNA virus pattern recognition receptors in the lower 
reproductive tract (cervix and vagina) at baseline, and speculate that this may be the 
reason vaginal infection with ZIKV is possible even in wild-type mice that are typically 
not susceptible to ZIKV infection. However, this does not explain why progesterone is 
required for ZIKV infection in the vagina, which I chose to study. 
1.10 SARS-CoV-2 Emergence 
Emerging viral infections continue to be a present and future threat. ZIKV was 
not the only viral infection to emerge and cause a pandemic during the course of this 
dissertation research. A cluster of pneumonia cases identified and reported to the WHO 
in late December 2019 in Hubei province in China was publicly identified weeks later as 
being caused by a novel β-coronavirus, severe acute respiratory syndrome coronavirus 
2 or SARS-CoV-2184–186. Like other β-coronaviruses that have caused recent outbreaks 
of human disease, SARS-CoV-2 emerged as a zoonosis, though the details remain 
unclear187,188. The most similar sequenced viruses have been identified from horseshoe 
bats185,189, and there has been speculation that pangolins served as intermediate 
hosts190. 
Aggressive containment measures in China were instituted too late after the 
outbreak had already spread among the population of Hubei. As of March 31, 2021, 
nearly 3 million deaths have resulted from almost 130 million cases around the globe191. 
The earliest virologically confirmed case in the United States presented in mid-January 
in Seattle, Washington and resulted in significant community transmission192193. Though 
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later it was revealed that there were likely multiple initial introductions of SARS-CoV-2 
into the United States194.  
Deaths from coronavirus disease 2019 (COVID-19), the disease caused by 
SARS-CoV-2, largely result from respiratory disease and inappropriate vascular 
coagulation following infection of epithelial cells and endothelial cells in the lungs and 
vasculature195. Mortality is strongly associated with age and various comorbidities196,197. 
Additionally, the burden of COVID-19 mortality in the United States has been amplified 
by systemic racism198. For example, COVID-19 case and hospitalization rates among 
Black, Latinx and Indigenous populations in the US are 2.5-4.5 times higher than those 
in white populations199. 
1.11 SARS-CoV-2 Antibody response 
Like flaviviruses, coronaviruses are enveloped positive-sense RNA viruses, 
though coronavirus genomes are substantially larger (~30kb compared to ~10kb for 
flaviviruses). Coronaviruses replicate in vesicles associated with the ER and then bud 
into the Golgi complex and ER-Golgi intermediate compartments, encasing the genome 
bound to nucleocapsid proteins (N)200,201. Budding requires the interaction of both the 
transmembrane proteins membrane (M) and envelope (E)202. Roughly 25 homotrimers 
of spike (S) proteins stud the surface of each viral particle203–205. The S protein is 
cleaved into two subunits, S1 and S2. S1 contains the receptor binding domain (RBD), 
which lies flat on top of the trimer and only flips upwards to expose the receptor binding 
site to engage with the entry receptor (ACE2 in the case of SARS-CoV-2)206,207. 
β-coronavirus infections can induce antibodies against all of these structural 
proteins, though antibodies to M and E are far fewer and less important208. There may 
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be some cross-reactivity between antibodies targeting N of SARS-CoV-2 and SARS-
CoV, and N-binding antibodies may not correlate as well as S- or RBD-binding 
antibodies with potent neutralization titers185,209. S-targeting antibodies dominate the 
neutralizing antibody response for the other two most recently emerged β-
coronaviruses, SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-
CoV)210–212. In particular, the RBD appears to be a vulnerable target for protective 
neutralizing antibodies and thus also is the target of therapeutic antibodies and vaccine 
immunogens213. The duration of protective immunity to these recently emerged β-
coronaviruses remains unknown. SARS-CoV antibody titers may decay after 2-3 
years214,215. For SARS-CoV-2, for at least 8 months after symptomatic infection there 
still appear to be substantial amounts of neutralizing antibodies with only a small 
amount of decay as expected for convalescence216. Of note, mild infections may result 
in lower SARS-CoV-2 antibody titers and conversely, severe disease correlates with 
increased antibody titers217.  
1.12 SARS-CoV-2 prevalence 
Due to factors including asymptomatic spread, disparities in healthcare access, 
and bottlenecks in diagnostic testing, there have been substantial issues obtaining 
accurate counts of SARS-CoV-2 infections. Knowing the true number of infections is 
essential to understanding rates of morbidity and mortality, the role of asymptomatic 
transmission, the effect of public health interventions, and differences in burden of 
disease among demographic groups. Serological testing offers a complementary 
method to PCR testing for evaluating the spread of SARS-CoV-2 and can be deployed 
efficiently at the population level218. Most seroprevalence studies employ an assay that 
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detects N-targeting IgG developed for diagnosing symptomatic infections in clinical 
practice. As a result, N-based assays may have decreased sensitivity among mild or 
subclinical infections219,220. 
Immediately in the wake of the first outbreaks in China, Iran, France, and Italy, 
SARS-CoV-2 seroprevalence ranged from as low as 7% in Milan, Italy up to almost 26% 
in Oise, France221–224. In New York City, seroprevalence may have been as high as 
20% following the initial outbreak in Spring 2020225. There is significant regional 
variation in seroprevalence estimates in the United States, because many outbreaks 
have been localized as well as the above discussed limitations. In North Carolina, 
Barzin et al found an estimated seroprevalence of 0.7 – 0.8%, and another study of 
177,919 remnant clinical laboratory samples from routine screening (3,817 from NC) 
from July 27-September 24, 2020 found an estimated seroprevalence of 2.5 – 
6.8%226,227. Many seroprevalence studies are limited by sampling methodology that is 
not reflective of the general population228. Additionally, although serologic tests have 
imperfect sensitivity and specificity, few studies have incorporated this assay 
uncertainty into the subsequent analysis and propagated that uncertainty through the 
estimated seroprevalence. An example of propagating assay uncertainty into 
seroprevalence analysis is an estimate from Switzerland using a state-of-the-art 
Bayesian inference model229. Briefly, a Bayesian inference framework assumes that (1) 
the probability that a  particular seroprevalence is true given the validation and study 
data is proportional to (2) the validation and study data given a particular 
seroprevalence230–232. The most likely seroprevalence estimates that fit the data can 
then be determined by algorithmically sampling numbers to form probability distributions 
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of the most likely seroprevalence, sensitivity, and specificity. However, this more 
rigorous analysis is more complex than other methods that simply approximate 
seroprevalence by subtracting the false positive rate and adding a false negative rate, 
an equation referred to as the Rogan-Gladen estimate for seroprevalence226,233. These 
approaches are required because at low seroprevalence (such as SARS-CoV-2 early in 
this outbreak), false positives can comprise a high proportion of the small number of 
positive samples, thus overestimating seroprevalence unless adjusted for false 
positives. The opposite is true at high seroprevalence (as is the case for DENV or ZIKV 
in Latin America), where false negatives comprise a high proportion of the small number 
of negative samples.  
Morbidity, mortality, and case rates disproportionately affect Black, Latinx, and 
Indigenous populations in the United States198,199,234. In addition, structural and 
occupational factors previously identified as drivers of race and ethnic disparities in 
health and COVID-19 include unequal labor market opportunities and higher 
representation in essential work positions that lack job security, access to infection 
prevention control, benefits, and sick leave235–240. 
1.13 Conclusions & Objectives 
Flaviviruses that cause human disease are typically arthropod-borne and induce 
potent antibody responses after natural infection and vaccination. The degree of cross-
reactivity between the newly emerged ZIKV and the related flavivirus DENV 
complicated serodiagnostics during the 2015-2016 outbreak. Despite the significant 
number of flaviviruses that cause human disease and long history of flavivirus research, 
the new and unanticipated clinical outcomes and transmission mechanisms for ZIKV 
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mean that significant questions are still left unanswered. The placental pathology 
observed in ZIKV disease is similar to that observed for other congenital infections. 
Because these other congenital infections cause decreased antibody transfer 
presumably via placental damage, we investigated whether ZIKV similarly impairs 
transplacental antibody transfer during gestational ZIKV infection. This investigation into 
ZIKV and DENV cross-reactive antibody transfer further led to questions in whether 
antibodies play a role in prevention of vaginal ZIKV infection, because there also remain 
many questions in whether antiviral mechanisms in the vagina may also protect against 
flaviviruses. In the course of investigating these mechanisms in non-
immunocompromised mice thought to be less susceptible to ZIKV infections, it became 
apparent that ZIKV susceptibility in the vagina may be different than systemic 
susceptibility and is regulated by the sex hormone progesterone. Further defining the 
mechanism by which progesterone regulates susceptibility to ZIKV infection may have 
implications for other flaviviruses that may also be sexually transmitted but have not yet 
emerged as significant human pathogens, such as SPOV.  
While conducting these investigations into the emerging ZIKV, another virus, 
SARS-CoV-2, emerged and became one of the most common causes of death in 2020. 
The expertise gained in antibody responses to viruses was leveraged to study the rate 
of SARS-CoV-2 seropositivity in central North Carolina. Previously published estimates 
have focused on asymptomatic infections using an assay that may not be sensitive for 
capturing asymptomatic or subclinical infections, and also suffer from undersampling of 




Figure 1.1 Zika virus E dimer structure. Two ZIKV E proteins in complex, PDB# 
5JHM33. Note the multicolored E protein antiparallel to the E protein in gold. Purple=DI, 
blue =DII, green=DIII, red=fusion loop.
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2.1 Summary 
Zika virus (ZIKV) is a newly-identified infectious cause of congenital disease. 
Transplacental transfer of maternal IgG to the fetus plays an important role in 
preventing many neonatal infections. However, antibody transfer can also have 
negative consequences, such as mediating enhancement of dengue virus (DENV) 
infections in early life, or trafficking of virus immune complexes to the fetal 
compartment. ZIKV infection produces placental pathology which could lead to impaired 
IgG transfer efficiency as occurs in other maternal infections, such as HIV-1 and 
malaria. In this study, we investigated whether ZIKV infection in the gestational parent 
during pregnancy impairs transplacental transfer of IgG. We enrolled pregnant 
individuals with fever or rash in a prospective cohort in Vitoria, Brazil during the recent 
ZIKV epidemic. ZIKV- and DENV-specific IgG, ZIKV and DENV neutralizing antibodies, 
and routine vaccine antigen-specific IgG were measured in gestational parental 
samples collected around delivery and in 20 paired cord blood samples. We concluded 
                                            
1The work presented in this chapter has been published as either Collins MH, McGowan E, Jadi R, 
Young E, Lopez CA, Baric RS, Lazear HM, de Silva AM. Lack of Durable Cross-Neutralizing Antibodies 
Against Zika Virus from Dengue Virus Infection. Emerg Infect Dis 2017; 23: 773–81 or as Singh T, Lopez 
CA, Giuberti C, Dennis ML, Itell HL, Heimsath HJ, Webster HS, Roark HK, Merçon de Vargas PR, Hall A, 
Corey RG, Swamy GK, Dietze R, Lazear HM, Permar SR. Efficient transplacental IgG transfer in women 
infected with Zika virus during pregnancy. PLoS Negl Trop Dis 2019; 13: e0007648. I performed all 
mouse infection experiments, virus purification and preparation, neutralization assays, sample 
categorization, and ZIKV qRT-PCR assays on placental samples.  
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that 8 of these individuals had a history of ZIKV infection and 12 were ZIKV-uninfected. 
The magnitude of flavivirus-specific IgG, neutralizing antibody, and vaccine-elicited IgG 
were highly correlated between gestational parent and infant cord blood plasma in both 
ZIKV-infected and -uninfected pregnancies. Moreover, there was no difference in the 
magnitude of flavivirus-specific IgG levels in plasma between gestational parent/infant 
dyads regardless of ZIKV infection status. Our data suggests that ZIKV infection in the 
gestational parent during pregnancy does not impair the efficiency of transplacental 
transfer of flavivirus-specific, functional, or vaccine-elicited IgG. These findings have 
implications for the neonatal outcomes of ZIKV infection in gestational parents during 
pregnancy and optimal administration of antibody-based ZIKV vaccines and 
therapeutics. 
2.2 Introduction 
The emergence of Zika virus (ZIKV) in the Americas in 2015 revealed that ZIKV 
could be congenitally transmitted and cause fetal neurological damage11,75,241. 
Neurodevelopmental defects associated with congenital Zika syndrome (CZS) include 
microcephaly, arthrogryposis, motor and cognitive impairment, as well as vision and 
hearing loss12. ZIKV is the first example of a teratogenic vector-borne disease in humans. 
Initial estimates during the epidemic detected a 42% rate of fetal or neonatal 
abnormalities in symptomatic ZIKV-infected pregnant individuals75. A recent meta-
analysis estimated that after adjusting for the baseline rate of all-cause congenital 
disease, 13% of first trimester ZIKV infections result in congenital disease, with risk 
decreasing later in gestation242.  ZIKV is likely to be a re-emerging and ongoing cause of 
congenital infections.  
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Transplacental transfer of IgG during pregnancy provides passive immunity to the 
fetus and is critical to protecting newborns against infections83. Immunization during 
pregnancy can boost levels of protective IgG transferred to the fetus, providing a valuable 
tool for reducing neonatal morbidity. For example, tetanus immunization of pregnant 
individuals, or those that could become pregnant, resulted in a 94% reduction in neonatal 
tetanus mortality rates84. Moreover, gestational parent influenza vaccination and the 
magnitude of vaccination-derived antibodies are associated with protection of infants from 
influenza illness85–87. These benefits have led to the recommendation of providing 
diphtheria, tetanus, pertussis combined vaccines and influenza vaccines routinely during 
pregnancy243,244. Therefore, transplacental transfer of IgG is an important feature of 
vaccination-induced and natural immunity that may be leveraged for protection against 
neonatal pathogens.  
Humoral immunity plays an important role in protection against flavivirus 
infections245–247. ZIKV-neutralizing antibodies likely provide durable protection against re-
infection, therefore eliciting robust antibody responses is a key goal of ZIKV vaccine 
development248. Given the severe consequences of ZIKV disease in neonates, an ideal 
ZIKV vaccine would not only prevent infection in vaccine recipients but also protect 
fetuses from ZIKV congenital transmission. One way to protect fetuses could be 
transplacental transfer of ZIKV vaccine-elicited IgG. Due to the key role of antibody 
transfer in newborn health, it is important to delineate the quantity and function of IgG 
transferred during pregnancy in the context of infections during gestation.  
However, the degree of cross-reactivity in the antibody responses between DENV 
and ZIKV may lead to risks in early life for DENV disease enhancement in infants through 
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transplacental transfer of flavivirus antibodies112,249–252. This risk is known to be mediated 
by antibodies generated from a prior DENV infection that can enhance DENV viremia and 
disease and ZIKV antibodies may have the potential to similarly enhance DENV 
infection53,253,254. Timing of past flavivirus infection also influences this risk as cross-
neutralization of DENV and ZIKV is restricted to early convalescence, and antibody 
populations become more virus-specific over time 255,256. While DENV-specific IgG are 
efficiently transferred in healthy pregnancies, waning flavivirus-specific IgG levels 
acquired from the gestational parent throughout the first year of life lead to increased risk 
for severe DENV infection in infants 112,257–259.  The available data suggest that DENV 
immunity provides modest and transient protection against ZIKV60,260, highlighting the 
need to better understand the impact of cross-reactive antibodies in flavivirus disease. 
Antibody-dependent transfer of ZIKV across the placenta, antibody-mediated 
enhancement of DENV disease in infants, and antibody-mediated protection of fetuses 
and newborns are all dependent on intact transplacental IgG transfer. 
IgG transfer during gestation occurs at placental villus trees in contact with parental 
blood91. In healthy pregnancies, IgG is transferred efficiently such that IgG concentrations 
in infant cord blood are often equivalent to or higher than the gestational parent’s levels 
at delivery 83,261. Many factors contribute to efficient transplacental IgG transfer via FcRn, 
such as IgG subclass, antibody avidity, gestational stage, and hypergammaglobulinemia 
91,262,263, and transfer can be impeded by placental pathology. Additionally, other Fcγ 
receptors may also play a supporting role in transfer of IgG across the placenta264.  
Gestational infection with DENV, a closely related flavivirus, leads to increased risk 
of mortality, pregnancy complications, premature birth, and low infant birth weight, as well 
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as placental damage68–72. Yet, DENV infection in pregnancy does not impair 
transplacental IgG transfer in normal birth weight infants113. ZIKV infection in pregnancy 
can result in prolonged viremia, suggesting a viral reservoir in an immune privileged site, 
potentially the placenta78,80–82.  Gestational malaria and HIV-1 infection have been 
established to differentially impact transfer of IgG subpopulations specific to routine 
pediatric vaccines110,265, which may be dependent on distinct Fc characteristics of each 
IgG population266. Gestational HIV-1 infection and placental damage due to malaria 
infection are two clinical settings associated with impaired IgG transfer107–111. Gestational 
ZIKV infection can result in similar placental damage97,99,267,268. While prior studies show 
efficient transfer of recently boosted flavivirus antibodies after the ZIKV epidemic269, we 
further examined whether pre-existing IgG subpopulations relevant to newborn health are 
efficiently transferred following gestational ZIKV infection. 
To investigate whether ZIKV infection in the gestational parent during pregnancy 
impairs transplacental transfer of IgG specific to flaviviruses and common vaccine 
antigens, we enrolled a prospective cohort of 26 pregnant individuals from Vitória, Brazil, 
who presented with fever and rash symptoms consistent with ZIKV infection during the 
recent Brazilian ZIKV epidemic. Of these, 20 paired plasma samples from gestational 
parents and infant cord blood samples were collected from delivery and used to define 
the efficiency of transplacental IgG transfer. Of these, we classified 8 gestational parents 
as ZIKV-infected based on viral RNA detection and/or neutralization serology, and 12 
gestational parents as ZIKV-uninfected. Comparing ZIKV-infected and uninfected groups, 
we detected no difference in transfer efficiency of IgG targeting ZIKV, DENV, or routine 
vaccine antigens. These findings indicate that the magnitude of IgG transferred across 
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the placenta was not deficient at the time of birth in the setting of gestational ZIKV 
infection. Sustained transplacental transfer with ZIKV infection in the gestational parent 
during pregnancy indicates that ZIKV exposure in utero should not impact protection 
mediated by gestational parent antibodies during early life, yet indicates potential risks of 
severe primary DENV infection in ZIKV-exposed infants in endemic regions. This passive 
antibody transfer in pregnancy is an important consideration for flavivirus vaccine and 
therapeutic development efforts.  
2.3 Materials and methods 
Study population and design 
Positive control sera were collected in North Carolina from residents who had 
possible DENV or ZIKV infection based on a combined history of symptoms and travel. 
Serum samples were assigned arbitrary identification numbers beginning with “DT”. All 
donations were collected in compliance with the University of North Carolina (UNC) 
Institutional Review Board (IRB) (protocol 08–0895). Infection history of these samples 
was determined on the basis of neutralizing antibodies to DENV serotypes and ZIKV, 
such that if the highest 50% focus reduction neutralization titer (FRNT-50) was >4-fold 
higher than for the other viruses, it was defined as a primary infection with that virus. 
Otherwise, it was defined as a secondary DENV or both ZIKV and DENV infection history, 
depending on whether ZIKV was within a 4-fold range of the highest FRNT-50 titer. 
The study enrolled 26 pregnant individuals living in Southeast Brazil, but from 
which only 20 delivery samples were collected. All enrollees presented with fever and/or 
rash during the ZIKV epidemic in 2016. Two groups of gestational parent-infant pairs are 
included in this observational study: one group with ZIKV infection during pregnancy, and 
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the other group without ZIKV infection during pregnancy. Therefore, pregnant individuals 
with rash or fever but without ZIKV infection served as a comparator group for those with 
ZIKV infection and symptomology. Participants in this study were enrolled from July 2016 
to October 2017 in the city of Vitória, which is the capital of the State of Espírito Santo. 
There are 4 million inhabitants and 50,000 births per year in Espírito Santo with the 
majority living in the metropolitan region of Vitória270,271. This region has had endemic 
DENV circulation for the past two decades272 so it was expected that many participants 
would have been exposed to DENV previously and be seropositive for DENV. The first 
clinically suspected cases of ZIKV infection in Brazil were described in May 2015, and six 
months later (November 2015) the first autochthonous ZIKV case was confirmed in 
Espírito Santo273–275. In the months preceding our enrollment, there was a ZIKV incidence 
of 3,100 cases per 100,000 inhabitants, and a DENV incidence of 901 cases per 100,000 
inhabitants in Espírito Santo272. In this timeframe, 77 CZS cases were reported to the 
State Health Department, including cases of microcephaly, defects of the central nervous 
system suggestive of congenital infection, or stillbirths272. Since this region reflected key 
features of flavivirus co-endemic settings and had ongoing ZIKV transmission, it was 
considered representative of regions with a burden of ZIKV disease and appropriate for 
study of ZIKV immunity during pregnancy.  
Recruitment 
The enrollment field site is based in the city of Vitória at the the Núcleo de 
Doenças Infecciosas (NDI), at the Universidade Federal do Espírito Santo. During our 
study, suspected ZIKV infection was considered a reportable condition to the State 
Health Department for all patients seen at public or private clinics within the state. 
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Within a week of a case reported by a physician to the State Health Department, a staff 
member reported notifications of pregnant suspected ZIKV cases within the State to 
NDI. Thus the recruitment strategy relied on passive surveillance systems, and no 
active recruitment was conducted in the community. Upon referral, staff at the NDI 
contacted pregnant suspected ZIKV cases within the Vitória metropolitan area by phone 
regarding interest in participating in this study. If interested, pregnant suspected ZIKV 
cases were invited to the NDI for written informed consent and first recorded visit in our 
study at the time of enrollment.  
Enrollment and follow-up 
At the initial visit for study enrollment, four inclusion criteria were confirmed: 1) 
currently pregnant; 2) rash or fever consistent with ZIKV infection; 3) patient was a 
minimum of 18 years of age; 4) willingness to participate in study through provision of 
written informed consent. No exclusion criteria were defined. During the enrollment visit, 
a clinical history and physical evaluation were performed by a licensed physician, and 
blood and urine were collected. The following demographic information was collected at 
enrollment: age, municipality, date of birth, last menstrual date, recall of prior DENV 
disease, family members or neighbors with symptoms of ZIKV infection, use of insect 
repellant, prior vaccination for yellow fever virus, sexual activity in the 10 days before 
symptoms of ZIKV infection, symptoms of ZIKV infection in sexual partners, partner’s 
use of insect repellent, and use of drugs, tobacco, or alcohol during pregnancy. Any 
clinical records and ultrasounds during the pregnancy before symptoms of ZIKV 
infection also were collected. All participants were referred for additional prenatal clinical 
care consultations and ultrasounds. Transportation to the NDI research site for every 
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visit, as well as all recommended consultations with obstetrician-gynecologists and 
ultrasounds were funded by the study. For each participant, gestational ages at the time 
of symptoms and delivery were calculated based on the last menstrual period date and 
confirmed by ultrasound (performed at 9-22 weeks).  
After the enrollment visit, all participants were followed up weekly for up to four 
weeks, and monthly visits thereafter until delivery. Though follow-up of the gestational 
parents and infants in this study is ongoing, the present report only includes samples 
through delivery. At every visit, a standardized questionnaire was administered in the 
form of a semi-structured interview by a trained research staff member at NDI. Through 
this questionnaire we collected information on the presence and duration of symptoms 
related to ZIKV infection. 
At the time of delivery, gestational parent blood and urine, infant cord blood, and 
placenta were collected. Newborn head circumference was measured by a nurse prior to 
hospital discharge, and reported to study staff. Head circumferences were converted to z 
score for the corresponding gestational age using the Newborn Cross-Sectional Study of 
the INTERGROWTH-21st Project standards. Microcephaly was defined per WHO and 
INTERGROWTH-21st guidelines as a z score lower than -1.88, which is the 3rd percentile 
of newborns at each gestational age276,277. 
Sample collection  
Blood samples were collected into heparin or EDTA tubes, stored at room 
temperature up to six hours, and centrifuged at 1300 x G for 10 minutes to obtain 
plasma. Infant umbilical cord blood was collected by clamping the cord, cutting it, and 
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draining blood into sterile collection tubes. Urine samples were collected mid-stream in 
a sterile screw-top container and stored at -80°C. Plasma samples were stored at -
80°C, then shipped to Duke University on dry ice. 
Ethics statement  
This prospective cohort study was approved by the Institutional Review Board of 
Hospital Cassiano Antonio Moraes, Brazilian National Research Ethics 
Committee (CEP/CONEP Registration number: 52841716.0.0000.5071), and Duke 
University Medical Center Institutional Review Board (Pro00100218). Individuals 
meeting enrollment criteria who provided written informed consent were included. 
RT-PCR assay for ZIKV detection 
Viral RNA was extracted from 140µL of plasma and urine using QIAmp Viral RNA 
Mini Kit (Qiagen). Previously described RT-PCR primers and probes specific for ZIKV 
were used for clinical diagnosis: ZIKV1086, ZIKV 1162c, and ZIKV1107-FAM 278. For 
this one-step RT-PCR reaction, 5µL of RNA was combined with 500nM primers, 250nM 
probe and nucleotides in a total volume of 20µL, including SuperScriptIII RT and 
Platinum Taq DNA polymerase Mix (Invitrogen). The negative controls were serum from 
a 30-year old asymptomatic subject in Vitoria collected in 2016, and PCR grade water 
(no template control). The positive control was supernatant from ZIKV-infected Vero 
cells. Samples and controls were tested in duplicate, and ZIKV positivity was indicated 
by detection of amplification at <38 cycles in both duplicate wells on the Applied 
Biosystems 7500 Fast platform. 
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ZIKV IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) 
The CDC MAC-ELISA (IgM antibody capture enzyme linked immunosorbent 
assay) was adapted and used to detect IgM specific for ZIKV in parental and cord blood 
plasma 279. Briefly, 96-well high-binding ELISA plates were coated with 20 µg/ml of 
mouse anti-human IgM (Sigma #I0759) overnight at 4°C. Plates were blocked for 30 
minutes at room temperature with 5% milk in 0.5% TBST, and then samples were 
added at a 1:40 dilution in quadruplicate for 1 hour at 37°C. Antigen (ZIKV H/PF/2013 
grown in C6/36 cells), or C6/36 conditioned media as a negative control, was added at a 
1:40 dilution overnight at 4°C. Then, an HRP-conjugated pan-flavivirus antibody (6B6C-
1) was added for 1 hour at 37°C, followed by TMB substrate. Plates were incubated for 
20 minutes, upon which 1N H2SO4 was added to stop the reaction. A positive result 
required that the absorbance for a particular plasma was >3-fold higher than the 
absorbance for that same plasma on C6/36 conditioned media. Samples run on each 
plate also include a confirmed ZIKV IgM positive and negative sample.  
Cell culture and virus stocks 
Vero-81 cells were grown in Dulbecco’s Modified Eagle Media (Gibco 11965092) 
supplemented with 5% heat-inactivated fetal bovine serum (Cellgro, Cat#35-016-CV) 
and L-alanyl-L-glutamine (Thermofisher, GlutaMAX Cat#35050079). Viruses used for 
the focus reduction neutralization test were DENV1 (WestPac74), DENV2 (S-16803), 
DENV3 (CH54389), DENV4 (TVP-360), obtained from Dr. Aravinda de Silva, University 
of North Carolina at Chapel Hill, ZIKV (H/PF/2013), obtained from the United States 
Centers for Disease Control and Prevention (Division of Vector-borne Diseases, Fort 
Collins, CO), ZIKV (MR766) and ZIKV (DAKAR 41525) obtained from the World 
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Reference Center for Emerging Viruses and Arboviruses (WRCEVA), University of 
Texas Medical Branch, Galveston, TX, USA. DAKAR 41525 in the laboratory and 
publication was previously incorrectly identified as DAKAR 41519 due most likely to a 
mislabeled tube received from WRCEVA but was later correctly identified through deep 
sequencing280. For the detection of virion binding antibodies, the following viruses from 
BEI were used: ZIKV (PRVABC59), DENV1 (Hawaii), DENV2 (New Guinea C), DENV3 
(Philippines), and DENV4 (H241). Virus stocks were grown in Vero-81 cells 
supplemented with 2% heat-inactivated fetal bovine serum and 10mM HEPES (Corning, 
Cat#25-060-CI).  
Placental sampling and examination 
Placenta samples were available from 11 ZIKV-infected and 8 ZIKV-uninfected 
subjects out of 26 individuals total in the cohort. Fragments were collected from the 
whole placenta up to 24 hours after delivery. Three sets of full thickness samples of 
placental parenchyma were obtained in every case and histology performed as 
previously described 281. For the histological analysis, sections were fixed in 4% 
formaldehyde phosphate buffered solution, paraffin embedded and 5µm sections were 
stained with hematoxylin and eosin. Histological sections were examined specifically for 
villous lesions by a pathologist. Villitis was diagnosed if inflammatory exudate was 
present in the trophoblast or in the villous stroma and was categorized by Knox & Fox 
and Redline criteria282,283. Placentas were assessed as low-grade villitis if fewer than 10 
villi were involved per focus, and high-grade if more than 10 villi were involved per focus 
282. 
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Focus reduction neutralization test 
We used previously described methods for FRNT-50 in a 96 well plate256. Briefly, 
serial 5-fold dilutions of heat-inactivated plasma were added to 50-80 focus forming units 
of either DENV or ZIKV and incubated for 1 hour at 37°C, then transferred to a confluent 
plate of Vero-81 cells and incubated for 1 hour at 37°C. Then an overlay of 1% 
methylcellulose was added. Cells were fixed with 2% paraformaldehyde and stained with 
1 µg/mL of E60 mouse monoclonal antibody targeting the conserved flavivirus fusion 
loop284, then detected with an anti-mouse IgG horseradish peroxidase conjugate and True 
Blue substrate (KPL). FRNT-50 values were calculated with the sigmoidal dose-response 
(variable slope) curve in Prism 7 (GraphPad), constraining values between 0 and 100% 
relative infection. A valid FRNT-50 curve required an R² >0.75, hill slope absolute value 
>0.5, and had to reach at least 50% relative infection within the range of the plasma 
dilutions in the assay.  
Detection of virion binding IgG 
High-binding 96-well ELISA plates (Greiner) were coated with 30 ng/well of 4G2 
antibody (clone D1-4G2-4-15) in carbonate buffer, pH 9.6 overnight at 4°C. Plates were 
blocked in Tris-buffered saline containing 0.05% Tween-20 and 5% normal goat serum 
for 1 hour at 37°C, followed by an incubation with either ZIKV, DENV1, DENV2, DENV3 
or DENV4 for 1 hour at 37°C. Plasma was tested at a 1:25 starting dilution in 8 serial 3-
fold, 5-fold, or 10-fold dilutions, incubating for 1 hour at 37°C. Horseradish peroxidase-
conjugated goat anti-human IgG antibody (Jackson ImmunoResearch Laboratories, Inc; 
109-035-008) was used at a 1: 5,000 dilution, followed by the addition of SureBlue 
reserve TMB substrate followed by stop solution (KPL). Optical densities (OD) were 
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detected at 450 nm (Perkin Elmer, Victor). ED50 values were calculated with the 
sigmoidal dose-response (variable slope) curve in Prism 7 (GraphPad), which uses a 
least squares fit. An ED50 value was considered valid if the OD at plasma dilution 1:25 
was two (2SD) or three (3SD) standard deviations above the mean OD observed for 11 
plasma samples from healthy U.S. subjects (2SD OD cut-offs: DENV-1 = 0.406, DENV-
2 = 0.648, DENV3 = 0.906, and DENV-4 = 0.885; 3SD OD cut-off: ZIKV = 0.596). 
Software generated ED50 values from curves with an OD at 1:25 plasma dilution below 
this cut-off were considered non-binding and plotted at the limit of detection. 
Determination of transplacental transfer of IgG against routine pediatric vaccines 
IgG binding to antigens from pediatric vaccines that are used routinely in Brazil 
was tested using a customized binding antibody multiplex assay on the Luminex 
platform as previously described285. Pediatric vaccine antigens used for screening 
included: hepatitis B virus surface antigen (antigenic combination: adw), rubella virus 
capsid (AbCam), Bordetella pertussis toxin and Corynebacterium diphtheriae toxin 
(Sigma-Aldrich), Haemophilus influenzae type B oligosaccharide-conjugated to human 
serum albumin (HbO-HA) and tetanus toxoid (Reagent Proteins). Antibody binding was 
detected with mouse anti-human IgG-PE (Southern BioTech) and the fluorescent output 
was measured on a Bio-Plex 200 system (Bio-Rad Laboratories). Antibody 
concentrations in µg or International Units per mL were interpolated from corresponding 
sigmoidal curves of serially diluted WHO international reference sera (National Institute 
of Biological Standards and Control, Potters Bar, UK; NIBSC code numbers: 07/164, 
09/222, 06/140, TE-3, 10/262, RUBI-1-94). The efficiency of transplacental IgG transfer 
was calculated for each gestational parent-infant pair by dividing the concentration of 
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infant pediatric vaccine-specific IgG by the concentration of gestational parent vaccine-
elicited IgG.  
Screening for neonatal TORCH pathogens  
Data on Toxoplasma, rubella, and syphilis serological status was extracted from 
the gestational parent’s prenatal visit clinical records. All tests were performed by State 
Health Department or clinical laboratories using commercially available kits approved by 
the Brazilian Health Regulatory Agency (ANVISA), as per the manufacturer’s instructions. 
Chemiluminescent microparticle immunoassay kits were used for detection of 
Toxoplasma IgM and IgG, as well as rubella virus IgG. Syphilis serostatus was assessed 
using a Venereal Disease Research Laboratory test, which is a nontreponemal test. 
Congenital CMV infection was evaluated using quantitative PCR of infant cord blood. To 
pellet CMV from plasma, 200 µL of infant cord blood was transferred to a high g-force 
micro-centrifuge tube and spun in an S45A fixed angle rotor at 30,000 rpm, 4°C, for 3 
hours in a Sorvall Discovery M120 Ultracentrifuge. Then the supernatant was removed 
and the pellet re-suspended in 200 µL of 1x PBS. DNA was extracted using the Roche 
High Pure Viral Nucleic Acid Kit according to the manufacturer’s protocol. To quantify and 
detect CMV DNA, extracted DNA from each sample was amplified in six replicates. For 
this reaction, 5 µL of DNA was added to 15 µL SYBR Select Master Mix with 
(ThermoFisher Scientific), 5 µL of water, and 300 nM primers designed to amplify the 
immediate-early 1 (IE1) gene of CMV (Integrated DNA Technologies). IE1 Forward 
Primer (20 bp): CAA GCG GCC TCT GAT AAC CA. IE1 Reverse Primer (24 bp): ACT 
AGG AGA GCA GAC TCT CAG AGG. For the negative control, PCR grade water was 
used as a substitute for extracted DNA in the reaction with in four replicate wells. A 10-
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fold, 7 series dilution of plasmid with the amplification region was serially diluted starting 
at 1x108 copies/mL to generate a standard curve for quantitation of CMV DNA in each 
sample. The lowest dilution on the standard that could be reliably amplified across 
replicates was considered as the threshold for positivity (250 viral DNA copies/mL).  
Definition of ZIKV infection 
As ZIKV viremia is transient, RT-PCR does not reliably detect ZIKV infection 
beyond 10-14 days from exposure286. Therefore, we combined a RT-PCR diagnostic with 
serological approaches based on gestational parent delivery plasma FRNT-50 titer 
(FRNT-50) against ZIKV and DENV (types 1-4). “Primary ZIKV” infection (no prior DENV 
or ZIKV infection) was defined as either i) a high ZIKV FRNT-50 (>300) and a low DENV1-
4 FRNT-50 (<300), or ii) a low ZIKV FRNT-50 titer that is still >25 and at least one DENV 
FRNT-50 >25, suggesting only a weak transient cross-neutralizing response between 
ZIKV and DENV. A history of both ZIKV and DENV (“DENV+ZIKV”) was defined as high 
ZIKV FRNT-50 (>300), and at least one DENV FRNT-50>300. DENV immunity only (no 
ZIKV immunity) was classified as low ZIKV FRNT-50 (<300), but DENV FRNT-50 >25. 
Thus, we defined ZIKV infection as “primary” or “secondary” ZIKV based on serological 
evidence of prior DENV exposure, whereas the ZIKV-uninfected group includes subjects 
naïve to both ZIKV and DENV or those exposed to only DENV.  
Since infection with one DENV serotype results in neutralizing activity only against 
that same serotype287, and a subsequent infection with a different serotype results in 
broad DENV cross-neutralizing activity, we designed criteria to differentiate primary and 
secondary DENV infections based on whether the second-highest DENV FRNT-50 was 
within four-fold of the highest DENV FRNT-50. To further account for serological cross-
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reactivity from recently infected subjects in assessing ZIKV infection status, we confirmed 
DENV-negative status by RT-PCR where acute samples were available. Sera with FRNT-
50 values below the limit of detection for all five viruses were classified as ZIKV and DENV 
naïve. This definition is based on the assumption that a dominant ZIKV neutralization 
response at delivery was attributable to the recent symptomatic illness during pregnancy 
and not a prior ZIKV infection, given the recency of ZIKV introduction to the region during 
the period of enrollment; this assumption will not be valid for future studies in the same 
region. RT-PCR results from a plasma sample collected <7 days after symptom onset 
that were discordant with the serological assessment were repeated.  
Statistical Analysis and Power.  
Statistical analysis was performed using SAS (version 9.4) and Prism software 
(GraphPad; version 7). Serological responses are presented as a magnitude of flavivirus 
binding IgG (ED50), neutralizing (FRNT-50), and vaccine antigen binding IgG (µg/mL or 
IU/mL). The percent IgG transferred from gestational parent to infant describes the 
transplacental transfer efficiency, and is calculated as the ratio of the magnitude of infant 
cord blood IgG binding level (measured as ED50 or µg/ml) to the gestational parent IgG 
binding level. Note that this percent transfer ratio is specific to each antigen tested. Data 
are presented as dot plots of percent transfer for each gestational parent-infant pair in the 
ZIKV-infected group as compared to the ZIKV-uninfected group. Scatter plots are used 
to display the relationship and distribution of the gestational parent IgG level as compared 
to the infant IgG level, by antigen. 
With a sample size of 26 gestational parents and 20 infant samples, this study is 
powered to reject the null hypothesis (no correlation between parental and infant antibody 
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responses), at an alpha of 0.05 with a power of 0.89 for neutralizing titer correlations, and 
0.99 for correlations of IgG binding to flaviviruses or vaccine antigens. Therefore, this 
study is adequately powered to detect associations between gestational parent and infant 
antibody measures. For Wilcoxon Rank tests comparing IgG transfer efficiency between 
ZIKV-infected and uninfected gestational parent-infant pairs, this study is powered to 
assess significant differences between ZIKV-infected and uninfected groups in flavivirus 
IgG binding at an alpha of 0.05 (power = 0.93), but not for vaccine antigen IgG (power = 
0.15) and neutralizing IgG (power = 0.48). This is due to differences in the extent of 
variability in measures by assay type. 
Due to the small size of this cohort, a Gaussian distribution could not be inferred 
and therefore non-parametric statistical tests were applied. To compare IgG binding 
between ZIKV-infected and -uninfected groups, the Wilcoxon Signed and Exact Wilcoxon 
Rank Sum tests were applied. For correction of multiple comparisons, the Bonferroni 
correction was applied. Data were not stratified beyond the ZIKV infection status 
exposure group. The Kendall Tau test was used to evaluate correlations between parental 
and infant responses with the alpha level of significance set to 0.05. 
Staining and sorting ZIKV-reactive B cells.  
Peripheral blood mononuclear cells (PBMCs) were thawed and stained with 1 x 
106 PFU of freshly thawed UV-inactivated ZIKV labelled with AF488. B cells were gated 
as CD14-/CD16-/CD3-/CD19+ and memory B cells were gated with an additional IgD-
/CD27. ZIKV-reactive cells were defined by those that bound to the UV-inactivated and 
AF488-labeled ZIKV.  
38 
Culturing B cells in vitro and EBV transformation to generate B cell lines.  
Cells were suspended and sorted by limiting dilution at a calculated 
concentration of 1-2 cells/well into 96-well round-bottom tissue culture plates in the 
presence of mouse CD40 ligand-expressing cells (3,000 cells/well). Cell culture 
supernatants were harvested on day 14 and assessed for secretion of any 
immunoglobulin by total IgG, IgM, and IgA ELISAs. Wells with detectable Ig were further 
evaluated for ZIKV-reactivity with a virion binding ELISA. The median IgG concentration 
of the cultures at the end of stimulation was 163 ng/ml (total IgG concentration range: 
1.1- 1357 ng/ml; n=85), the median IgM concentration was 299 ng/mL (total IgM 
concentration range: 5.4 - 1304 ng/mL; n=20), and the median IgA concentration was 
138 ng/mL (total IgA concentration range: 0.6 – 561 ng/mL; n=10).  
Isolation of V(D)J immunoglobulin regions.   
RNA from select positive cultures was extracted using standard procedures 
recommended by the manufacturer (Qiagen RNeasy Minikit), and the VH and VL genes 
were amplified288. The first round VH PCR products were pooled for heavy chain second 
round nested PCR. Samples of second round PCR products were analyzed on 2% 
agarose gels. Positive wells were purified and sequenced by Genewiz. Sequencing 
results were analyzed by Clonalyst software to obtain needed Ig classification 
information289. When more than one heavy- or light-chain pair was obtained from a 
single culture, the clonal pairs were identified from sorted single B cells of the respective 
cultures by using the same procedure described above. All available antibody pairs 
were processed to overlapping PCR and transient transfection for further analysis as 
reported before288.  
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Production of recombinant antibodies.  
Recombinant IgG and Fab were synthesized as previously described290. Isolated 
DH1017 VH and VL Ig genes were cloned into pcDNA3.1(+) plasmid gene expression 
cassettes containing the CMV promoter and either the IgG heavy- and light-chain 
constant regions or to generate Fab, a partial heavy-chain constant region up to the VH 
hinge region (GenScript). Plasmids were transformed into MAX Efficiency DHα 
Competent Cells and amplified by Plasmid Plus kit (Qiagen). Heavy chain plasmids 
were co-transfected with appropriate light chain plasmids at an equal ratio in Expi 293i 
cells (Invitrogen). Supernatant containing antibody was harvested and filtered, and co-
incubated with a Protein A affinity resin (Thermo Fisher Scientific) for IgG antibody or 
LambdaFabSelect Agarose Beads (GE Healthcare Life Sciences) at 4°C on a rotating 
shaker overnight. The bead and supernatant mixture was then column purified. Purified 
antibody concentration was determined by Nanodrop and product was evaluated by 
reducing and nonreducing SDS-polyacrylamide gel electrophoresis and Coomassie 
Blue staining. 
Mouse infections  
All mouse husbandry and experiments were performed with approval of the 
University of North Carolina at Chapel Hill’s Institutional Animal Care and Use Committee. 
Five to six-week old Ifnar1-/- mice were infected with 1000 FFU of ZIKV H/PF/2013. One 
day before and one day after inoculation, 100µg of either the ZIKV-neutralizing antibody 
CDH1017.IgM or non-ZIKV binding antibody 119-4-G11 were administered intravenously 
via retro-orbital injection. Serum was separated at 8000 rpm for 5 minutes and stored at 
-80°C ready for RNA extraction with the Qiagen viral RNA minikit. ZIKV genomes were 
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then quantified by Taqman one-step qRT-PCR on a CFX96 Touch real-time PCR 
detection system (BioRad) and were reported on a log10 scale measured against standard 
curves from a ZIKV A-plasmid as previously described291.  
2.4 Results 
Neutralization assays can differentiate flavivirus infection history 
Early in the course of the ZIKV outbreak in Latin America, diagnosis of ZIKV was 
challenging because viremia is only transient and the antibody response between DENV 
and ZIKV is so cross-reactive that they are indistinguishable via most binding assays 
against the E protein. Given the significant degree of antigenic cross-reactivity between 
DENV and ZIKV, we evaluated to what extent sera against one virus would also cross-
neutralize the other because neutralization assays have more specificity between viruses 
and can even be used to distinguish between different DENV serotypes which are also 
strongly cross-reactive on most antibody binding assays62,256,292–294. We tested whether 
convalescent DENV immune sera, or sera collected from 4 individuals who traveled in 
2015 to Brazil and were classified on the basis of serology of having both ZIKV and DENV 
exposure, could neutralize the prototype ZIKV strain MR766 (Uganda 1947, non-
glycosylated variant Figure 2.1A)291. Most convalescent sera from individuals exposed 
only to DENV did not cross-neutralize ZIKV. Those who did neutralized ZIKV less well 
than convalescent sera from individuals exposed to ZIKV or both DENV and ZIKV.  
Additionally, to determine whether the neutralization profiles of these sera are 
similar for more recent ZIKV strains, we compared the neutralization of a subset of these 
sera to two historic African lineage ZIKV strains (MR766 and DAKAR 41525 and two 
contemporary Asian lineage ZIKV strains (H/PF/2013 and PRVABC59) (Figure 2.1B-C). 
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The secondary DENV serum sample poorly neutralized these 4 ZIKV strains, but all were 
neutralized well by sera after prior ZIKV exposure. Historic and contemporary ZIKV 
strains display similar neutralization profiles. 
Almost half of the study cohort is ZIKV seropositive 
Pregnant individuals aged 18 to 39 years were enrolled based on symptoms 
suggestive of ZIKV infection, such as rash, arthralgia, and fever (Table 2.1). Nearly all 
enrolled participants (24/26) were from the Vitoria metropolitan area. All subjects were 
tested for common congenital “TORCH” pathogens where samples were available 
(Table 2.2). These data indicated no recent Toxoplasma infections (no gestational 
parent IgM detected), high IgG seropositivity to rubella virus (consistent with widespread 
MMR vaccination), and no evidence for syphilis infection. Testing of infant cord blood for 
CMV DNA found one case of congenital CMV transmission in the ZIKV-uninfected 
group. One subject (B1_0037) exhibited prolonged viremia, which was detected in 
serum by RT-PCR up to 42 days post symptoms.  
ZIKV testing by RT-PCR was performed in serum and urine, collected between 2 
and 15 days post symptom onset in 22 out of 26 individuals (Table 2.3) As expected, 
most were DENV seropositive, regardless of ZIKV infection status. The remaining 
individuals were referred for enrollment only after the resolution of symptoms, at 36 to 
217 days since symptoms, and thus their negative ZIKV RT-PCR results were 
inconclusive. All individuals with acute samples available were negative for DENV by 
RT-PCR at enrollment, and one (B1_0035) was positive for chikungunya virusby RT-
PCR (Table 2.3).  
42 
Because ZIKV viremia typically is detected only in the acute phase of infection 
(≤14 days after exposure), and because of the possibility of a false positive RT-PCR 
ZIKV test, we used serology to classify gestational parent ZIKV exposure as well as 
prior DENV infection history. Since detection of ZIKV-binding antibodies by ELISA does 
not distinguish ZIKV exposure from other flaviviruses, and this region has high DENV 
seroprevalence, we determined the FRNT-50 of all gestational parent plasma samples 
collected at delivery, which ranged from 39 to 217 days following onset of ZIKV 
symptoms. With the knowledge that ZIKV as well as DENV-recovered individuals do not 
have extensive cross-neutralizing antibodies against the virus to which they were not 
exposed, we designed an algorithm to define ZIKV and DENV exposure history. The 
algorithm is described in the methods and displayed in Figure 2.2. By these definitions, 
11 out of 26 individuals had serological evidence of ZIKV infection, only 2 of which were 
DENV naïve, indicating a primary ZIKV infection (Table 2.4). Two out of 26 individuals 
were naïve for both ZIKV and DENV, and the rest had serological evidence of DENV 
infection with no ZIKV infection. Though one individual classified as ZIKV naïve 
(Primary DENV) by serology (B1_0009) had a positive RT-PCR result at initial 
presentation, subsequent RT-PCR testing of stored plasma was negative, suggesting 
that the initial result was a false positive. Of note, when tested we tested the samples 
classified as likely ZIKV exposed, two (B1_0002 and B1_0037) were ZIKV IgM positive 
at delivery, suggesting that these individuals had a recent ZIKV infection. 
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IgG transfer is maintained in the context of ZIKV infection of the gestational 
parent during pregnancy.  
At birth, all infants born to ZIKV negative gestational parents were assessed to be 
healthy. Of the 11 infants born to gestational parents with serological evidence of ZIKV 
infection, one infant (born to B1_0001) presented with microcephaly at birth, with a head 
circumference below 3rd percentile based on WHO International Standards, and 
neurologic abnormalities including cortical-subcortical calcifications, dysgenesis of the 
corpus callosum, pachygyria, and colpocephaly upon transfontanellar ultrasound and CT 
scan295. Delivery cord blood sample was not available for this infant.  
Lymphohistiocytic chronic villitis (inflammatory lesions in the placenta with an 
infiltrate of lymphocytes and macrophages)296, was observed in the placentas of 5 of 11 
(45%) ZIKV-infected gestational parents (Table 2.5 and Figure 2.3). The villitis was focal, 
involving less than 10 villi per focus, consistent with mild, low grade chronic villitis282,283. 
One placenta (B1_0004) demonstrated mild necrosis in the villitis focus and two placentas 
(B1_0004 and B1_0014) demonstrated small focal avascular villi with stromal fibrosis, 
consistent with fetal artery thrombosis in the absence of any other abnormality. In 
contrast, no vilitis was observed in any of the 8 ZIKV-uninfected subjects. We tested 
frozen placental samples from 8 ZIKV-positive individuals by qRT-PCR but did not detect 
ZIKV RNA.  
To determine if ZIKV infection during pregnancy disrupts transplacental transfer of 
flavivirus-specific IgG, we compared the magnitude of flavivirus-specific antibody binding 
responses in gestational parent plasma at delivery and infant cord blood plasma by virion 
capture ELISA in 20 gestational parent-infant pairs with delivery samples available. For 
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those gestational parents with ZIKV infection, IgG binding to ZIKV, DENV1, DENV2, 
DENV3, and DENV4 virions was not significantly different between gestational parent 
plasma and paired infant cord blood from delivery (Wilcoxon Signed Rank Test; 
Bonferroni adjusted P >0.05 for all viruses tested). The efficiency of transplacental 
transfer of flavivirus-specific IgG was calculated as the ratio of the magnitude of infant 
cord blood antibody binding response to the gestational parent response, expressed as 
a transfer efficiency percentage (Figure 2.4). For those with paired parental and infant 
samples available, we compared the flavivirus-specific IgG transfer efficiencies in ZIKV-
infected (n=8) and uninfected (n= 12) individuals, and found no significant difference in 
the transplacental transfer efficiency of flavivirus-specific IgG between the groups (Exact 
Wilcoxon Rank Sum Test; Bonferroni adjusted P > 0.05 for all viruses tested), indicating 
that ZIKV infection during pregnancy did not disrupt transplacental transfer of flavivirus-
specific IgG.  
As expected, in the virion capture ELISA we observed significant cross-reactive 
binding to ZIKV from individuals who were defined as ZIKV-uninfected based on 
neutralizing antibody titers. These ZIKV-uninfected subjects also demonstrated transfer 
of ZIKV-binding (cross-reactive, non-neutralizing) IgG. No ZIKV-specific IgG were 
detected from 2 ZIKV/DENV naïve individuals or in 2 DENV seropositive individuals and 
therefore percent IgG transfer could not be calculated for these subjects. Of the 8 DENV 
seropositive subjects with ZIKV-reactive IgG transferred to cord blood, 5 were 
seropositive for multiple DENV serotypes (B1_0016, B1_0024, B1_0026, B1_0033, and 
B1_0034), and 2 were seropositive for only a single DENV serotype (B1_0009 and 
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B1_0011), indicating that ZIKV cross-reactive IgG can be transferred to the fetus in the 
case of primary or secondary DENV exposure history.  
Importantly, we also assessed whether there was efficient transplacental transfer 
of flavivirus neutralizing IgG in ZIKV-infected pregnant individuals. The DENV FRNT-50 
of paired parental and cord blood plasma also were positively correlated, suggesting that 
functional gestational parent IgG were transferred efficiently to the fetus (Figure 2.5).  
To assess whether ZIKV infection during pregnancy impacts transplacental 
transfer of IgG against vaccine antigens, we measured the magnitude of IgG binding 
against a panel of standard vaccine antigens from hepatitis B virus, rubella virus, 
Haemophilus influenzae type B, Corynebacterium diphtheriae, Bordetella pertussis, and 
Clostridium tetani. There were no significant differences in the magnitude of vaccine-
specific IgG in gestational parent plasma and infant cord blood from delivery, in both 
ZIKV-infected and uninfected individuals (Wilcoxon Signed Rank Test, P > 0.05 for all 
vaccine antigens). We observed strong positive correlations in the concentration of 
vaccine-specific IgG between gestational parent plasma and infant cord blood for all 
vaccine antigens tested, indicating efficient placental transfer of vaccine-specific IgG 
levels regardless of ZIKV infection status (Figure 2.6). Based on the protective vaccine-
specific IgG levels established by the WHO, infants born to individuals who had protective 
levels of vaccine-specific IgG and ZIKV infection during pregnancy, received similarly 
protective IgG levels as infants born to ZIKV-naïve individuals297.  
Kinetics of ZIKV IgG binding over the course of pregnancy 
ZIKV infection during pregnancy has been associated with prolonged viremia in 
humans and non-human primates78,298–300, and one individual in our study (B1_0037) 
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exhibited prolonged viremia, with plasma testing positive for ZIKV RNA up to 42 days post 
onset of symptoms (Figure 2.7A). We compared ZIKV neutralization titers between 
patient B1_0037 and the two other ZIKV-infected individuals from the cohort for whom 
sequential serum and urine samples were available for analysis (B1_0014 and B1_0030). 
B1_0030 only tested positive for ZIKV in urine by RT-PCR at the first 2 visits (within 18 
days of symptoms), and B1_0014 tested ZIKV-negative by RT-PCR but was classified as 
ZIKV-infected by serology. These individuals have different flavivirus exposure histories 
as B1_0014 had prior exposure to DENV, and B1_0030 had a primary ZIKV infection. All 
three subjects sustained high levels of ZIKV-neutralizing titers throughout pregnancy.  
Monoclonal antibodies were isolated from B1_0037 after viremia subsided.  
We evaluated the ZIKV-neutralizing activity of 4 antibodies that bound ZIKV by 
ELISA: 1 IgM and 3 IgG.  We determined that two IgG were non-neutralizing, one IgG 
was weakly neutralizing (119-4-D6, FRNT50 = 770ng/ml), and the IgM was potently 
neutralizing (DH1017.IgM, 6.6ng/ml) (Figure 2.7B). IgM are pentavalent (10 Fab 
compared to 2 Fab for IgG) so the potency of DH1017.IgM could result from the 
pentavalent IgM having 5 times as many Fab regions on a single molecule compared to 
IgG, or additional features of the IgM could contribute to avidity for the epitope and thus 
neutralization. To distinguish these possibilities, the Fab sequence of DH1017.IgM was 
expressed on an IgG backbone and we measured ZIKV neutralizing activity. We would 
expect pentavalency to result in DH1017.IgM being 5-fold more potent than DH1017.IgG 
when assessed on a molecular basis. Instead, we found that DH1017.IgG had 40-fold 
less potent neutralization than DH1017.IgM by molarity (Figure 2.7C), suggesting that 
additional properties of the IgM antibody contribute to its potent neutralizing activity. 
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Both human and mouse IgG are stabilized in circulation in mice by FcRn301. 
However, human IgM does not interact with FcRn and is thus less stable in circulation. 
IgM also is not transported into the fetal circulation by FcRn, meaning that ZIKV-
neutralizing IgM potentially could be administered to pregnant individuals to restrict 
parental infection without the risk of passively transferred antibodies conferring enhanced 
DENV infection in infants. To determine whether this potently ZIKV-neutralizing IgM is 
able to protect against infection and disease in mice, we infected Ifnar1-/- mice with ZIKV 
by subcutaneous inoculation in the footpad and treated them intravenously one day 
before and one day after inoculation with either DH1017.IgM or a control IgM that does 
not bind ZIKV but was isolated from the same patient. We found that DH1017.IgM 
protected against ZIKV infection as measured by viremia, as well as mortality (Figure 
2.7D).  
2.5 Discussion 
Transplacental transfer of IgG provides passive immunity to fetuses, which is 
critical to protecting newborns in their first months of life83. However, conditions and 
infections during pregnancy may disrupt IgG transfer via mechanisms including placental 
impairment and inflammatory responses302. Moreover, viral antigenic complexity and 
natural history of infection shapes the IgG populations elicited, which have different 
propensities to be transferred across the placenta by FcRn302,303. Thus, we investigated 
the impact of gestational infection with ZIKV on transplacental IgG transfer in 20 
gestational parent-infant pairs from a prospective cohort in Vitoria, Brazil. We assessed 
transfer of key IgG populations, including ZIKV and DENV binding and neutralizing IgG, 
as well as IgG specific to routine vaccine antigens. 
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For all flavivirus and vaccine antigens tested, we found that gestational parent and 
infant binding IgG levels were highly correlated in both ZIKV-infected and -uninfected 
groups. Also, there were no significant differences in the magnitude of flavivirus-binding 
IgG levels between gestational parents and infants among those parents with gestational 
ZIKV infection. Moreover, DENV neutralization and binding IgG levels were highly 
correlated between gestational parent-infant pairs regardless of gestational ZIKV 
infection. Outliers from these linear trends were shifted such that the magnitude of infant 
IgG neutralization was greater than that of the gestational parent neutralizing titer, 
indicating efficient IgG transfer. This positive association of gestational parent and infant 
IgG levels represents active transfer that is not solely dependent on the magnitude of the 
type-specific IgG in gestational parent plasma. Also, the substantially overlapping ranges 
in antibody levels between gestational parents and infants suggests no biologically 
relevant differences in transplacental transfer of flavivirus binding and neutralizing IgG, or 
of vaccine specific IgG after ZIKV infection in pregnancy. As different viral antigen-specific 
IgG subpopulations may be differentially impaired in placental transfer due to other 
infections and conditions during pregnancy266,304, we tested IgG transfer of non-flavivirus 
antibodies that are specific to diverse vaccine antigens. IgG elicited by routine pediatric 
and boosted parental vaccines were also transferred efficiently despite gestational ZIKV 
infection. Cumulatively, these data indicate no evidence of impairment in the 
transplacental IgG transfer at the time of birth after gestational ZIKV infection, as 
compared to individuals with fever and rash during pregnancy without ZIKV infection.  
Our study corroborates recent findings demonstrating efficient transfer of 
neutralizing antibodies against ZIKV, DENV3, and DENV4 in pairs of gestational parents 
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and infants from the Northeast of Brazil in 2016269. Specifically, Castanha et al found that 
newborns with the outcome of microcephaly, some of whom were exposed to ZIKV in 
utero, had no evidence of impaired transfer of neutralizing antibodies at birth as compared 
to controls without microcephaly269. Our work complements the finding from that case-
control study through a prospective cohort design, in which we identified individuals with 
ZIKV infection during pregnancy and followed up until birth to quantify impact on 
transplacental IgG transfer. This prospective design adds a temporality to the association 
between ZIKV infection and neutralizing IgG transfer observed earlier269. Moreover, our 
study represents a geographically distinct site in Southeast Brazil, with lower ZIKV 
prevalence. Another recently published study with 3 serologically confirmed gestational 
ZIKV infections found similar levels of ZIKV-binding IgG in both gestational parent and 
cord blood, corroborating our findings that transplacental IgG transfer is preserved in the 
context of gestational ZIKV infection305. Altogether, this work strengthens the body of 
evidence indicating that transplacental IgG transfer is sustained during ZIKV infection in 
pregnancy.  
This study further aimed to complement existing evidence of placental pathology 
caused by ZIKV infection, and determine whether this could have a role in the 
transplacental transfer of humoral immunity. Previous observations of impaired 
transplacental IgG transfer in the setting of gestational HIV and malaria infection generally 
have been noted in conjunction with identifiable placental pathology110,302. Although we 
did not detect ZIKV RNA in placentas from our study, another study identified ZIKV RNA 
in 54% of placentas from 44 ZIKV-infected individuals268. We found that 5 of 11 ZIKV-
infected individuals in our cohort had chronic placental villitis, higher than the 5-15% 
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expected for term placentas306. Notably, this pathology is similar to that described in 
placental infection with CMV, rubella virus, or Toxoplasma gondii296. In contrast, no villitis 
was observed in the 8 placentas assessed from ZIKV-uninfected gestational parents, 
suggesting that the observed villitis may result from ZIKV infection in pregnancy. To 
assess the impact of ZIKV-associated placental pathology on IgG transfer, subgroups of 
ZIKV-infected subjects with noted placental pathology would have to be compared to a 
ZIKV-infected subgroup without placental pathology. However, our limited sample size of 
8 ZIKV-infected individuals with paired infant samples precludes formal comparison.  
We found that despite disruption of placental architecture in nearly half the ZIKV-
infected individuals in the cohort, transplacental transfer of flavivirus-binding and -
neutralizing IgG was sustained. This finding is relevant to future studies of vaccine-elicited 
fetal protection against ZIKV, as animal studies demonstrate neutralizing antibodies as 
correlates of protection against ZIKV infection307,308. Transfer of flavivirus-neutralizing 
antibody is relevant because neutralization titers are known to correlate with vaccine 
protection against other flaviviruses, including Japanese encephalitis virus, yellow fever 
virus, and tick-borne encephalitis virus309–312.  
In ZIKV-infected individuals with serial plasma collection during their pregnancies, 
ZIKV-specific IgG levels were sustained throughout gestation after peak response within 
3 weeks of symptoms. These kinetics suggest that transfer of flavivirus-specific IgG to the 
fetus should readily occur throughout the 2nd and 3rd trimester of pregnancy following 
ZIKV infection. While it is possible that  ZIKV infection during pregnancy could result in a 
transient disruption of transplacental IgG transfer that is restored by the time of birth, our 
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goal was to evaluate levels of IgG present at delivery as these transferred IgG have the 
potential to modulate protection or disease risk in infants59,83–86,313,314.  
There are several implications of the findings in our study. Efficient transfer of 
ZIKV-neutralizing IgG could transfer protective humoral immunity despite infection during 
pregnancy. Notably, transfer of protective levels of vaccine-specific IgG to boost passive 
immunity in the newborn is a key goal of immunizing gestational parents 315 and our 
findings suggest that ZIKV infection during pregnancy does not impair this protective 
mechanism. With candidate ZIKV vaccines or therapeutics, this may be one mode of 
conferring passive immunity to the fetus and reducing the burden of congenital and 
neonatal ZIKV infection. However, transfer of cross-reactive non-neutralizing DENV-
binding antibodies may pose a risk as antibodies from primary DENV infection can 
enhance secondary DENV infection, leading to more severe disease in infants as parental 
antibody titers wane53,257.  
Limitations of this study include the small sample size of only 20 gestational parent-
infant pairs with delivery samples available, but two other studies of small cohorts similarly 
found that antibody transfer is maintained in the wake of ZIKV infection during pregnancy 
in the gestational parent269,305. Though each study suffers independently from small 
sample size, together they suggest that antibody transfer is maintained despite 
gestational ZIKV infection even in the presence of placental inflammation. 
Another limitation of our study is the challenge of determining whether subjects 
were truly exposed to ZIKV during pregnancy, as symptoms could have resulted from 
other infections and/or ZIKV infection could have occurred prior to pregnancy. Since 
viremia may have subsided by the time of study enrollment, we developed an algorithm 
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to define ZIKV infection serologically, even in the context of cross-reactive antibodies from 
prior DENV infection. This algorithm and ZIKV case definition were based on the rational 
assumption that ZIKV seropositivity resulted from a recent infection (i.e. during 
pregnancy) due to the timing of our study relative to the introduction of ZIKV into Brazil. 
This assumption will not apply in future studies, since the high force of infection during 
the 2015-2017 outbreak and the potential for subsequent endemic transmission mean 
many individuals will already be ZIKV seropositive before pregnancy. Moreover, this study 
reflects the findings in a symptomatic pregnancy cohort, whereas the majority of ZIKV 
infections are asymptomatic316–318. 
ZIKV infection during pregnancy can result in prolonged viremia , as was the case 
for one of the individuals in this study who displayed persistent viremia for 1 month while 
most ZIKV infections are typically viremic for <2 weeks. To our knowledge, no ZIKV-
neutralizing IgM have been previously isolated and no flavivirus-neutralizing IgM have 
been isolated. It may have been easier to do so in the case of DH1017.IgM because of 
the prolonged viremia in this individual. The binding epitope of this IgM is still under 
investigation by Tulika Singh, in collaboration with Dr. Richard Kuhn, Purdue University; 
defining this epitope and comparing it to epitopes targeted by other potently neutralizing 
ZIKV MAbs may provide insight into the development of neutralizing IgG that make up 
the convalescent antibody response to natural ZIKV infection. This particular monoclonal 
antibody also could be the basis of prophylactic protection against ZIKV infection in 
pregnant individuals, as it also appears to protect mice from severe disease. One concern 
of other ZIKV monoclonal antibody therapies for pregnant individuals is that DENV 
disease in infants could be made more severe by ZIKV antibodies acquired via 
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transplacental antibody transfer60. IgG can be engineered with Fc modifications to prevent 
or decrease FcRn-mediated binding transfer either by mutating residues at the interface 
of the FcRn-IgG interface or by introducing steric inhibition of the interaction319,320. 
DH1017.IgM would however not require such modification as IgM are natively not 
transported across the placenta. Additionally, it will not bind the Fcγ receptors implicated 
in ADE of DENV. Perhaps most importantly, DH1017.IgM displays particularly potent 
ZIKV neutralization, more than would be expected from a simple 5-fold increase of the 
DH1017.IgG. 
In summary, this study demonstrates efficient transplacental transfer of IgG 
specific to diverse flaviviruses and routine vaccine antigens following ZIKV infection 
during pregnancy in a unique prospective cohort of gestational parent-infant pairs from 
the Latin American ZIKV outbreak. Transplacental transfer of ZIKV-specific IgG in 
pregnancy may contribute to protection of the fetus from congenital Zika syndrome and 
the infant from ZIKV infection. However, efficiently transferred IgG might mediate adverse 
effects in infants including increased risk of severe DENV in infancy, as well as potentially 
mediating FcRn-dependent transfer of ZIKV immune complexes into the fetal 
compartment. The relationship between efficient parental IgG transfer and reduced or 
enhanced congenital infection or disease remains to be further elucidated. Delineating 
ZIKV-specific IgG levels and function that favor fetal and neonatal protection will be key 
for guiding a strategic timeline for pediatric vaccine boosts, timing of vaccine 
administration during pregnancy, and dosing of antibody therapies targeted for 
pregnancy. Longitudinal investigations of neonatal immunity, in the context of 
transplacental transfer of flavivirus antibodies will be a valuable area of investigation to 
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define serological mediators of risk or protection for infants. Given the uncertain benefits 
or risks of efficient transfer of flavivirus IgG, ZIKV and DENV vaccine strategies will need 











Figure 2.1 ZIKV strains are serologically distinct from DENV by neutralization assay 
A. Immune sera from North Carolina individuals with travel history to DENV-endemic 
regions was tested for neutralization of ZIKV strain MR766 via serial dilution. Samples 
were previously classified as either a single DENV infection with 1 of 4 serotypes, multiple 
DENV infections (secondary DENV), ZIKV exposure alone, or both ZIKV and DENV 
exposure history. B. Neutralization curves for 4 Zika virus strains, including African 
lineage (MR766 and DAKAR41525) and Asian lineage (H/PF/2013 and PRVABC59) 
strains. C. Table of FRNT-50 values from B. ND=not determinable because the 








Figure 2.2 Algorithm used to categorize flavivirus exposure history according to 
ZIKV and DENV FRNT-50 titers. Gestational parent plasma were tested by FRNT-50 
against 5 viruses (ZIKV and 4 DENV serotypes) and FRNT-50 titers used to infer 
flavivirus exposure history. All samples were anti-flavivirus IgM negative, reducing the 










Figure 2.3 Histology of the placenta from a ZIKV-infected pregnant individual. 
Placental tissue from subject B1_0004 was stained with hematoxylin and eosin. 
Lymphocytes and macrophages are present in the chorionic villi (A-100X, B-400X). The 




































Figure 2.4 Efficient transplacental transfer of flavivirus-specific IgG. Plasma 
antibody binding to ZIKV, DENV1, DENV2, DENV3, and DENV4 was measured via a 
virion capture ELISA using serial dilutions of gestational parent plasma and infant cord 
blood collected at delivery. The dilution at 50% of maximal binding (ED50) was calculated 
and the infant ED50 was assessed as a percentage of the parental ED50 to yield percent 
transfer. Dotted line indicates 100% transfer and the solid line indicates the median. No 
significant differences in percent transfer were found in comparing ZIKV-infected and 
uninfected individuals for the all viruses tested by Exact Wilcoxon Rank Sum Test; 













Figure 2.5 Gestational ZIKV infection does not disrupt transplacental transfer of 
DENV neutralizing IgG. Kendall Tau correlation of focus neutralization reduction titer-50 
(FRNT-50) for gestational parent plasma and infant cord blood, separated by parental 
ZIKV serostatus. All correlations are P<0.05, except ZIKV-infected gestational parent 
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Figure 2.6 Gestational parent and infant vaccine-elicited IgG levels are highly 
correlated regardless of gestational parent ZIKV infection status. IgG response to 
vaccine antigens in infant cord blood plasma and gestational parent plasma collected at 
delivery were measured via a binding antibody multiplex assay. Concentrations of 
vaccine-elicited IgG responses were calculated from reference sera standards as 
International Units (IU)/mL or µg/mL. ZIKV-infected (n=8) and uninfected (n=12) subjects 
are indicated in red and black respectively, and dotted lines denote WHO established 
protective IgG levels. Kendall Tau correlations were performed for each ZIKV infection 











Figure 2.7 A ZIKV-targeting IgM monoclonal antibody isolated from a pregnant 
individual protects against ZIKV infection in mice. A. ZIKV focus reduction 
neutralization titers from serial samples during gestation for each of three individuals 
(Filled symbols = time points when ZIKV viremia was detected by RT-PCR, Red = blood 
draw from which PBMCs were isolated from which to generate monoclonal antibodies). 
B. ZIKV neutralization curves of 4 monoclonal antibodies isolated from B1_0037. C. ZIKV 
neutralization curves and FRNT50 values for DH1017 on the native IgM and cloned IgG 
backbone. D. and E. Five week old Ifnar1-/- mice were then infected with 1000 FFU of 
ZIKV strain H/PF/2013 by footpad inoculation on day 0. On day -1 and 1, they were 
administered intravenously 100µg of either DH1017.IgM or a control IgM, 119-4-G11. 
Viral RNA was extracted from serum collected every 2 days in and ZIKV RNA measured 









ZIKV PCR+ (n=9) ZIKV PCR- (n=13) 
ZIKV PCR ND 
(n=4) Total (n=26) 
  9/26 13/26 4/26 26/26 
Proportion of individuals symptomatic in each gestational trimester 
First  3/9 3/13 2/4 8/26 
Second 4/9 7/13 2/4 13/26 
Third 2/9 3/13 0/4 5/26 
Percent with symptoms       
Rash 8/9 13/13 3/4 24/26 
Arthralgia 5/9 4/13 3/4 12/26 
Fever 3/9 5/13 3/4 11/26 
Conjunctivitis 4/9 4/13 3/4 11/26 
Myalgia 5/9 4/13 1/4 10/26 
Headache 4/9 7/13 3/4 14/26 
Retro-orbital pain 2/9 4/13 2/4 8/26 
Lymphadenopathy 1/9 1/13 0/4 2/26 
Table 2.1 Symptomatology of patient cohort. Symptoms were collected by survey at 
the time of enrollment as well as a blood draw for ZIKV RT-PCR. ZIKV=Zika virus, RT-






















Table 2.2 Clinical results of prenatal screening for TORCH infections. Clinical test 
results for Toxoplasma antibodies, rubella IgG, and venereal disease research 
laboratory (VDRL) test for syphilis from pregnant individuals. Also included is whether 
cytomegalovirus (CMV) viremia was present in cord blood collected at delivery. 
Proportion of individuals with positive test results are reported as the numerator, 















0/8 0/9 3/20 
Toxoplasma 
IgG 
3/8 7/10 2/20 
Rubella IgG 6/7 9/9 4/20 
Cord blood 
CMV viremia 
0/7 1/11 2/20 























B1_0001 38 73 1 4 + N/A 
B1_0002 29 97 2 4 + N/A 
B1_0003 28 66 1 7 - N/A 
B1_0004 21 94 2 4 + N/A 
B1_0005 26 31 1 3 + N/A 
B1_0006 22 68 1 217 - N/A 
B1_0007 29 78 1 210 - N/A 
B1_0008 22 95 2 2 + N/A 
B1_0009 31 40 1 4 + N/A 
B1_0011 26 232 3 5 - - 
B1_0014 19 27 1 4 - - 
B1_0015 34 117 2 8 - N/A 
B1_0016 35 99 2 90 - N/A 
B1_0019 28 157 2 15 - N/A 
B1_0021 30 75 1 3 - N/A 
B1_0023 18 167 2 7 - N/A 
B1_0024 30 136 2 36 - N/A 
B1_0026 31 224 3 12 - N/A 
B1_0027 23 179 2 14 - - 
B1_0030 20 203 3 2 + N/A 
B1_0031 39 257 3 4 + N/A 
B1_0033 19 174 2 9 - - 
B1_0034 28 173 2 2 - N/A 
B1_0035 32 176 2 3 - - 
B1_0037 19 159 2 4 + N/A 
B1_0039 29 225 3 4 - N/A 
 
Table 2.3 Timeline of infection. Age of each pregnant individual, trimester of symptom 








Classification Days since symptoms 
FRNT50 ZIKV RT-
PCR  
ZIKV DENV1 DENV2 DENV3 DENV4 
B1_0015 Naïve  NA <25 <25 <25 <25 <25 - 
B1_0019 Naïve  75 <25 <25 <25 <25 <25 - 
B1_0021 Naïve 213 <25 <25 <25 <25 <25 - 
B1_0039 Naïve 35 <25 <25 <25 <25 <25 - 
B1_0008 Primary ZIKV 184 3918 126 209 251 106 + 
B1_0030 Primary ZIKV 77 1399 <25 <25 <25 <25 + 
B1_0001 DENV+ZIKV 193 10858 898 597 1270 491 + 
B1_0002 DENV+ZIKV 173 14959 1524 666 5571 502 + 
B1_0004 DENV+ZIKV 164 2533 1348 1818 3047 537 + 
B1_0005 DENV+ZIKV 217 5213 1379 4218 2270 359 + 
B1_0007 DENV+ZIKV 208 5503 1371 2511 822 353 - 
B1_0014 DENV+ZIKV 210 3095 354 1625 930 388 - 
B1_0031a DENV+ZIKV 94 1610 2723 2492 10521 1510 + 
B1_0027 DENV+ZIKV 91 654 1079 1711 3730 513 - 
B1_0037 DENV+ZIKV 117 11764 2141 8019 22873 4029 + 
B1_0009b Primary DENV2 240 <25 205 1887 238 240 + 
B1_0035 Primary DENV2 114 107 68 1201 106 68 - 
B1_0011 Primary DENV3 39 <25 374 640 3172 362 - 
B1_0006 Primary DENV3 211 <25 89 308 4735 82 - 
B1_0003 Secondary DENV 217 <25 797 122 304 72 - 
B1_0016 Secondary DENV 172 <25 232 3222 2051 74 - 
B1_0023 Secondary DENV 92 <25 4417 1693 380 <25 - 
B1_0024 Secondary DENV 146 <25 1395 1362 505 299 - 
B1_0026 Secondary DENV 46 <25 2848 1876 635 292 - 
B1_0033 Secondary DENV 91 220 3123 1996 843 197 - 
B1_0034 Secondary DENV 111 <25 193 568 939 76 - 
a FRNT-50 based on maternal plasma 3 months after delivery 
b Likely false positive ZIKV RT-PCR result 
 
Table 2.4 ZIKV and DENV serotype specific humoral immune profile. Serologic 
classification of maternal flavivirus infection history was determined by focus reduction 
neutralization titer 50% (FRNT-50) against ZIKV and DENV in plasma taken at delivery. 
ZIKV RT-PCR performed on serum collected at enrollment. NA=Not Available 
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Subject  Placental Histology Findings 
ZIKV infected 
B1_0001  Villitis was not observed 
B1_0002  Villitis was not observed 
B1_0004  Villitis was observed in two foci, consistent 
with mild, low grade, chronic villitis of 
unknown etiology, occurrence of stromal 
fibrosis and occurrence of necrosis 
B1_0005  Villitis was not observed 
B1_0007  Villitis was not observed 
B1_0008  Villitis was not observed 
B1_0031  Villitis was not observed 
B1_0027  Villitis was observed in two foci, consistent 
with mild, low grade, chronic villitis of 
unknown etiology 
B1_0030  Villitis was observed in one focus, consistent 
with mild, low grade, chronic villitis of 
unknown etiology 
B1_0014  Villitis was observed in two foci, consistent 
with mild, low grade, chronic villitis of 
unknown etiology and occurrence of stromal 
fibrosis 
B1_0037  Villitis was observed in one focus, consistent 
with mild, low grade, chronic villitis of 
unknown etiology 
ZIKV uninfected 
B1_0003  Villitis was not observed 
B1_0009  Villitis was not observed 
B1_0033  Villitis was not observed 
B1_0026  Villitis was not observed 
B1_0023  Villitis was not observed 
B1_0016  Villitis was not observed 
B1_0034  Villitis was not observed 
B1_0015  Villitis was not observed 
Table 2.5 Placental Pathology: In 5 of 11 ZIKV-infected cases, focal villitis was 





The unique ability of Zika virus (ZIKV) to be spread via vector-borne as well as 
sexual transmission raised many questions about cellular tropism, as well as innate and 
adaptive immune control. The skin has been studied as the inoculation site for 
flaviviruses but the vagina contains many unique immune mechanisms which had not 
previously been investigated with regards to flaviviruses. Mucins and antibody 
complexes provide an additional barrier before viruses can access the vaginal 
epithelium and interferon-λ (IFN-λ) can restrict viral infections at epithelial barriers. ZIKV 
generally replicates poorly in wild-type mice due to an inability to antagonize interferon 
signaling in mice, so ZIKV pathogenesis studies typically employ Ifnar1-/- mice or 
otherwise ablate type I interferon (IFN-αβ) signaling. Yet in this study, we confirmed 
previous reports that ZIKV can infect wild-type mice intravaginally even when these 
mice are not susceptible to systemic infection. In contrast to a previous report, we did 
not find that IFN-λ signaling restricts intravaginal ZIKV infection in contrast with a 
previous report. Rather, progesterone appears to control whether ZIKV infection can 
proceed in either wild-type or IFN-αβ-signaling deficient mice. The mechanism by which 
progesterone makes mice susceptible does not appear to be due to a DMPA-induced 
                                            
2The work presented in this chapter will be published as Lopez CA, Dulson SJ, Carbaugh DL, Lazear HM. 
Progesterone regulates Zika virus infection in the vagina. Manuscript in progress.  
I performed all mouse infections, neutralization assays, virus purification, and growth curves. 
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thinned weaker epithelium being more susceptible to a tear resulting from the instillation 
because vaginal abrasion did not render mice susceptible to vaginal infection in the 
absence of progesterone treatment. We considered that progesterone might modulate 
the vaginal immune milieu, but found that exogenous progesterone did not diminish 
IFN-stimulated gene expression or change leukocyte populations in vaginal tissue. Our 
data suggest that progesterone regulates antiviral immunity in the vagina, though the 
mechanism remains to be determined.  
3.2 Introduction 
The unprecedented size of the 2015-2016 Zika virus pandemic in the Americas 
(millions of people infected8–10) revealed new disease manifestations and transmission 
mechanisms11. This ZIKV outbreak was associated with cases of microcephaly and a 
constellation of other congenital defects now established to be caused by congenital 
ZIKV infection11–13. This outbreak also confirmed the ability of ZIKV to spread via sexual 
transmission in addition to mosquito-borne transmission, although ZIKV sexual 
transmission had been reported previously following infection in Africa16–19. Flaviviruses 
are transmitted to humans by arthropod vectors (mosquitoes and ticks), and ZIKV is the 
first example of a flavivirus that spreads between humans via sexual transmission 321–
323. The best evidence that ZIKV is sexually transmitted is travel-associated cases in the 
United States, Europe, and elsewhere, wherein women without mosquito exposure 
became infected after their male partners returned from ZIKV-endemic areas15,17,114,323–
327. Of ZIKV cases acquired within the continental United States since 2016, close to 
20% were acquired through presumed sexual transmission328. Of 5,483 travel-
associated ZIKV cases in the US since 2015, 52 resulted in confirmed transmission to a 
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sexual partner. Though this represents only 1% of ZIKV cases in the US with forward 
sexual transmission, this is likely an underestimate of the rate at which ZIKV-infected 
men transmit to their partners, since ~80% of ZIKV infections are asymptomatic317 and 
screening was focused on symptomatic women with travel-related exposure. The first 
report of ZIKV sexual transmission pre-dates the 2015-2016 epidemic and resulted from 
ZIKV infection in Africa323, suggesting that sexual transmission is a general property of 
ZIKV, not a new trait coincident with its emergence in the Americas.  The ability of ZIKV 
to spread via sexual transmission in addition to mosquito-borne transmission expands 
the geographic range over which ZIKV transmission can occur, could change the 
epidemiology of ZIKV even in areas with mosquito-borne transmission, and has the 
potential to produce distinct pathologic outcomes if congenital infection occurs via an 
ascending route rather than a hematogenous transplacental route. Thus, it is important 
to understand the antiviral mechanisms that ZIKV may encounter in the vagina that are 
distinct from antiviral mechanisms present at the skin following mosquito inoculation.  
The mucosal environment of the vagina contains specialized mechanisms not 
typically encountered by mosquito-borne viruses. For example, antibodies at mucosal 
surfaces can access additional protective mechanisms not available to antibodies in the 
circulation. In mice, prior ZIKV infection protects against vaginal ZIKV infection and is 
largely antibody-mediated despite low levels of ZIKV IgG in vaginal mucus159. This 
protective effect of low IgG concentrations in the vagina is in contrast to mosquito-borne 
transmission, where protection requires virus neutralization42. A single IgG molecule has 
transient interactions with mucins, but multiple IgG molecules bound to the same 
particle (e.g. a virus) can immobilize that particle through the combined affinity of 
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multiple IgG-mucin interactions148–151. The antibody response after DENV infection 
includes antibodies that bind to ZIKV virions (cross-reactive) but do not render those 
virions non-infectious (non-neutralizing)250,251,256. If ZIKV is trapped by antibody-mucin 
complexes, cross-reactive antibodies could provide additional protection against sexual 
transmission of ZIKV in DENV endemic regions. 
ZIKV replication is restricted by the IFN response in mice because ZIKV is 
unable to antagonize mouse STAT2 and STING141,329. Thus, mouse models of ZIKV 
pathogenesis typically employ mice lacking IFN-αβ signaling, usually through genetic 
loss of the IFN-αβ receptor (Ifnar1-/-) alone or in combination with the IFN-γ 
receptor128,134, or by treatment of wild-type (WT) mice with an IFNAR1-blocking 
monoclonal antibody (MAR1-5A3)129. Treatment with MAR1-5A3 results in increased 
ZIKV viremia (with higher antibody doses producing higher viremia) but does not elicit 
the weight loss and lethality observed in Ifnar1-/- mice134, implying that partial loss of 
IFNAR1 activity may allow sufficient ZIKV replication to study pathogenic phenotypes.  
Antiviral signaling in the vagina includes a role for type III interferons (IFN-λ) in 
addition to the type I and II IFNs involved in systemic antiviral responses160. IFN-λ 
signals through a different receptor on the cell surface but activates many of the same 
signaling pathways and transcriptional responses as IFN-αβ. Despite the similarities, 
IFN-λ can also perform unique restriction of viruses independent of other IFN signaling 
pathways161. IFN-λ restricts HSV infection in the vagina162 and may also play a role in 
restricting ZIKV infection in the vagina of ovariectomized mice in a model where the 
hormonal state is tightly controlled by hormone replacement129.  
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The ZIKV mouse vaginal infection model includes pre-treating mice with 
progesterone and is based on the infection models for other sexually transmitted 
pathogens such as herpes simplex virus (HSV) and Chlamydia muridarum177,178. The 
mechanism by which progesterone makes mice susceptible to ZIKV remains unknown, 
but it has been hypothesized to be due to a combination of increased inflammatory 
infiltrate that may be susceptible to ZIKV infection, thinned epithelium, or deficiencies in 
antiviral signaling due to decreased expression of antiviral sensing genes128,183.  
Many studies have evaluated ZIKV vaginal infection in mouse models, but these 
typically have used mice lacking IFN-αβ signaling, the same models that are used to 
study ZIKV pathogenesis by footpad and other inoculation routes because these mice 
are permissive to disseminated infection including fetal pathology with either footpad or 
intravaginal inoculation99,128,129,134,135,330. Here we first use that model to study whether 
there is a role for mucus-IgG trapping of virions. However, we then move into a WT 
mouse infection model under the assumption that they are less susceptible to ZIKV 
infection. We show that although WT mice largely are resistant to ZIKV infection via 
footpad inoculation, vaginal inoculation results in productive local ZIKV replication 
equivalent to that found in Ifnar1-/- mice. In contrast to previous work by others, we did 
not find that IFN-λ signaling restricts intravaginal ZIKV infection. We further show that 
permissiveness to vaginal ZIKV replication is determined by hormonal status, even in 
mice lacking IFN-αβ signaling, suggesting that hormone variation can regulate 
susceptibility to viral infection in the vagina independently from the IFN-dependent 
restriction of systemic ZIKV infection. Additionally, we show that pregnancy, another 
high progesterone state, is also sufficient for vaginal ZIKV infection in wild-type mice. 
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The mechanism by which progesterone makes mice susceptible to vaginal ZIKV 
infection does not appear to be due to thinned or weaker epithelium as vaginal abrasion 
did not render mice susceptible to vaginal infection in the absence of progesterone 
treatment. We considered that progesterone might modulate the vaginal immune milieu, 
but found that exogenous progesterone did not diminish IFN-stimulated gene 
expression or change leukocyte populations in vaginal tissue. Our data suggest that 
progesterone regulates antiviral immunity in the vagina, though the mechanism remains 
to be determined.  
3.3 Materials and methods 
Cells and viruses  
Vero cells were maintained in Dulbecco’s modified Eagle Media (DMEM) 
supplemented with 5% heat-inactivated fetal bovine serum (FBS) and L-glutamine at 
37°C with 5% CO2. ZIKV strain H/PF/2013 was obtained from the U.S. Centers for 
Disease Control and Prevention331. Spondweni virus (SPOV) strain SA AR 94 and 
Usutu virus (USUV) strain SA AR 1776 were obtained from the World Reference Center 
for Emerging Viruses and Arboviruses332,333.  DENV3 WHO reference strain (CH54389) 
was provided by Dr. Aravinda de Silva (UNC)334,335, and RUBV strain M33 was obtained 
from Dr. Michael Rossmann (Purdue University)336. Liver homogenate from HAV 
infected mice was provided by Dr. Stanley Lemon (UNC)337. 
Flavivirus and RUBV stocks were grown in Vero cells in DMEM supplemented 
with 2% FBS and HEPES and titered by focus forming assay (FFA)338. Virus was 
serially diluted in duplicate in DMEM supplemented with 2% FBS and HEPES and 
added to confluent Vero cells in 96 well plates for 1-3 hours at 37°C with 5% CO2 before 
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being overlaid with 1% methylcellulose in minimum essential Eagle medium (MEM) 
supplemented with 2% FBS, HEPES, and penicillin and streptomycin. Cells were then 
incubated for 40-45 hours at 37°C with 5% CO2 before being fixed with 2% 
paraformaldehyde for 1 hour at room temperature. Cells were then rinsed with 0.05% 
Tween-20 in PBS and then incubated for 2 hours at room temperature or overnight at 
4°C with 1µg/mL mE60, which recognizes the conserved flavivirus fusion loop284. in a 
saponin buffer to permeabilize the cells. Following another rinse, cells were then 
incubated in a 1:5000 dilution of a horseradish peroxidase (HRP) conjugated goat anti-
mouse IgG (Sigma). Titration of RUBV was performed similarly but with a polyclonal 
anti-RUBV goat IgG at 1:4000 (LifeSpan BioSciences, LS-C103273) and a HRP 
conjugated anti-goat IgG at 1:5000(Sigma). Color was then developed for 30 minutes in 
TrueBlue substrate (KPL). Foci were quantified with a CTL Immunospot Analyzer.  
UV-inactivated ZIKV was generated by placing 200µL ZIKV H/PF/2013 at 1 x 106 
FFU/mL in a petri dish and exposing to UV light at 0.9999 J/cm2 for 10 minutes at room 
temperature. Mock-inactivated ZIKV was generated similarly, but placed under light in a 
biosafety cabinet instead of UV-light. Inactivation was confirmed by amplifying UV- and 
mock-treated virus stocks on Vero cells for 4 days and then titering by FFA. 
Fluorophore-labeled ZIKV and imaging in mucus 
ZIKV was grown in C6/36 cells at 28°C in DMEM supplemented with 2%FBS and 
HEPES at an MOI of 0.01. Supernatant was collected at day 4, 6, and 8, stored at 4°C 
and replaced with fresh media. Virus supernatant was then concentrated using 100 kD 
Centricon Plus-70 filters (UFC710008), then centrifuged through a continuous 15-60% 
sucrose gradient for 17 hours at 17,000 x g at 4°C. The most concentrated fractions 
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were determined by measuring the quantity of viral genomes by qRT-PCR and 
infectious particles by FFA. Purified virus was then labeled with a succinimidyl ester 
dye, Alexa Fluor 555 (Cat# A20009) according to manufacturer instructions. 
Vaginal mucus collection 
Vaginal mucus was collected under the approval of University of North Carolina 
(UNC) Institutional Review Board (IRB) #10-1817. Local North Carolina volunteers self-
collected vaginal mucus by inserting a disposable menstrual cup for 60 seconds and 
placing the cup into a 50mL conical which was then centrifuged at 230 x g. Mucus was 
then collected and stored at 4°C and used within 3 days. All samples were confirmed to 
have pH <4.5 and were negative for bacterial vaginosis by microscopic inspection.  
Imaging of ZIKV particles in vaginal mucus 
ZIKV was mixed with 5 µg/ml of monoclonal IgG and incubated for 15 minutes at 
room temperature. Particles were visualized with an inverted epifluorescence 
microscope (AxioObserver D1, Zeiss). Particle paths were tracked with MetaMorph 
software. At least 150 particles were tracked for each vaginal mucus sample at each 
antibody condition.  
Antibodies used in mucus experiments 
HSV-targeting mouse monoclonal antibodies MC14 and DL11 were obtained 
courtesy of Dr. Gary Cohen (University of Pennsylvania)339,340. ZIKV-targeting mouse 
monoclonal antibodies were obtained courtesy of Dr. Michael Diamond (Washington 
University in St. Louis)34 and produced from hybridomas by the UNC Protein Expression 
Core Facility.  
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Mouse infections 
All mouse husbandry and experiments were performed with approval of the 
University of North Carolina at Chapel Hill’s Institutional Animal Care and Use 
Committee. All mice used were on a C57BL/6J background, except BALB/cJ mice used 
for HSV infections. Ifnar1-/- mice were originally obtained from Dr. Jason Whitmire 
(UNC) and were bred on site. WT mice were either bred on site or purchased from 
Jackson Laboratory. BALB/cJ mice were also purchased form Jackson Laboratory 
Unless otherwise indicated, 5-10 week old female mice were subcutaneously injected 
with 2mg depot medroxyprogesterone acetate (DMPA)128,182,183 obtained via the UNC 
pharmacy, diluted in 100µl of PBS. 5 days later, mice were challenged with 1000 FFU of 
virus in 5µL via vaginal instillation or 50µl via footpad. Vaginal abrasion was 
accomplished by scrubbing the vagina of isoflurane-anesthetized mice with an 
interdental brush341 (GUM Proxabrush Go-Betweens tight-sized cleaners) a total of 10 
combined full rotations and insertions. For experiments where mice were vaginally 
infected with virus-antibody complexes, we premixed equal volumes of 1000 FFU ZIKV 
or HSV and IgG at a concentration of 5µg/mL for 1 hour at 37°C. The virus-antibody 
mixture was then inoculated by vaginal instillation in 20µL. 
Vaginal washes were collected in a total of 100 µl by twice pipetting 50 µl of PBS 
with 0.4x protease inhibitor (cOmplete, EDTA-free) into the vagina and collecting 
immediately, every 2 days after infection. Blood was collected into serum blood 
collection tubes (BD) days 2 and 6 after infection via submandibular bleed with a 5 mm 
Goldenrod lancet or via terminal bleed cardiac puncture. Serum was separated at 8000 
rpm for 5 minutes. Tissues were collected from mice after euthanasia by isoflurane 
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overdose, cardiac bleed, and perfusion with 5-10 mL PBS. Tissues, vaginal washes, 
and serum were stored at -80°C until RNA extraction.  
For experiments where we investigated the responsiveness of tissues to  
immunogenic RNA, we first treated 5-6 week old mice with either PBS or 2mg DMPA 
subcutaneously. Four days later, mice were treated with 50 µg polyinosinic:polycytidylic 
acid (pI:C), low molecular weight (Invivogen, TLRL-Picw) either intraperitoneally in 
100µL or intravaginally in 20µL.  
Generation of IFN-λ receptor knock out mice 
Mice with a floxed allele of the IFN-λ receptor (Ifnlr1f/f) were received from Dr. 
Herbert Virgin (Washington University in St. Louis). Ifnlr1f/f mice were crossed with mice 
expressing Cre recombinase under the β-actin promoter (Jackson Labs # 019099, 
obtained from Dr. Jenny Ting, UNC) to generate Ifnlr1f/f mice with ubiquitous Cre 
recombinase expression from a hemizygous Cre allele (resulting in Ifnlr1-/-). These mice 
were then crossed with Ifnlr1f/f mice to generate litters in which 50% of pups lacked IFN-
λ signaling (Ifnlr1-/-, Cre+) and 50% retained it (Ifnrl1+/-, Cre-). Females were used for 
vaginal infection experiments which were conducted in a blinded manner, as genotyping 
for Cre and Ifnlr1 was performed after the experiment was completed.  
Mice were genotyped from DNA extracted from tails. The actin-Cre allele was 
amplified with forward primer Cre-3 (GCGGTCTGGCAGTAAAAACTATC) and reverse 
primer Cre-4 (GTGAAACAGCATTGCTGTCACTT) at 94°C for 3 minutes followed by 35 
cycles of 94°C for 15 seconds, 62°C for 20 seconds, and 68°C for 1 minute. The floxed 
Ifnlr-/- allele was amplified with forward primer Ifnlr1F1 
(AGGGAAGCCAAGGGGATGGC) and two reverse primers Ifnlr1R1 
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(AGTGCCTGCTGAGGACCAGGA) and Ifnlr1R3 (GGCTCTGGACCTACGCGCTG) at 
94°C for 3 minutes followed by 35 cycles of 94°C for 15 seconds, 60°C for 20 seconds, 
and 68°C for 1 minute. Amplicons were then run on 2% agarose gels. 
Quantifying RNA and neutralization titers  
RNA from vaginal washes and serum was extracted with the Qiagen viral RNA 
minikit. RNA from tissues was extracted with the Qiagen RNeasy minikit after 
homogenization in a MagNA Lyser instrument (Roche Life Science) with zirconia beads 
(BioSpec) in 600µl PBS followed by incubation at room temperature for 10 minutes in an 
equal volume RLT buffer for lysis. Viral genomes were quantified by Taqman one-step 
qRT-PCR on a CFX96 Touch real-time PCR detection system (BioRad) and were 
reported on a log10 scale measured against standard curves from either a ZIKV A-
plasmid as previously described291, or from 400 bp gBlock double stranded DNA 
fragments (Integrated DNA Technologies, IDT). ZIKV RNA was quantified as previously 
published278,291 and other viruses with the gBlocks and primers in Tables 3.1 and 3.2. 
 RNA from tissues was quantified after extraction as above with the primers in 
Table 3.2. To quantitate the expression of Ifit1 in each tissue, the difference in Ct values 
between Ifit1 and ActB as a housekeeping gene was calculated for each tissue sample 
and plotted as -ΔCt.  
Neutralization assays were performed by FFA as previously described342. Virus 
was first diluted to 50 focus-forming units per well and incubated with serial dilutions of 
heat-inactivated serum from mice (inactivated at 56°C for 30 minutes) in DMEM 
supplemented with 2% FBS and HEPES. The virus-antibody mixtures were then 
incubated at 37°C in 5% CO2 for 1 hour before being added to Vero cells and proceeding 
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with the FFA protocol as above. Neutralization data was quantified by determining the 
number of foci at a given dilution of naïve mouse serum and determining the percentage 
of foci present at that same dilution of sera from infected animals. Neutralization curves 
were generated in Graphpad Prism with the log (inhibitor) vs response curve function with 
variable slope, setting the lower and upper bounds of relative infectious particles to 0% 
and 100%. A valid FRNT-50 curve required an R² >0.75, hill slope absolute value >0.5, 
and had to reach at least 50% relative infection within the range of the serum dilutions in 
the assay.  
In situ hybridization 
Tissues were collected from euthanized mice after exsanguination cardiac 
puncture, perfusion with 10 mL of PBS followed by 10 mL of 10% neutral buffered 
formalin (NBF). Tissues were then stored overnight in 1mL of 10% NBF at 4°C before 
being transferred to PBS at 4°C for longer term storage. Tissues were then sliced at a 
5µm mm thickness by the University of North Carolina at Chapel Hill Histology 
Research Core and stained with a ZIKV-specific RNA probe (ACDBio, 
#467871)118,120,129,343 and a hematoxylin counter-stain. Positive and negative staining 
controls for RNA-specific staining were confirmed with probes against peptidyl-prolyl 
cis-isomerase B (PPIB, #321651) and dihydrodicipicolinate reductase (dapB, #320751) 
as recommended by the manufacturer. 
Flow cytometry 
Spleens and iliac lymph nodes (iLNs) were mechanically dissociated and red 
blood cells were lysed using RBC lysis buffer (0.84% NH4Cl in PBS). Cells were 
pelleted by centrifugation and resuspended in media (RPMI 1640  with 1% FBS). Cells 
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were filtered through a 70-μm cell strainer to make a single-cell suspension. Cells were 
resuspended in media at a concentration of 1x107 cells/mL for flow cytometric analysis. 
Murine vaginal tissue was excised, minced with scissors, and digested in HBSS 
(with Ca2+ and Mg2+) containing 1mg/mL collagenase I and 0.05mg/mL DNAse I for 
60min at 37°C in a shaking incubator. After incubation, 1mL FBS was added to stop 
digestion and cells were serially filtered through a 70- and 40-μm cell strainer and 
washed with HBSS (with Ca2+ and Mg2+). Cells were centrifuged and resuspended in 
media at a concentration of 1x107 cells/mL for flow cytometry analysis. 
Isolated cells were stained in PBS with 1% FBS for 20–30 min in the dark on ice. 
Fc receptor blockade was performed with anti-CD16/32 mAb prior to surface staining. 
Dead cells were excluded from analysis using Zombie UV (BioLegend). Cells were fixed 
in 2% paraformaldehyde, and samples were acquired using an LSRII flow cytometer 
(UNC Flow Cytometry Core Facility) using fluorescence-minus-one compensation 
controls. Data were analyzed using FlowJo software (Tree Star). 
The following markers were used to identify immune cell populations: T cells 
(CD45+CD3e+), B cells (CD45+CD19+), NK cells (CD45+NK1.1+), dendritic cells 
(CD45+CD11c+), neutrophils (CD45+CD11b+Ly6G+), and monocytes 
(CD45+CD11b+Ly6G-Ly6C+/-).  
The following antibodies were used in this study: anti-CD16/32 (clone 2.4G2; BD 
Biosciences), anti-CD45 AF700 (clone 30-F11; BioLegend), anti-CD3e APC-Fire/750 
(clone 17A2; BioLegend), anti-CD19 PE-Cy7 (clone 6D5; BioLegend), anti-NK1.1 PE 
(clone PK136; BioLegend), anti-CD11b APC (clone M1/70; BioLegend), anti-CD11c 
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BV650 (clone N418; BioLegend), anti-Ly6G FITC (clone IA8; BioLegend), and anti-Ly6C 
BV605 (clone HK1.4; BioLegend).  
Statistical analysis 
Statistical tests were performed with Graphpad Prism 9.0. Tests used include 
unpaired multiple Mann-Whitney analyses with the Holm-Šídák method and two-way 
ANOVA with matched time points where multiple time points of the same mouse were 
taken, the Geisser-Greenhouse correction for lack of sphericity, comparison to control 
cell means, and the Dunnett correction for multiple comparisons.  
3.4 Results 
Evaluating whether ZIKV may be immobilized in human vaginal mucus in an IgG-
dependent fashion 
To evaluate if ZIKV could be immobilized in vaginal mucus in the presence of 
binding IgG, we first generated fluorescently-labelled ZIKV virions to use in microscopy 
assays. We purified ZIKV by density gradient and then covalently labelled with a 
fluorescent dye. Individual labeled particles were then tracked via inverted 
epifluorescence microscopy in the presence of monoclonal human antibodies in fresh 
vaginal mucus from human donors. Mucus donors were North Carolina residents and 
thus unlikely to have antibodies against ZIKV or closely related flaviviruses, although we 
did not ascertain the flavivirus immune status of the donors. We observed that in the 
presence of either of two cross-reactive DENV antibodies (1M7 and C8), ZIKV particles 
diffused through vaginal mucus at a slower speed than in the presence of a non-binding 
monoclonal antibody (VRC01 which targets HIV) or no exogenous antibodies (Figure 
3.1A). The percentage of fast-moving particles was determined, defining fast-moving as 
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capable of diffusing through a 50µm mucus layer in 30 minutes (Figure 3.1B), the same 
expected thickness of mucus overlying the vaginal epithelium in humans344. However, 
subsequent experiments did not yield similar results and it was too challenging to 
produce labeled virions without aggregation so we did not continue to pursue this 
avenue of investigation. 
Non-neutralizing IgG do not protect against intravaginal ZIKV infection 
Microscopy studies suggested human vaginal mucus could lead to decreased 
transmissibility of ZIKV in the presence of ZIKV-binding IgG (e.g. from a prior DENV 
infection). To test this in an animal model, we challenged Ifnar1-/- mice intravaginally 
with ZIKV premixed with either a neutralizing or non-neutralizing monoclonal mouse IgG  
that bind ZIKV (Figure 3.2A-B). Five days prior to infection, mice were treated with 
depot medroxyprogesterone acetate (DMPA) by subcutaneous injection, as is standard 
in infection models for HSV, Chlamydia, and ZIKV128,177,178. We observed no difference 
in either the number of mice that become infected or in viral load in vaginal washes or 
serum in mice treated with the non-neutralizing monoclonal antibody, but a ZIKV-
neutralizing antibody did provide protection from infection. These results were in 
contrast to prior studies showing that a non-neutralizing antibody provided protection 
from HSV vaginal infection in BALB/c mice153. To test this effect in our hands, we 
infected BALB/c mice intravaginally with HSV-1 that had been pre-incubated with a 
potently neutralizing monoclonal antibody (DL11) or a non-neutralizing one (MC14) and 
found that the non-neutralizing antibody provided minimal protection from HSV-1 
infection (Figure 3.2C). The difference between our observations and other studies 
could be due to the HSV-1 strain used, the specific monoclonal antibodies tested, or 
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other factors. We next considered whether the lack of protection we observed with non-
neutralizing antibodies was because the Ifnar1-/- mice we used for ZIKV studies were 
highly susceptible, limiting our ability to observe modest protection phenotypes. To 
assess whether a protective effect for non-neutralizing antibodies in the vagina might be 
more apparent in WT mice, we first determined the infectious dose needed to infect WT 
mice by vaginal inoculation, with the expectation that WT mice would be less 
susceptible to ZIKV infection (Figure 3.2D)134. Unexpectedly, we found robust ZIKV 
replication in the vaginas of mice inoculated with 1000 FFU (the standard infectious 
dose used in studies with Ifnar1-/- mice) and no significant increase in viral loads when 
mice were inoculated with 10,000 FFU. We then tested whether non-neutralizing 
antibodies could protect against intravaginal ZIKV inoculation in WT mice by premixing 
ZIKV with potently neutralizing (ZV-67) or non-neutralizing (4G2) mouse monoclonal 
antibodies, but still found that non-neutralizing antibodies did not protect against vaginal 
ZIKV infection (Figure 3.2E).  
ZIKV productively replicates in the vaginas of WT mice 
Given the important role for IFN-αβ signaling in controlling ZIKV infection in mice, 
we were surprised to observe robust ZIKV replication in the vaginas of WT mice. To 
investigate this further, we pre-treated WT and Ifnar1-/- mice with DMPA then 5 days 
later infected with 1000 FFU of ZIKV via intravaginal instillation. We observed similar 
ZIKV replication kinetics and RNA burden in the vagina of WT compared to Ifnar1-/- mice 
from 2 days post-infection (dpi) through 8 dpi (Figure 3.3A). Although WT mice 
supported ZIKV replication in the vagina, they did not support systemic infection as 
viremia was detected only in Ifnar1-/- mice (Figure 3.3B). Likewise, Ifnar1-/- mice 
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supported ascending infection into the upper female reproductive tract (uterus, ovary, 
and oviduct) whereas ZIKV infection in WT mice was restricted to the lower female 
reproductive tract (vagina and cervix) (Figure 3.3C). These results show that ZIKV can 
replicate in the vagina of WT mice, but that IFN-αβ signaling restricts systemic spread.  
We found that the amount of ZIKV RNA in vaginal washes increased over time, 
consistent with productive viral replication, but we were not able to detect infectious 
ZIKV by FFA directly from vaginal washes collected in PBS. When we instead collected 
vaginal washes in DMEM with 2% FBS on days 2, 4, 6, and 8 and allowed the virus to 
amplify on Vero cells prior to titering, we did detect infectious ZIKV (Figure 3.4A) 
altogether consistent with low but productive ZIKV replication in the vagina. These 
observations also are consistent with our experience that ZIKV infectivity is not stable in 
unsupplemented PBS (Figure 3.4B). 
To confirm that the ZIKV RNA we detected in vaginal washes represented 
replicating virus, we inoculated mice with either infectious ZIKV or UV-inactivated virus 
and measured viral RNA in vaginal washes collected 2 through 8 dpi. No ZIKV RNA 
was detected in vaginal washes from mice inoculated with UV-inactivated virus, further 
supporting that the viral RNA detected in vaginal washes results from productive 
infection (Figure 3.5A). Additionally, we collected serum from mice 14 days after ZIKV 
inoculation and measured neutralizing activity against ZIKV by focus reduction 
neutralization assay (Figure 3.5B). In one experiment, 2 of 3 mice inoculated with 
infectious ZIKV seroconverted but in a second experiment, 0 of 3 mice seroconverted. 
The mouse that did not seroconvert in the first experiment was the same mouse which 
had a ZIKV load in the vagina 1 hour post-infection, but did not have detectable ZIKV in 
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vaginal washes at any other timepoint, potentially indicating that productive replication 
did not occur in this mouse because ZIKV remained in the vaginal lumen. No mice 
challenged with UV–inactivated ZIKV had detectable FRNT-50 titers. Altogether, the 
neutralization assay data indicate that vaginal administration of inactivated ZIKV antigen 
is not sufficient to induce an antibody response, and that even productive ZIKV 
replication in the vagina did not consistently induce seroconversion by 14 days post-
infection. 
It has previously been reported that IFN-λ restricts ZIKV infection in the vagina, in 
the context of IFN-αβ signaling inhibited by administration of an IFNAR1-blocking 
antibody129. To test whether IFN-λ controls vaginal ZIKV infection in mice with intact 
IFN-αβ signaling, we treated Ifnlr1+/- and Ifnlr1-/- mice with DMPA and infected with 1000 
FFU of ZIKV by intravaginal instillation. We measured viral loads in vaginal washes by 
qRT-PCR and found no significant difference between Ifnlr1+/- and Ifnlr1-/- mice, 
suggesting that IFN-λ signaling does not restrict ZIKV replication in the vagina in this 
model system (Figure 3.6). 
A high-progesterone state is required for vaginal ZIKV infection. 
Since we found that WT mice were susceptible to ZIKV infection via an 
intravaginal but not a subcutaneous inoculation route, we considered whether DMPA 
treatment rendered WT mice broadly susceptible to ZIKV infection. We treated WT mice 
with DMPA or PBS, then 5 days later infected with 1000 FFU of ZIKV via an intravaginal 
or subcutaneous route and measured viral RNA in vaginal wash and in serum by qRT-
PCR. As expected, DMPA treatment increased the permissiveness of WT mice to 
intravaginal infection: ZIKV RNA was detected in the vaginal wash from 10 of 10 DMPA-
85 
treated mice compared to only 5 of 10 PBS-treated mice (Figure 3.7A-B). DMPA-treated 
mice also sustained higher viral loads in the vagina than PBS-treated mice with RNA 
titers (DMPA-treated mice sustained as high as 100-fold higher viral loads in the vagina 
than PBS-treated mice). Consistent with previous experiments, DMPA-treated WT mice 
supported ZIKV replication in the vagina but no ZIKV RNA was detected in the serum 
following intravaginal inoculation. Furthermore, no ZIKV RNA was detected in the serum 
of mice inoculated by footpad regardless of DMPA treatment indicating that DMPA 
treatment was not sufficient to render WT mice broadly susceptible to ZIKV infection. 
Surprisingly, although Ifnar1-/- mice are considered to be highly susceptible to ZIKV 
infection, vaginal infection and systemic dissemination with ZIKV was dependent on 
DMPA treatment in these mice as well (Figure 3.7 C-D).  
To determine if other high progesterone states also confer susceptibility to ZIKV 
replication in the vagina, we evaluated vaginal ZIKV infection in pregnant mice (without 
DMPA treatment). We mated 7-to-10-week old WT dams with WT sires and inoculated 
7 days post-mating (roughly one-third of gestation) intravaginally with 1000 FFU of 
ZIKV. We collected vaginal washes and serum and measured ZIKV RNA by qRT-PCR 
to assess local replication in the vagina and systemic spread, and all mice were 
harvested at 8 dpi to assess congenital infection. Pregnant mice supported vaginal ZIKV 
replication (4 of 5 pregnant mice) but ZIKV RNA was not detected in the vaginal lavage 
of non-pregnant mice (0 of 12 mice) (Figure 3.8A). Consistent with our observations in 
DMPA treated WT mice, pregnant WT mice did not support systemic ZIKV spread, as 
ZIKV RNA was not detected in serum, even in the context of robust replication in the 
vagina (Figure 3.8B). Additionally, ZIKV RNA was detected in only 1 of the 40 placentas 
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and none of the corresponding fetuses (Figure 3.8C), consistent with the lack of 
ascending or systemic infection we observed after vaginal ZIKV inoculation in DMPA-
treated WT mice. Altogether these data suggest that a high progesterone state (DMPA 
treatment or pregnancy) is required for vaginal permissiveness to ZIKV infection.  
A physically compromised vaginal epithelial barrier is not sufficient to render WT 
mice susceptible to ZIKV infection.  
The vaginal epithelium of mice in diestrus, the high progesterone state of the 
estrus cycle, is thinned and lacks the keratinized layer protecting the vaginal epithelium 
during the estrus phase128,172,345. Since DMPA induces a diestrus-like state, it has been 
hypothesized that a thinned epithelial barrier is more easily targeted by ZIKV, explaining 
the susceptibility of WT mice to vaginal ZIKV infection following DMPA treatment. To 
test whether an impaired epithelial barrier could overcome the requirement for DMPA 
treatment, we abraded the vaginal epithelium with an interdental brush prior to 
intravaginal inoculation with 1000 FFU of ZIKV and measured ZIKV RNA in vaginal 
washes by qRT-PCR. However, vaginal infection was only detected in mice that were 
treated with DMPA, regardless of vaginal abrasion (Figure 3.9A) suggesting that 
physical access to epithelial cells is not sufficient for productive ZIKV infection in the 
vagina. Vaginal abrasion also did not facilitate ZIKV dissemination as ZIKV RNA was 
not detected in serum even of abraded mice (Figure 3.9B). In DMPA-treated mice, 
abrasion did not result in higher viral loads in vaginal washes, altogether suggesting that 
compromised epithelial barrier integrity is not the mechanism by which DMPA treatment 
promotes vaginal ZIKV infection.   
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The vagina is permissive to replication of diverse IFN-αβ-restricted flaviviruses. 
ZIKV is unique among flaviviruses in its ability to spread among humans via both 
vector-borne (mosquito) and vector-independent (sexual) transmission routes. To 
assess whether this reflects an unusual vaginal tropism of ZIKV, we evaluated vaginal 
infection with 3 additional flaviviruses, Spondweni virus (SPOV), Usutu virus (USUV), 
and dengue virus (DENV). SPOV and DENV are closely related with ZIKV, wheras 
USUV is more distant. These flaviviruses were selected because, like ZIKV, they 
replicate poorly in WT mice. WT mice were treated with DMPA 5 days prior to 
intravaginal inoculation with 1000 FFU of ZIKV, SPOV, USUV, or DENV3 and viral RNA 
was measured by qRT-PCR from vaginal washes on days 2, 4, 6, 8 (Figure 3.10). Viral 
RNA was detected in vaginal washes after ZIKV, USUV, and SPOV infection, 
suggesting that these viruses could replicate in the vagina of WT mice and at levels 
similar to ZIKV. In contrast, DENV3 RNA was not detected. To test whether the vagina 
is permissive to other RNA viruses that generally are restricted by innate antiviral 
responses in WT mice337, we inoculated WT mice intravaginally with 1000 FFU of 
rubella virus (Matonaviridae) or 5µl of mouse liver homogenate containing 5 x 108 
genome equivalents of hepatitis A virus (Picornaviridae), but detected no viral RNA in 
vaginal washes at any of the time points evaluated through 8 days post-inoculation 
(data not shown). Altogether, these data show that vaginal infection is not a unique 
property of ZIKV among flaviviruses. Rather, in WT mice the vagina is more permissive 
to flavivirus replication compared to other inoculation sites, but does not allow 
unrestricted replication of all RNA viruses. 
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DMPA treatment does not inhibit ISG expression  
It has previously been reported that the mouse lower female reproductive tract 
(LFRT, vagina and cervix) expresses lower levels of viral RNA pattern recognition 
receptors (PRRs) compared to the upper female reproductive tract (UFRT, uterus, 
ovaries, and ovarian ducts) regardless of DMPA treatment183. Therefore this treatment 
does not explain why DMPA is required for ZIKV infection in the vagina or whether 
these differences in PRR expression lead to functional differences in downstream IFN-
stimulated gene (ISG) expression. To determine for ourselves whether the previously 
observed decreased expression of viral RNA pattern recognition receptors (PRRs) after 
DMPA treatment leads to decreased ISG expression, we treated mice with pI:C 
intravaginally or intraperitoneally with or without DMPA pre-treatment and measured 
expression of Ifit1, an ISG that is highly induced by viral infection and PRR signaling. 
We did not observe any DMPA-dependent change in Ifit1 induction in the spleen or 
LFRT following intravaginal or intraperitoneal pI:C stimulation (Figure 3.11A-B). In the 
UFRT, DMPA increased Ifit1 expression at baseline and induction in response to 
intravaginal pI:C treatment (Figure 3.11C). Additionally, the expression of IFIT1 does 
not appear to be different between the LFRT, spleen, and UFRT under any condition 
(Figure 3.11 A-C) Altogether, these results suggest that DMPA treatment does not 
promote ZIKV vaginal infection by broadly inhibiting ISG expression in the vagina.  
ZIKV infection in the vagina is localized to the epithelium 
To better define the location of infected cells in the vagina, we harvested vaginal 
tissue 2 to 10 dpi and detected ZIKV RNA using in situ hybridization (RNAscope) 
(Figure 3.12). ZIKV positive cells were rare and sporadically distributed in the vagina, 
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but they tended to be clusters of adjacent epithelial cells located along the vaginal 
lumen although there was some positive staining in the parenchyma as well. 0 of 3 mice 
contained positive staining at 2 dpi, 1 of 2 at 4 dpi, 3 of 3 at 6 dpi, 2 of 2 at 8 dpi, and 0 
of 5 at 10 dpi. The largest clusters of infected cells were detected at 6 dpi. There was no 
tendency for infected cells to be nearer to the cervix or nearer to the vaginal opening. 
No sections from infected mice exhibited leukocyte infiltrate into to the vaginal tissue 
relative to uninfected DMPA treated mice. Altogether, these results indicate that ZIKV 
infection in the vagina primarily targets epithelial cells (rather than the leukocytes that 
are the main targets of ZIKV systemic infection) and that infected cells are not 
associated with a pronounced immune infiltrate. 
DMPA does not induce changes in the number of leukocytes in the LFRT or 
secondary lymphoid tissue 
We next determined if the numbers of specific leukocyte populations were 
changed after DMPA treatment or ZIKV infection in either the LFRT, spleen, or iLN. We 
treated WT mice with DMPA or PBS and 5 days later some DMPA-treated mice were 
also infected with ZIKV. At 6 days post-infection, LFRT tissue, iLN, and spleen were 
collected and leukocytes isolated for immunophenotyping. We found that ZIKV infection 
caused an increase in the number of B cells in secondary lymphoid tissues relative to 
mice only treated with DMPA (Fig. 3.13A-B). In the LFRT, greater numbers of dendritic 
cells were observed after ZIKV infection (Fig. 3.13C). However, DMPA treatment alone 
caused no change in T cells, NK cells, B cells, dendritic cells, eosinophils, monocytes, 
or neutrophils in any of these tissues (Fig. 3.13A-C). In the spleen and iLN, These 
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results suggest that DMPA-induced susceptibility to vaginal ZIKV infection does not 
result from a dramatic change in the immune milieu of the vagina.  
Altogether, our data show that although WT mice generally do not support ZIKV 
replication, the vagina is an unique site that supports the replication of ZIKV (and other 
flaviviruses) in WT mice and the immune system is able to clear the localized infection. 
The ability of ZIKV to replicate in the vagina of WT mice requires a high progesterone 
state (pregnancy or DMPA treatment) but the mechanism by which progesterone 
promotes ZIKV vaginal infection remains unclear. 
3.5 Discussion 
The emergence of ZIKV in Latin America in 2015-2016 not only revealed new 
severe disease manifestations but also confirmed a prior report of sexual transmission 
as an additional mode of transmission for ZIKV, making ZIKV the first arbovirus 
demonstrated to spread between humans through sexual contact. Most ZIKV cases in 
the Americas are presumed to be due to transmission via mosquitoes, but sexual 
transmission may still represent a significant transmission mechanism. It is difficult to 
estimate to the extent to which sexual transmission contributes to ZIKV transmission in 
areas with frequent and concurrent mosquito-borne transmission. However, a 
retrospective study of ZIKV serology in Brazil found that cohabitants with a ZIKV 
seropositive sexual partner had a 4-fold greater risk of also being seropositive 
compared to cohabitating with a ZIKV-seronegative partner. Cohabitating with a ZIKV-
seropositive non-sexual partner was associated with less than a 2-fold greater risk, 
supporting a role for sexual transmission even in areas with mosquito-borne 
transmission346. Sexual transmission may thus have contributed to the high force of 
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infection of ZIKV in this epidemic even in Latin America where any ZIKV cases were 
presumed to have been acquired via mosquito.  
IgG-mucin complexes can immobilize sexually transmitted viruses in vaginal 
mucus and may contribute to protection153,347. The significant degree of cross-reactivity 
between DENV and ZIKV led us to hypothesize that mechanisms of immune protection 
dependent on antibody binding and the presence of mucins in the vagina may also 
apply to protection from ZIKV infection. We found preliminary evidence that ZIKV may 
be immobilized by antibody-mucin interactions in human vaginal mucus, though these 
experiments were technically challenging and subject to effects of mucus donor 
variability. Our initial observations were not reproduced in subsequent experiments, 
which may be attributable to technical considerations, but these studies were not 
pursued further. Despite the potential interaction of antibodies and mucins in vitro, our 
data in a mouse vaginal infection model did not support a role for non-neutralizing 
antibodies in protection against vaginal ZIKV infection.  
ZIKV infection is often modeled in Ifnar1-/- mice to produce consistent 
disseminated infection, including via vaginal inoculation. Though others have also 
observed productive ZIKV vaginal infection in WT mice135,159,182,183, these studies did not 
specifically investigate the mechanisms that make the vagina an unusually susceptible 
site for ZIKV replication in WT mice. We found that ZIKV replicates efficiently in the 
vagina of WT mice as measured by viral genomes detectable in both the vaginal 
washes and cervix. Additionally, we did not find increased ZIKV replication in the vagina 
in mice lacking the IFN-λ receptor, contrasting with a prior study reporting that IFN-λ 
plays a protective role against ZIKV infection in the female reproductive tract129. This 
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previous study involved treating mice with an antibody blocking IFNAR1, so the effect 
observed for IFN-λ may only be in the context of deficient IFN-αβ signaling though we 
also found that ZIKV replicated equally well in the vaginas of WT and Ifnar1-/- mice. This 
other study also was done in the context of ovariectomized mice which then need to be 
supplemented with sex hormones, though our study was performed in mice with 
exogenous progesterone in addition to sex hormones natively present in the mice. 
Another key difference is that the strain used in our study (H/PF/2013) is different from 
the mouse-adapted ZIKV strain used in the previous study (DAKAR 41525)348. Further 
investigation is needed to clarify to what extent IFN-λ can control viral infections in the 
vagina.  
Sexual transmission among humans appears to be an unusual property of ZIKV 
compared to other flaviviruses, although the incidence and epidemiology of most 
flaviviruses precludes certainty about the absence of sexual transmission. The most 
prevalent human flavivirus infection is DENV, with an estimated >100 million infections 
worldwide annually349. The best evidence for ZIKV sexual transmission derives from 
travel-associated cases in areas without endemic mosquito-borne transmission. By 
comparison, there have only been 2 recently described cases of sexual transmission of 
DENV despite tens of thousands of travel-associated DENV cases over the years350,351. 
Our data in mice suggest that the vagina may be a permissive site for flavivirus 
replication, as we observed replication of other flaviviruses (SPOV and USUV) that do 
not generally replicate in WT mice. Since human infections with those flaviviruses are 
rare it is not known whether they may share with ZIKV the ability to spread through 
sexual transmission. Sexual transmission would also require these viruses to have 
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tropism for the male reproductive tract as well as secretion into semen. It may be that 
there exists a subset of flaviviruses capable of sexual transmission that have not yet 
been observed because of the lack of a large enough outbreak for that to be detected. 
Interestingly, SPOV has been observed in semen in mice and also can cause fetal 
pathology in mice, though it has reduced tropism for the male reproductive tract 
compared to ZIKV139,140. A high progesterone state confers susceptibility to vaginal 
ZIKV infection in both WT and Ifnar1-/- mice, including high progesterone induced by 
pregnancy. It is not clear to what extent sex hormones modulate susceptibility to ZIKV 
infection in humans, though there is precedent for increased HIV susceptibility following 
progesterone treatment174–176. Likewise, progesterone increases susceptibility to HSV in 
mice170,177. The fact that pregnancy in mice causes susceptibility to vaginal ZIKV 
infection could be important as in humans, some of the most severe ZIKV outcomes 
result from congenital defects and congenital transmission after either mosquito or 
sexual transmission. It also is not known whether infection of the fetus via an ascending 
route via the uterus could be mechanistically different from hematogenous transmission 
across the placenta such that fetal outcomes may be different.  
The mechanism by which progesterone confers susceptibility to vaginal ZIKV 
infection in this WT mouse model remains unclear. Vaginal abrasion was not sufficient 
to permit vaginal ZIKV infection, so a thinned epithelial barrier caused by DMPA 
treatment is unlikely to be the primary mechanism by which the vagina becomes 
susceptible to ZIKV infection. Likewise, we did not observe a significant change in the 
relative proportions of immune cells in vaginal tissue after DMPA treatment though it is 
possible that there may be more subtle changes in subpopulations or activation 
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phenotypes. The lack of immune cell infiltrate after DMPA treatment is consistent with 
prior observations that sex hormones alone do not modulate large changes in immune 
cell profiles within the LFRT in the absence of infection171. 
The increase in dendritic cells in the vagina and concurrent increase in T and B 
cells that we observed within the spleen and draining lymph node is consistent with a 
mechanism where dendritic cells are recruited to the vagina and then migrate to these 
secondary lymphoid organs to facilitate adaptive immune priming352, despite the lack of 
systemic infection or viremia in this ZIKV vaginal infection model. The antibody 
response induced by systemic ZIKV infection can provide potent protection from vaginal 
ZIKV infection159, though it remains to be seen whether the local vaginal ZIKV infection 
induced in WT mice can also provide protective immunity to a subsequent intravaginal 
challenge. In one experiment we found that WT mice infected intravaginally with ZIKV 
developed ZIKV-neutralizing serum titers but in a subsequent vaginal infection 
experiment, no neutralizing activity was induced. Neutralizing antibody titers may be 
more consistently detected at later time points than the 14 dpi timepoint we evaluated, 
as this is a mild viral infection that does not appear to cause significant inflammation by 
histology and does not spread to other tissues or systemically.  
It has also been hypothesized that WT mice are susceptible to intravaginal ZIKV 
infection because the vagina may be deficient in expression of viral RNA PRRs at 
baseline and after DMPA treatment183. Yet this would not explain why progesterone is 
required for ZIKV infection. Accordingly, we did not find that DMPA negatively affects 
expression of Ifit1, an antiviral ISG, either in the vagina or the spleen in response to 
pI:C. We also did not find a difference in the relative expression of Ifit1 between the 
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LFRT, UFRT, and spleen. Subtle differences in expression of viral RNA sensors 
themselves are not necessarily predictive of whether or not cells can mount an antiviral 
response as measured by expression of downstream ISGs. Further, our results suggest 
that DMPA does not induce a global downregulation of ISG expression that would 
promote viral infection.  
 We found that most ZIKV-infected cells in the vagina were epithelial cells and 
that there did not appear to be substantial immune infiltrate present near sites of 
infection. The observation that epithelial cells appear to be infected has been reported 
before in mice with impaired immune signaling129. The fact that epithelial cells appear to 
be the cells primarily infected in vaginal tissue is surprising because ZIKV has particular 
tropism for myeloid cells in systemic infection21,22. 
 Progesterone controls ZIKV susceptibility in the vagina to an even greater extent 
than IFN signaling. Though there aren’t significant changes in overall leukocyte 
populations or antiviral signaling, DMPA might be inducing small changes in either the 
quality or quantity of the leukocyte population that were not observed by flow cytometry. 
Likewise, there may remain a subtle change in antiviral signaling pathways in 
subpopulations of epithelial cells that are not actively proliferating that are not 














































Figure 3.1 ZIKV diffuses slower through human vaginal mucus in the presence of 
ZIKV-binding IgG. Purified ZIKV was covalently labeled with a succinimidyl ester dye 
and imaged via inverted epifluorescence microscopy. Each dot represents the mean of 
150-900 tracked individual particle paths within 1 human vaginal mucus sample.  A. The 
diffusivity of labeled ZIKV particles. B. The percentage of particles within a vaginal 













Figure 3.2 Non-neutralizing IgG do not confer protection against intravaginal 
infection in vivo. A-B. 7 week old Ifnar1-/- mice were pre-treated with 2 mg DMPA then 
infected via vaginal instillation with 100 FFU ZIKV with either a potently neutralizing 
(ZV67) or weakly neutralizing (4G2) antibody at 5µg/mL. Viral RNA was measured by 
qRT-PCR in vaginal washes (A) or serum (B). C. 7 week old BALBc/J mice were pre-
treated with 2 mg DMPA then infected via vaginal instillation with 1000 FFU HSV-1 
premixed for 1 hour with either a potently neutralizing (DL11) or weakly neutralizing 
(MC14) mouse monoclonal antibody. HSV-1 was titered by focus-forming assay directly 
from vaginal washes. D-E. 6-7 week old WT mice were pre-treated with 2 mg DMPA 
then infected via vaginal instillation with 1000 FFU or 10000 FFU of ZIKV. Viral RNA 
was measured by qRT-PCR in vaginal washes. In E., 1000 FFU of ZIKV was premixed 
for 1 hour with potently neutralizing (ZV-67) or weakly neutralizing (4G2) mouse 






Figure 3.3 WT mice are susceptible to ZIKV vaginal infection. 6 to 7 week-old WT 
and Ifnar1-/- mice were pre-treated with 2 mg DMPA and inoculated with 1000 FFU of 
ZIKV by intravaginal instillation 5 days later. Viral RNA extracted from vaginal washes 
(A), serum (B), or tissues (C) was measured by qRT-PCR. Data are combined from 2 
independent experiments. WT and Ifnar1-/- groups were compared by Mann-Whitney 























Figure 3.4 ZIKV in vaginal washes is infectious but not stable in unsupplemented 
PBS. A. 6 week old WT mice pre-treated with 2 mg DMPA were inoculated with 1000 
FFU of ZIKV by intravaginal instillation. Vaginal washes were collected 2 to 8 dpi in 
DMEM supplemented with 2% FBS and HEPES. Vaginal washes were inoculated onto 
Vero cells and virus amplified for 2 days. Vaginal washes and Vero cell supernatants 
were titered by focus assay. B. 1 x 105 FFU/mL ZIKV was diluted in either PBS or PBS 
supplemented with 2% FBS and incubated for 2 hours on ice for the indicated times 

















Figure 3.5 ZIKV productively replicates in the vagina of WT mice. 6 to 7 week-old 
WT mice were pre-treated with 2 mg DMPA and inoculated intravaginally with 1000 FFU 
of either mock inactivated ZIKV or UV-inactivated ZIKV. A. Viral RNA was extracted 
from vaginal washes and measured by qRT-PCR. Data are combined from 2 
independent experiments. Sera were collected 14dpi and ZIKV neutralization measured 
















































Figure 3.6 IFN-λ does not restrict ZIKV infection in the vagina. 5-6 week old Ifnlr1+/- 
or Ifnlr1-/- mice were pre-treated with 2 mg DMPA and inoculated with 1000 FFU of ZIKV 
by intravaginal instillation 5 days later. Viral RNA was measured by qRT-PCR from 
vaginal washes. Statistical analysis was performed via Mann-Whitney with adjustment 






Figure 3.7 DMPA does not sensitize WT mice to ZIKV infection by footpad 
inoculation. 6 week old WT (A-B) or Ifnar1-/- mice (C-D) were pre-treated with either 
PBS or 2 mg DMPA then infected with 1000 FFU of ZIKV by intravaginal instillation (A- 
D) or subcutaneous footpad inoculation (A-B). Viral RNA was measured by qRT-PCR in 
vaginal washes (A, C) or serum (B, D). Data in A-B are combined from 2 independent 
experiments, C-D represent a single experiment. Statistical analysis in A-B was 
performed via two-way ANOVA with multiple group correction and time point matching, 
compared to DMPA only as the control group (ns, not significant p>0.05; *, p<0.05; **, 
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Figure 3.8 Pregnant WT mice are susceptible to intravaginal ZIKV infection. 7-10 
week old WT dams were mated with WT sires and inoculated 7 days afterwards 
intravaginally with 1000 FFU of ZIKV. Viral RNA was measured by qRT-PCR in vaginal 
washes (A), serum (B), or fetal tissues harvested at day 8 post-infection (C). Data are 
combined from 2 independent experiments. Statistical analysis was performed via 











Figure 3.9 Vaginal abrasion is not sufficient to sensitize WT mice to ZIKV 
intravaginal infection. 6 week old WT mice were treated with 2mg DMPA 5 days prior 
to challenge, or vaginally abraded with an interdental brush immediately prior to 
challenge with 1000 FFU ZIKV via vaginal instillation. Viral RNA was measured by qRT-
PCR in vaginal washes (A) or serum (B). Data are combined from 2 independent 
experiments. Statistical analysis was performed via two-way ANOVA with multiple group 
correction, comparing to DMPA only as the control group (ns, not significant p>0.05; *, 




































Figure 3.10 Flaviviruses other than ZIKV are able to replicate in the vagina of WT 
mice. 6 week old WT mice pre-treated with 2mg DMPA were challenged with 1000 FFU 
of ZIKV, Usutu virus (USUV), Spondweni virus (SPOV), or dengue virus (DENV3). Viral 

















Figure 3.11 DMPA does not downregulate Ifit1 induction in the vagina. 5-6 week 
old WT mice were either treated with PBS (mock) or DMPA. Four days later, mice were 
treated with PBS intravaginally (i.vag) or pI:C i.vag. or intraperitoneally (i.p.) and tissues 
were harvested the next day. Expression of Ifit1 was measured from RNA extracted 
from spleen (A), LFRT (B), or UFRT (C) and quantitated as the difference in Ct values 
between actin in mock-treated mice receiving PBS i.vag and Ifit1. Bars represent the 
geometric mean, and statistical analysis was performed via Mann-Whitney with 
adjustment for multiple comparisons (*, P<0.5) between mock and DMPA treatment 



















Figure 3.12 ZIKV primarily infects epithelial cells in the vagina. 5-6 week old WT 
mice were treated with 2mg DMPA and 5 days later, infected with 1000 FFU ZIKV 
intravaginally. Mice were then harvested 2 to 10 dpi and fixed tissues were H&E stained 
or labeled for ZIKV RNA via in situ hybridization. Pictured is a single field at 20x (scale 
bars indicate 0.1mm) from 1 mouse from each harvest time point, including an 











Figure 3.13. Progesterone alone does not alter the immune profile of the lower 
female reproductive tract. 5-6 week old mice were either left untreated, treated with 
2mg of DMPA, or treated with DMPA and 5 days later infected with 1000 FFU of ZIKV 
intravaginally. All mice were harvested 6 days after ZIKV infection (11 days after DMPA 
treatment). Cells were isolated from spleens, lymph node, and lower female 
reproductive tract, and analyzed by flow cytometry. Total cell counts were calculated for 
T cells, NK cells, B cells, DCs, eosinophils, monocytes, and neutrophils for spleen (A), 
iLN (B) or LFRT (C). All cells were gated first for live-dead staining and then for CD45 
expression. Statistical analysis was performed via two-way ANOVA with multiple group 





infected groups to mice that were only DMPA treated. Only significant results are 




















Virus & strain Accession # gBlock sequence 
Usutu virus 
(USUV)  





















































Table 3.1 gBlock fragments used in this study. Viruses and strains listed along with 









































































Table 3.2. qRT-PCR primers used in this study.  
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4.1 Summary 
Robust community-level SARS-CoV-2 prevalence estimates have been difficult to 
obtain in the American South and outside of major metropolitan areas. Furthermore, 
though some previous studies have investigated the association of demographic factors 
such as race with SARS-CoV-2 exposure risk, fewer have correlated exposure risk to 
surrogates for socioeconomic status such as health insurance coverage. 
We used a highly specific serological assay utilizing the receptor binding domain 
of the SARS-CoV-2 spike protein to identify SARS-CoV-2 antibodies in remnant blood 
samples collected by the University of North Carolina Health system. We estimated the 
prevalence of SARS-CoV-2 in this cohort with Bayesian regression, as well as the 
association of critical demographic factors with higher prevalence odds. 
Between April 21st and October 3rd of 2020, a total of 9,624 samples from unique 
individuals were collected from clinical sites in central NC and we observed a 
seroprevalence increase from 2.9 (95% credible interval, CI, 1.7, 4.3) to 9.1 (95% CI 7.2, 
                                            
3The work presented in this chapter will be published as Lopez CA*, Cunningham CH*, Pugh S, Brandt K, 
Vanna UP, Delacruz MJ, Guerra Q, Goldstein SJ, Hou YJ, Gearhart M, Wiethorn C, Pope C, Amditis C, 
Pruitt K, Newberry-Dillon C, Schmitz J, Premkumar L, Adimora AA, Emch M, Boyce R, Aiello AE, Fosdick 
BK, Larremore DB, de Silva AM, Juliano JJ, Markmann AJ. Disparities in SARS-CoV-2 seroprevalence 
among individuals presenting for care in central North Carolina over a six-month period. Manuscript 
resubmission in progress. 
I performed a portion of the receptor-binding domain assays for both assay validation and study samples 
in this chapter as well as decisions on ICD-10 categorization and statistical analysis. 
CHAPTER 4 – DISPARITIES IN SARS-COV-2 SEROPREVALENCE AMONG 
INDIVIDUALS PRESENTING FOR CARE IN CENTRAL NORTH CAROLINA OVER A 
SIX-MONTH PERIOD3 
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11.1) over the study period. Individuals who identified as Latinx were associated with the 
highest odds ratio of SARS-CoV-2 exposure at 7.77 overall (95% CI 5.20, 12.10). 
Increased odds were also observed among Black individuals and individuals without 
public or private health insurance. Our data suggest that for this care-accessing cohort, 
SARS-CoV-2 seroprevalence was significantly higher than cumulative total cases 
reported for the study geographical area six months into the COVID-19 pandemic in North 
Carolina. The increased odds of seropositivity by ethnoracial grouping as well as by 
health insurance status highlights the urgent and ongoing need to address underlying 
health and social disparities in these populations. 
4.2 Introduction 
In December 2019, a cluster of pneumonia cases in China’s Hubei province 
heralded the beginning of what would become a global pandemic caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite attempts to contain the virus, 
SARS-CoV-2 has spread around the world, causing over 100 million infections and 3 
million deaths due to the respiratory disease it causes, COVID-19353. Serological testing 
complements molecular testing for evaluating the spread of SARS-CoV-2 and can be 
deployed efficiently at the population level218. Recently, large prevalence studies around 
the United States using remnant samples from healthcare settings have reported 
substantial geographic variation in prevalence by state: around 30% in New York state 
but less than 2% in North Carolina (NC), the focus of the present study354,355. Notably, 
two other studies overlap with the present cohort both temporally and geographically. One 
study of 4,422 asymptomatic inpatients and outpatients in central NC from April 28-June 
19, 2020 found an estimated seroprevalence of 0.7 – 0.8%, and another study of 177,919 
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remnant clinical laboratory samples from routine screening (3,817 from NC) from July 27-
September 24, 2020 found an estimated seroprevalence of 2.5 – 6.8%226,227. While overall 
seroprevalence estimates of a given study depend on sampling method, assay 
characteristics, geography, temporal factors, and statistical methodology, seroprevalence 
studies can provide information on the spread of COVID-19 that is missed by looking at 
the number of confirmed acute cases alone.  
Seroprevalence studies are also useful for identifying demographic factors such 
as racial, ethnic and socioeconomic disparities among those exposed to SARS-CoV-2355–
357. The COVID-19 pandemic has been shaped by the deep and historic impacts of 
structural racism on disease disparities in US society as identified by serologic studies as 
well as hospitalization and mortality rates198,358. For example, COVID-19 case and 
hospitalization rates among Black, Hispanic and Native American populations in the US 
are 2.5-4.5 times higher than those in white populations199. Structural and occupational 
factors previously identified as drivers of race and ethnic disparities in health include lack 
of sick leave, inadequate access to infection prevention control, and unequal labor market 
opportunities as well as higher representation in essential work positions that lack job 
security and health insurance benefits235–240. Here, we confirm the findings of disparate 
SARS-CoV-2 exposure among racial and ethnic groups in the US by measuring 
seroprevalence using remnant blood samples from a large health care seeking cohort in 
the southern United States. By October 3rd, 2020, 52,722 SARS-CoV-2 cases in the study 
catchment area were diagnosed via cumulative total PCR or antigen test359,360. These 
cases represented 2.7% of the population and resulted in 1,266 confirmed deaths (a 2.4% 
case fatality rate). We used an in-house enzyme-linked immunosorbent assay (ELISA) 
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against the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2361 and 
applied Bayesian inference230 to estimate seroprevalence and demographic risk factors 
of SARS-CoV-2 infection in a healthcare-seeking cohort over a six-month period.  
4.3 Materials and Methods 
Sampling Strategy and Data Collection.  
Remnant plasma and serum samples were collected from four hospital-based 
clinical laboratories affiliated with the University of North Carolina (UNC) Health system. 
These laboratories receive and process clinical samples from inpatient units as well as 
outpatient clinics in NC. Each week, up to 300 remnant samples from individuals 5-99 
years of age were arbitrarily selected by the clinical laboratory for testing from each 
location. Samples were collected between April 21st, 2020 – October 3rd, 2020. Medical 
record numbers were recorded for each sample and duplicates were discarded. We 
abstracted the following demographic and clinical data from electronic medical records 
(EMR, Epic): age, sex, ethnicity, race, address including city, state and ZIP code, 
insurance coverage, insurance type, inpatient or outpatient status, encounter diagnosis 
(ICD-10 code), inpatient date of discharge, and whether or not COVID-19 testing was 
performed within a 30-day window prior to study sample collection. Written informed 
consent was not required due to the use of routinely collected samples. All data for this 
study were collected under UNC IRB #20-0791, which is conducted under Good Clinical 
Research Practices (GCP) and compliant with institutional IRB oversight. De-identified 
samples used for assay validation were collected under UNC IRBs #20-0913 and #08-
0895. 
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Enzyme-Linked Immunosorbent Assays.  
Dr. Premkumar Lakshmanane developed a total Ig ELISA (combined IgG, IgM, 
and IgA) as well as IgM SARS-CoV-2 RBD ELISA, neither of which cross-reacts with 
common endemic human coronaviruses; both assays were used in this study as 
previously described361. Briefly, the SARS-CoV-2 RBD (amino acids 331-528, 
accession: QIS60558.1) containing three purification tags (6x histidine, Halo, and 
TwinStrep) was cloned into the pαH mammalian expression vector and expressed in 
Expi293 cells (ThermoFisher) and then purified using nickel-nitrilotriacetic acid agarose.  
The spike protein N-terminal domain (NTD) antigen used in another ELISA 
(amino acids 16–305, Accession: P0DTC2.1) was cloned similarly. All ELISA 
measurement was conducted in duplicate and duplicate values with variance > 25% 
and/or one value above assay cutoff were repeated.  
To account for plate-to-plate variability (i.e., batch effects) we used P/N ratios, 
rather than using the raw optical density (OD) values. P/N ratios were defined as 
P/N= 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑂𝑂𝑂𝑂 𝑠𝑠𝑎𝑎𝑠𝑠𝑠𝑠𝑠𝑠𝑎𝑎 
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑂𝑂𝑂𝑂 𝑛𝑛𝑎𝑎𝑎𝑎𝑎𝑎𝑛𝑛𝑛𝑛𝑎𝑎𝑎𝑎 𝑐𝑐𝑐𝑐𝑛𝑛𝑛𝑛𝑎𝑎𝑐𝑐𝑠𝑠
 where the negative control values were those from the 
same plate as the sample362. Accounting for batch effects with a P/N ratio removes the 
need to define plate specific cutoffs, and instead allowed us to define a single cutoff 
based on a fold increase of sample OD value compared to the negative control OD 
value on the same plate. 
The CDC recommends selecting cutoffs such that the test has 99.5% 
specificity363. We followed this recommendation, specifying the cutoff to be the standard 
estimate of the 0.995 quantile (based on the quantile function in R) of the negative lab 
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samples. Validation sera were collected from 145 PCR-confirmed SARS-CoV-2 positive 
cases from the laboratories of Dr. Jennifer Dan, Dr. Alessandro Sette, and Dr. Shane 
Crotty at La Jolla Institute of Immunology and 274 negative controls collected prior to 
2020 from UNC IRBs #20-0913 and #08-0895 (Table 4.1). The P/N ratio cutoff was 2.57 
with empirical sensitivity of 89.7% and empirical specificity of 99.3%. Therefore, a 
sample was considered positive if its average OD value was ≥2.57 times larger than the 
average OD of the corresponding plate negative controls.  
Nucleocapsid protein ELISA.  
Detection of IgG antibody to SARS-CoV-2 N antigen was performed with the EUA 
approved Abbott SARS-CoV-2 IgG assay (Abbott Laboratories) on the Abbott Architect 
i2000SR immunoassay analyzer as previously described364. 
SARS-CoV-2 Neutralization Assays.  
To further characterize the SARS-CoV-2 antibody responses of this study, viral 
neutralization assays were performed for 110 ELISA-positive samples that were selected 
randomly using the sample_n() function of the dplyr R package. Luciferase-expressing, 
full-length SARS-CoV-2 isolate WA1 strain (GenBank Accession#: MT020880) was 
engineered and recovered via reverse genetics and used to titer serially diluted sera on 
Vero E6 USAMRID cells as described previously365. Neutralization titers were calculated 
with a sigmoidal dose-response (variable slope) curve in Prism 9 (Graphpad), 
constraining values between 0 and 100%.   
Statistical Methods and Analyses.  
We fit two statistical models to estimate seroprevalence, previously described but 
applied and further developed by Sierra Pugh working with Dr. Bailey Fosdick (Colorado 
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State University)230. First, we fit a Bayesian autoregressive logistic model to estimate 
weekly prevalence across the six-month study period while accounting for uncertainty in 
the assay specificity and sensitivity due to finite lab validation samples. Second, we fit a 
Bayesian logistic regression model to estimate prevalence and conditional odds ratios by 
subpopulation with main effects for sex, race/ethnicity, age, in/out-patient status, and 
health insurance payor, while again accounting for uncertainty in the assay test 
characteristics. Each group was compared to females, non-Latinx white, ages 5-17, 
outpatient, and private payor health insurance status as respective baseline categories. 
These Bayesian hierarchical models (BHM) simultaneously model study data and 
validation data to produce prevalence estimates and credible intervals that reflect both 
uncertainty due to the finite study sample as well as the uncertainty in the sensitivity and 
specificity of the ELISA, with statistical uncertainty represented by 95% credible intervals.  
Demographic data categorization. 
To categorize individual clinical encounters associated with the blood draws we 
sampled, we obtained International Classification of Diseases, 10th revision (ICD-10) 
codes from any inpatient or outpatient visit at the same location within 14 days of when 
we received and sampled the blood draw. We prioritized inpatient visits over outpatient 
visits unless no inpatient visit was available. If there was no visit within the past 14 days 
of the blood draw, we instead used the visit closest to the most recent specimen collection 
date within a 30-day period. Individuals with no visit at the same location within 30 days 
of their blood draw were excluded from analysis. To capture any upper respiratory 
infection, respiratory disease due to external agents, interstitial lung disease, imaging 
abnormalities of the lung, cough, fever, and dyspnea, we used the ICD-10 codes J00-
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J006, J009-J018, J20-J22, J40-J47, J60-J70, J80-J84, J96-J99, R91, R05, R06.0, and 
R50.  COVID-19 diagnosis was defined as presence of the U07.1 code in the visit nearest 
the sampled blood draw.  Likewise, acute or trauma cases were defined as any of the 
following ICD-10 codes: O00, O01, O02, O03, O04, O07, O08, O015.1, all S codes, all T 
codes (except T36-T39, T41, T46, T50, T80-T88), all V codes, all W codes, all X codes, 
all Y codes (except Y62-Y84 and Y-90-99).  
Insurance status was determined from the most recent clinical encounter prior to 
the sampled blood draw. “Private Insurance” was classified as any of the following listed 
for a patient’s visit: Blue Cross/Blue Shield, private health insurance, or state government 
insurance. “Public Insurance” was classified as any of these following: Medicaid applicant, 
Medicaid, Medicare, Department of Veteran’s Affairs, Tricare, and Corrections State 
insurance. “Self-pay” includes anyone paying out of pocket. “Unknown/Other” consists of 
individuals for whom the health insurance payor was left blank or otherwise unidentifiable, 
as well as listed insurance that read “Legal Liability / Liability Insurance”, “Other specified 
but not otherwise classifiable (includes Hospice - Unspecified plan)”, and “Other”.  
Race and ethnicity identity was ascertained from that listed in the EMR for each 
patient. The categories listed under Epic’s EMR that we received included “American 
Indian or Alaska Native”, “Asian”, “Black or African American”, “Native Hawaiian or other 
Pacific Islander”, “Other Race”, “Patient Refused”, “Unknown” or “White or Caucasian”. 
For ethnicity, we received information on whether patients self-identified as “Hispanic or 
Latino”, or were listed as “Patient Refused” or “Unknown”. In our report, we collapse race 
and ethnicity from separate variables into a single variable in order to investigate the 
impact of systemic racism on SARS-COV-2 seroprevalence by both race and ethnicity at 
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the same time, though the constructs of race and ethnicity are inherently surrogate 
measures of racism and other forms of marginalization366. 
We therefore binned individuals into the following groups: Any Black or African 
American individuals that indicated “Non-Hispanic or Latino,” “Patient Refused,” or 
“Unknown” were binned as “Non-Latinx Black”. The same was done for White or 
Caucasian individuals, binning them into “Non-Latinx White” and similarly for all other 
groups as “Non-Latinx Other”. Any Hispanic or Latino individuals were binned as “Latinx”, 
and therefore could self-identify as any of the above race categories. We did not further 
separate out other intersections of race and ethnicity because the number of individuals 
was too small to make conclusive claims on odds of seropositivity. We here opt to use 
Latinx in place of “Hispanic”, though neither is the only way to refer to this grouping of 
individuals that often share cultural characteristics, language, religion, and ancestral 
geography and history367. We also compared racial, ethnic, and age demographics in the 
study population to the demographics of the 6-county area where most of the study 
population resided using US Census Data359. 
4.4 Results 
Cohort Characteristics.  
From April 21, 2020 – October 3, 2020, after excluding duplicate samples, 9,624 
remnant samples were analyzed from four UNC Health hospitals in central North 
Carolina. The six counties most heavily sampled were Orange, Johnson, Chatham, 
Wake, Durham and Alamance, with 6,946 (72.2%) of individuals residing in these 
counties. The study consisted of 5,417 females (56.3%) and 4,206 males (43.7%) which 
is similar to the demographics of this region (Table 4.2). Less than 6% of individuals were 
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in the youngest age group (5-17 years old), though this age group represents over 18% 
of the study area’s population. Approximately 90% of study individuals were insured, with 
8% falling into the self-pay category, but we do not know whether this is representative of 
the area. The majority of sampled individuals were seen at UNC Memorial Hospital, ~3% 
were acute or trauma cases, and ~5% had a visit diagnosis of fever or respiratory 
symptoms. Overall, approximately 1% of patients had an associated COVID-19 visit 
diagnosis, most of which were inpatients (2.8% compared to 0.3% outpatients) (Chi-
squared test; p<0.0001).  
Seroprevalence in central North Carolina 
The six-month period of the study was divided into three, two-month cohorts. The 
Bayesian Hierarchical Model (BHM)-derived seroprevalence estimates increased from 
around 3% in April/May to around 9% in August/September (Table 4.3). Raw 
seroprevalence estimates also showed a similar increasing trend over the study period, 
but because this does not take into account assay performance uncertainty, they are 
slightly higher at ~5% and ~11%. Furthermore, seroprevalence estimates peaked in early 
August following a hospitalization peak in mid-July (Figure 4.1A, 4.1C). The most rapid 
accumulation of cases occurring from June to August (Figure 4.1B). Unexpectedly, 
seroprevalence peaked and was followed by a slight decrease in the final weeks of the 
study. This pattern was related to raw seroprevalence estimates at Johnston County 
hospital which surged from 7.8% in the first two months to 18.0% in the second two 
months, then declined to 14.8 in the final two-month period. The surge and then decline 
in seroprevalence at Johnston County hospital is associated with a peak in PCR-
confirmed cases in the region (Table 4.4). This peak and decline was not affected by the 
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removal of cases with ICD-10 visit codes for “COVID-19” or those we identify as 
“respiratory disease”.  
Clinical and demographic differences in seroprevalence estimates  
Latinx-identifying individuals had higher SARS-CoV-2 seroprevalence increased 
from 15 to 33% compared to non-Latinx individuals which increased from 1-11% 
seroprevalence over the study period (Table 4.3). Individuals with “Other/Unknown” or 
“Self-pay” insurance status had a higher estimated seroprevalence (increasing from 20-
40% or ~1-18%, respectively) than those with private or public health insurance 
(increasing from 3-9%). Approximately 30% of Latinx individuals in this study were in the 
other/unknown or self-pay health categories, disproportionately comprising ~27% of 
these two categories but only accounting for ~8% of our study population (Table 4.5). 
We calculated conditional odds ratios for each variable we collected using the BHM 
(Table 4.6). Latinx individuals had the highest odds of SARS-CoV-2 seropositivity 
throughout the study period compared to non-Latinx white individuals, OR 7.77 overall 
(95% credible interval 5.20, 12.10), ranging from 14.53 (6.47, 36.72) in the first two 
months to 4.34 (2.61, 7.41) in the last two months of the study. Individuals with unknown 
insurance status also had an elevated odds ratio of seropositivity at 3.81 (2.23, 6.54) 
compared to those with private insurance status. Over the entire period of the study, non-
Latinx Black individuals, individuals aged 50-64 years, and inpatients, also had increased 
odds ratios of approximately two-fold compared to non-Latinx white individuals, 
individuals aged 0-17, and outpatients, respectively. The overall difference in odds ratios 
by age appears to be driven primarily by increased odds ratios in the first two months. 
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SARS-CoV-2 RBD positive subset analysis.  
To determine the SARS-CoV-2 antibody repertoire in a subset of RBD Ig 
seropositive individuals, 110 randomly selected RBD Ig positive sera were tested for RBD 
IgM, NTD IgG, and SARS-CoV-2 neutralizing antibodies. About 75% of these individuals 
were positive for RBD IgM, 60% had NTD IgG antibodies, and about 50% had detectable 
neutralizing antibodies (Figure 4.2A). Of the participants with detectable neutralizing 
antibodies, 23% had a high titer > 1:1280, 47% had a moderate titer of 1:160-1:1279, and 
30% had a lower titer of 1:10-1:159. Furthermore, RBD Ig P/N antibody signal correlated 
more strongly with functionally neutralizing antibody levels (Figure 4.2B), than NTD IgG 
signal (Figure 4.2C). We also found that 36% (29/80) of those in this subset with an ICD-
10 code binned as “Other” had neutralizing antibodies, while 83% (25/30) of individuals 
with an ICD-10 code of “COVID-19” or what we identify as “respiratory disease” had 
neutralizing antibodies (Figure 4.2D). There was substantial agreement between the RBD 
Ig ELISA results reported here and 150 study individuals for which a clinical SARS-CoV-
2 nucleocapsid IgG (Abbott assay) was available (Cohen’s kappa=0.685) (Table 4.10). 
4.5 Discussion 
Here we describe SARS-CoV-2 seroprevalence in a total of 9,624 unique 
healthcare-seeking individuals in central North Carolina using clinical remnant samples 
from four regional hospitals between April and October 2020. Employing a Bayesian 
framework230 to capture assay uncertainty in both lab validation data as well as study 
data, we estimated a significant increase in overall seroprevalence from 2.9% (95% CI 
1.7% - 4.3%) at the start of the study period, to 9.1% (95% CI 7.2% - 11.1%) at the end 
of the study period, approximately six months after the first case in the state. The end-of-
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study prevalence identified here is significantly higher than the cumulative number of 
cases identified by PCR or antigen testing in the same county region at the same date, 
though determining the degree to which the identified cases undercount true infections 
requires more representative sampling.  
A previous study from central North Carolina that overlaps with the first two months 
of our study period found seroprevalence in an asymptomatic healthcare-seeking cohort 
below 1% using the Abbott nucleocapsid IgG assay226. This is much lower than the ~3% 
seropositive estimate in our cohort over this time period, and may be due to under-
sampling of Latinx individuals in that study and/or preferential sampling of asymptomatic 
individuals, as that study excluded individuals reporting symptoms consistent with SARS-
CoV-2 infection. There is also growing concern about the use and performance of 
nucleocapsid IgG assays in individuals with asymptomatic or mild disease because the 
nucleocapsid assays appear to be less sensitive in asymptomatic disease cohorts but 
have comparable sensitivity to spike or RBD assays in symptomatic disease 
cohorts219,368. A nationwide CDC study that used remnant clinical samples from inpatients 
and outpatients found a seroprevalence of 6.8% in NC in September 2020, which is closer 
to our estimate of 9.1% during the final two months of this analysis.  
The conditional odds ratios we calculated assume that all other variables are held 
constant while estimating the effect of one demographic variable at a time. We found that 
Latinx individuals had the highest odds of SARS-CoV-2 seropositivity, and that non-Latinx 
Black individuals also had high odds of SARS-CoV-2 seropositivity, corroborating 
previous observations355–357. The high odds ratios by race and ethnicity decreased over 
time, consistent with the virus spreading first among individuals with high exposure risk 
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and later to the rest of the population. Residential segregation, crowded households, 
socioeconomic disadvantage, mass incarceration, as well as inequities in access to 
insurance, health care, testing, and vaccination have all been cited as factors that have 
contributed to the large and sustained racial and ethnic disparities in COVID-19 in the 
US236,238,369–371. We also observed that individuals who fell into the “self-pay” category for 
their healthcare or otherwise had unknown health insurance status had higher SARS-
CoV-2 seropositivity and odds ratios. The significant overlap in the Latinx population and 
these insurance categories is concerning because the high odds ratios and 
seroprevalence in these categories can lead to much higher exposure risk among the 
significant number of underinsured Latinx individuals372.  
Studies of PCR-positive symptomatic COVID-19 cases have reported detectable 
neutralizing antibody responses in these individuals373. Thus, it was surprising that we 
observed 51% of individuals in our RBD-positive subset analysis did not have detectable 
neutralizing antibodies. Though we do not know what proportion of individuals in our study 
had asymptomatic infections, low neutralizing antibody titers may be explained by short 
duration of viral replication in respiratory compartments and low to no viral replication in 
the serum or blood of those with mild or asymptomatic disease. Not surprisingly, when 
we looked at our neutralizing antibody results by ICD-10 code, the majority of individuals 
with a “respiratory disease” or “COVID-19” diagnosis had developed neutralizing 
antibodies. Reports from mild disease COVID-19 cohorts support the idea that detectable 
neutralizing antibody titers are not necessarily identified after mild COVID-19216,219,364. In 
this subset analysis we also found that 75% had RBD IgM antibodies, indicating that their 
infections likely occurred within the past three months364. Furthermore, a majority of 
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individuals in this subset had detectable NTD IgG antibodies; the NTD has recently been 
found to be an important target for the B.1.1.7, B.1.351, and B.1.1.28.1 SARS-CoV-2 
variants374. 
The primary limitation of this study is that the study population, composed of 
individuals accessing care at UNC area hospitals and clinics may differ from the overall 
population in central North Carolina in ways that are not captured in demographic data 
(e.g., overall health status). Accordingly, we have chosen to not weight our dataset to 
county demographics and therefore do not provide overall estimates of seroprevalence 
in the six-county area as that would require more representative sampling 
methodology228. Furthermore, many clinics and hospital elective procedures were closed 
or only seeing patients virtually during the first few months of the study period.  
The unexpected seroprevalence peak observed at the Johnston County hospital 
suggests that the population accessing care at these clinical sites did not have consistent 
exposure risk over time. As expected, seroprevalence estimates in this cohort track 
closely with COVID-19 hospitalizations in the four hospitals in this study with a two-week 
lag which could be due to time to seroconvert. Declining antibody over this time period to 
undetectable levels is unlikely, as the length of the study is shorter than it takes for 
antibodies to decline to undetectable levels, although little is known about antibody levels 
over time in the asymptomatic population373. 
Other limitations of the study include that we could not disaggregate odds ratios 
by all races and/or by race and ethnicity at the same time, or by multiracial categories 
because the number of individuals became too small to allow robust interpretation. 
Finally, though the “self-pay” insurance category includes the uninsured, we cannot 
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confidently state that everyone in this category was uninsured because lack of insurance 
is not a specific category that is captured in the EMR. Although SARS-CoV-2 
seroprevalence of healthcare-seeking individuals is an imperfect comparison to the 
general population, we maintain that it is a useful sentinel population to understand overall 
trends, especially when attempting to surveil rural populations residing in areas without 
strong public health systems and spread over a large geographic area.  
Based on our estimates of seroprevalence in the population accessing healthcare, 
cumulative case numbers confirmed by molecular diagnostics are likely under-
representing the true number of cases. Public health distancing measures, mask wearing, 
and vaccination should continue to be prioritized in order to lower the transmission of 
SARS-CoV-2 and subsequent loss of lives while transmission remains high and vaccine 
coverage remains incomplete. Our findings of a significantly higher odds of SARS CoV-2 
seropositivity among Latinx and non-Latinx Black populations corroborate numerous 
studies describing large racial and ethnic disparities in SARS-CoV-2 infection, morbidity 
and mortality in the US355–357. Vaccination programs should address structural and 
occupational factors that drive race and ethnic disparities in health outcomes in the US to 
ensure that individuals at particularly high exposure risk of SARS-CoV-2 have timely 






Figure 4.1. Trends in seroprevalence estimates. (A) Weekly posterior mean 
seroprevalence estimates by ELISA and 95% credible intervals of the hospital samples 
plotted over time over the course of the study period. (B) Cumulative daily COVID-19 
PCR+ cases from the six-county area 4/19-10/3, and (C) weekly COVID-19 
hospitalizations in the six-county area 4/19-10/3 from NC Department of Health and 






























Figure 4.2 Antibody repertoires in an RBD Ig positive subset. 110 RBD Ig positive 
samples were chosen at random to undergo SARS-2 antibody repertoire analysis. (A) 
Percent of individuals with RBD IgM, NTD IgG and functionally neutralizing antibodies 
(NT50). (B) Correlation plot of NT50 and RBD Ig. (C) Correlation plot of NTD IgG and 
RBD Ig, rs = Spearman correlation coefficient displayed in the top left of panels (B) and 
(C). (D) NT50 values for each diagnosis binning category based on ICD-10 codes. Line 





Table 4.1 RBD Ig ELISA Validation Data. Serum from PCR-confirmed COVID-19 
patients and from individuals prior to 2020 were obtained from the University of North 
Carolina (UNC) and La Jolla Institute of Immunology.  CI, confidence interval; PCR, 





















Table 4.1. ELISA Validation Data 
 % Sensitivity (95% CI) % Specificity (95% CI) 
RBD total Ig ELISA 
(≥ 9 days post symptom onset) 89.7% (130/145) (84.7, 94.6) 99.3% (272/274) (98.3, 100.0) 
 
PCR+ controls (n = 145) N = 32 (Crotty Lab, La Jolla) 
 N = 113 (UNC convalescent plasma donor cohort) 
 
Negative controls (n = 274) N = 122 (UNC pre-2019 healthy adults) 
 N = 48 (UNC pre-COVID-19 arboviral samples, tuberculosis endemic region) 
 N = 44 (UNC, clinical pre-organ transplant) 
 N = 28 (UNC, clinical HIV+) 
 N = 16 (healthy adults, Crotty Lab, La Jolla) 



























Table 4.2 Patients by demographic factors of interest. Note, because of how the NC 
census reports data, the sex and age breakdowns of the 6-county demographics 
includes only individuals over the age of 4 (including those over age 99), but the 
race/ethnicity breakdown includes individuals of all ages. Additionally, the 65-99 age 
















Table 4.2 Study participant demographics 
 4/19-6/13 6/14-8/08 8/09-10/03 6-county 
Demographics 
(%) 
N (%) N (%) N (%) 
Sex 
Female 1947 56.2 2020 57.3 1450 55.1 51.8 
Male 1515 43.7 1508 42.7 1183 44.9 48.2 
Unreported 1 0.0 0 0.0 0 0.0 — 
Age 
5-17 259 7.5 163 4.6 150 5.7 18.4 
18-49 1311 37.9 1052 29.8 830 31.5 48.7 
50-64 926 26.7 1030 29.2 725 27.5 19.7 
65-99 967 27.9 1283 36.4 928 35.2 13.1 
Race/Ethnicity 
NL White 2113 61.0 2267 64.3 1628 61.8 59.7 
NL Black 845 24.4 803 22.8 603 22.9 21.0 
NL Other 210 6.1 195 5.5 194 7.4 8.2 
Latinx 295 8.5 263 7.5 208 7.9 11.1 
In/Out patient 
Inpatient 1057 30.5 961 27.2 839 31.9 — 
Outpatient 2394 69.1 2562 72.6 1792 68.1 — 
Unknown 12 0.3 5 0.1 2 0.1 — 
Payor 
Public 1825 52.7 2050 58.1 1509 57.3 — 
Private 1249 36.1 1172 33.2 920 34.9 — 
Self-Pay 326 9.4 254 7.2 181 6.9 — 
Other/Unknown 63 1.8 52 1.4 23 0.8 — 
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Table 4.3 Cohort prevalence estimates 







4/19-6/13 6/14-8/08 8/09-10/03 
    Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Overall 5.3 10.5 10.8 2.9 (1.7, 4.3) 8.8 (7.1, 10.6) 9.1 (7.2, 11.1) 
Age 
5-17 3.1 9.8 9.3 1.4 (0.3, 3.3) 8.1 (3.9, 13.4) 7.6 (3.5, 13.0) 
18-49 6.0 12.6 10.5 3.6 (2.2, 5.4) 11.1 (8.6, 13.8) 8.7 (6.2, 11.5) 
50-64 5.9 10.4 13.0 3.7 (1.9, 5.8) 8.7 (6.3, 11.3) 11.5 (8.5, 14.7) 
65-99 4.3 9.0 9.6 1.5 (0.2, 3.4) 7.1 (5.0, 9.4) 7.7 (5.2, 10.4) 
Sex  
Female 4.5 10.3 10.7 2.1 (1.0, 3.5) 8.5 (6.6, 10.6) 8.9 (6.8, 11.3) 
Male 6.3 10.7 10.9 3.9 (2.3, 5.8) 9.2 (7.1, 11.3) 9.2 (6.9, 11.8) 
Race/Ethnicity  
NL White 3.7 7.5 8.3 1.4 (0.5, 2.7) 5.4 (3.7, 7.3) 6.3 (4.3, 8.4) 
NL Black 5.6 12.0 12.8 2.6 (0.6, 5.0) 10.4 (7.5, 13.4) 11.4 (8.2, 14.8) 
NL Other 5.7 10.3 11.3 2.0 (0.1, 5.9) 8.5 (3.9, 13.9) 9.3 (4.5, 14.9) 
Latinx 15.9 31.9 24.0 14.8 (10.4, 19.6) 33.2 (26.8, 40.0) 23.9 (17.5, 31.1) 
In/out patient 
Outpatient 4.3 9.0 9.1 2.0 (1.0, 3.3) 7.1 (5.4, 9.0) 7.1 (5.1, 9.2) 
Inpatient 7.7 14.6 14.4 5.0 (2.9, 7.4) 13.3 (10.5, 16.2) 13.3 (10.3, 16.4) 
Payor 
Private 5.2 9.0 8.9 2.9 (1.5, 4.6) 7.3 (5.3, 9.6) 7.1 (4.7, 9.6) 
Public 5.0 9.8 10.7 2.5 (1.2, 4.2) 7.9 (5.9, 9.9) 8.9 (6.8, 11.2) 
Self-Pay 4.0 18.9 17.1 1.3 (0.2, 3.5) 18.3 (13.1, 23.8) 16.3 (10.4, 23.1) 
Other/ 
Unknown 
22.2 30.8 43.5 21.1 (11.8, 31.7) 31.2 (19.4, 44.5) 40.4 (22.4, 60.6) 
 
Table 4.3 Cohort prevalence estimates. Raw seropositivity (%) and posterior mean 
seroprevalence estimates (%) from BHM with 95% credible intervals (lower bound, upper 





















Table 4.4 Raw antibody test positivity by hospital 
 4/19-6/13 6/14-8/08 8/09-10/03 
Johnston Hospital 7.81 18.00 14.80 
Chatham Hospital 7.45 8.69 12.08 
UNC Hospitals 4.03 9.93 10.38 
Rex Hospital 4.04 5.93 7.71 
Table 4.4 Raw antibody test positivity (percent) by hospital. Unadjusted percentage 






































Table 4.5 Insurance category by race/ethnicity 
 Private Public Self-Pay Other/Unknown 
 N (%) N (%) N (%) N (%) 
NL White 2173 36.2 3439 57.2 347 5.8 49 0.8 
NL Black 641 28.5 1402 62.3 177 7.9 31 1.4 
NL Other 323 53.9 223 37.2 42 7.0 11 1.8 
Latinx 204 26.6 320 41.8 195 25.5 47 6.1 
TOTAL 3341 34.7 5384 55.9 761 7.9 138 1.4 
Table 4.5 Insurance category by race/ethnicity. Numbers and percentage of 


































Table 4.6 Conditional odds ratios of being SARS-CoV-2 seropositivity over the study period. 
 4/19-6/13 6/14-8/08 8/09-10/03 4/19-10/03 (overall) 
 Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Sex 
Female — — — — — — — — 
Male 2.05 (1.08, 4.25) 1.10 (0.80, 1.51) 0.91 (0.64, 1.29) 1.27 (0.98, 1.69) 
Race/Ethnicity 
NL White — — — — — — — — 
NL Black 1.66 (0.53, 4.28) 1.94 (1.31, 2.92) 1.82 (1.20, 2.79) 1.80 (1.19, 2.65) 
NL Other 1.26 (0.12, 5.74) 1.58 (0.74, 3.19) 1.81 (0.87, 3.57) 1.54 (0.66, 2.84) 
Latinx 14.53 (6.47, 36.72) 7.43 (4.70, 11.97) 4.34 (2.61, 7.41) 7.77 (5.20, 12.10) 
Age 
5-17 — — — — — — — — 
18-49 3.09 (0.99, 11.43) 1.38 (0.68, 3.05) 0.89 (0.42, 2.03) 1.56 (0.92, 2.77) 
50-64 3.62 (1.13, 13.56) 1.34 (0.64, 2.99) 1.56 (0.76, 3.54) 1.96 (1.15, 3.55) 
65-99 1.62 (0.28, 6.90) 1.49 (0.71, 3.34) 1.13 (0.52, 2.64) 1.40 (0.71, 2.61) 
In/out patient 
Outpatient — — — — — — — — 
Inpatient 2.50 (1.31, 5.10) 1.91 (1.38, 2.68) 1.92 (1.34, 2.80) 2.09 (1.59, 2.85) 
Payor 
Private — — — — — — — — 
Public 0.85 (0.41, 1.73) 0.89 (0.58, 1.34) 1.16 (0.74, 1.85) 0.96 (0.70, 1.30) 
Self-Pay 0.18 (0.03, 0.64) 1.78 (1.07, 2.93) 1.94 (1.03, 3.63) 0.85 (0.45, 1.41) 
Other/ 
Unknown 
3.08 (1.15, 8.23) 2.73 (1.25, 5.98) 6.60 (2.29, 
18.71) 
3.81 (2.23, 6.54) 
 
Table 4.6 Conditional odds ratios of SARS-CoV-2 seropositivity over the study 
period. Data are divided into into three two-month long periods. Odds ratios of 
seropositivity calculated from the BHM with 95% credible intervals (lower bound, upper 
bound) are reported where the baseline groups for comparison are female, Non-Latinx 
white, age 5-17, outpatient, and private insurance. Odds ratios that do not overlap a value 






5.1 Overview of Zika virus vector-independent transmission 
Like other vector-borne flaviviruses, ZIKV is capable of transmission between two 
very different animals (humans and mosquitoes), but ZIKV remains an oddity in that it is 
capable of being transmitted directly between humans via two distinct mechanisms, 
sexual and congenital transmission. There is little evidence of significant human-to-
human transmission of other flaviviruses, though it may be that other flaviviruses have 
not emerged in a sufficiently large outbreak to reveal rare transmission mechanisms 
and outcomes. At the time this dissertation research was initiated, there was little 
information available about pathogenesis resulting from human-to-human transmission 
of flaviviruses.  
Some of the features of ZIKV transmission and pathogenesis in the female 
reproductive tract have become clearer during the course of the work detailed here. 
Though ZIKV infects neural progenitor cells within the developing fetus and may thus 
cause microcephaly directly74,375, placental pathology is also observed during gestation 
and may be the cause of intrauterine growth restriction also observed as a result of 
ZIKV infection73,97–99,135,136. Additionally, in mouse models significant fetal loss can be 
induced by ZIKV infection in pregnant WT mice despite a lack of infection in the fetuses 
themselves, suggesting that fetal damage can be caused by immunopathology267. Other 
pathogens such as Plasmodium falciparum can cause similar placental damage as 
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gestational ZIKV and in doing so, results in decreased transplacental IgG transfer to the 
fetus103–109. Transfer of IgG targeting different pathogens can be differentially impaired 
as has now observed during other inflammatory processes such as SARS-CoV-2 
infection during pregnancy266,304,376,377. This difference in transfer of IgG targeting 
different pathogens is likely because transfer is dependent on IgG subclass with 
particular preference for IgG1 and IgG4266. Certain Fc glycosylations such as 
fucosylation are associated with decreased transplacental transfer, possibly because of 
decreased binding to FcγRIIIa266.  
IgG received during gestation are crucial for health in early life before infants 
have a chance to develop their own immunity, so it was critical to determine if ZIKV 
similarly decreased IgG transfer across the placenta. Initially, it was also thought that 
cross-reactive DENV antibodies that facilitate worsened DENV disease may also be 
driving fetal damage in gestational ZIKV but it appears that unlike DENV, ZIKV infection 
is not enhanced by DENV antibodies62. It is likely that the same lack of ZIKV ADE will 
be observed from infants that receive passively transferred antibodies during gestation. 
By contrast, ZIKV-targeting antibodies can promote ADE of DENV60. Interestingly, ADE 
preferentially occurs as a result of antibodies with low fucosylation which are thus able 
to mediate ADE via FcγRIIIa, although they have a lower rate of transfer across the 
placenta266,378. 
The pathogenic mechanisms surrounding sexual transmission of ZIKV have also 
become clearer. ZIKV is found in semen124–126,379,380 and most cases follow ejaculation 
of infected seminal fluid into the vagina. ZIKV then may be infecting a variety of 
epithelial and immune cells128,129. Most mouse pathogenesis models use mice lacking 
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type I IFN signaling128,134 because ZIKV is unable to antagonize mouse STAT2 and 
STING and is therefore unable to disseminate and cause disease in mice141,329. All ZIKV 
vaginal infection models in non-pregnant mice treat with progesterone, similar to 
common HSV and Chlamydia infection models128,135,159,182,183. The reasons 
progesterone sensitizes mice to vaginal infections remain unclear. Some have 
hypothesized that susceptibility to infection increases as the keratin barrier to infection 
becomes thinner in a high progesterone state128.  
Recently, Khan et al have provided evidence that viral RNA PRRs in the LFRT 
might be expressed at a lower level than in the UFRT or draining lymph node183. They 
found a minimal role for DMPA treatment in regulating PRR expression, though Yao et 
al found that DMPA treatment increases PRR expression in the vagina381. However, 
both of these studies focused on the expression of PRRs themselves rather than 
induction of ISGs downstream of PRR signaling so more evidence was needed in order 
to make this claim that there are functional decreases in downstream ISG signaling. 
Even immunodeficient mice require some level of progesterone treatment in order for 
susceptibility to infection, so it is difficult to imagine that small decreases in viral RNA 
PRRs lead to more severe immunosuppression than already exist in mice lacking both 
Ifnar1 and Ifngr receptors128. 
5.2 Overview of SARS-CoV-2 prevalence and impact in the United States.  
During the course of this dissertation research, SARS-CoV-2 emerged and has 
caused millions of deaths around the world, over 500,000 of which are in the United 
States191. Multiple efforts have been made to define SARS-CoV-2 seroprevalence in 
order to assess the total number of infections, identify the hardest hit communities and 
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target resources accordingly, and to understand how many individuals remain 
susceptible to infection. Molecular testing via PCR is limited by disparities in access and 
bottlenecks in reagent availability so the total number of infections needs to be 
evaluated with serological testing which can assay for history of past infection.  
Almost every serology study in the United States is limited by unrepresentative 
sampling methodology228, though it is very challenging to overcome this without 
sufficient funding and support to representatively sample across the nation as has been 
done elsewhere with government support219. Some studies have gone so far as to 
provide prevalence estimates that overestimate their certainty and are statistically likely 
to comprise entirely false positives because they did not take into account the sensitivity 
and specificity of their assay228. Furthermore, most studies have been limited by their 
choice of a nucleocapsid test that is not as sensitive at detecting mild or subclinical 
infections219,220, though this test was likely chosen because it is readily available and 
approved for clinical use.  
All three limitations were present in a recent study of SARS-CoV-2 
seroprevalence in North Carolina by Barzin et al226. This study of healthcare-accessing 
individuals prioritized sampling from asymptomatic individuals, limiting the study’s 
conclusions. Second, though they do correct for the sensitivity and specificity of the 
assay, they do so using a calculation that assumes a binomial distribution around the 
final prevalence estimate when instead it should be skewed because of the large effect 
of false positives at low seroprevalence232. Additionally, their cohort is not 
representative of the general population’s demographics (e.g. significant undersampling 
of Latinx individuals).  Finally, the clinically approved nucleocapsid assay used has 
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reduced sensitivity in individuals after asymptomatic infection—the very population 
specifically recruited in the study. 
Serologic assays must be chosen for serosurveys based on what the expected 
seroprevalence is in a given area. High specificity (low false positivity rate) needs to be 
prioritized when exposure is likely to be low, because there are expected to be very few 
true positives but many negative samples. The likelihood of drawing a false positive 
sample is high on a background of many true negative samples. This is true for serology 
at the start of an outbreak or for a rare exposure, as was the case early in the SARS-
CoV-2 outbreak.  
The opposite is true for flavivirus serology in endemic areas. Nearly everyone 
has been exposed by adulthood, so there are very few true negatives. There are many 
positive samples, a large number of which may be false positives even with a low false 
positive rate simply because there are so many positive samples. Thus sensitivity (low 
false negative rate) is critical for serology in flavivirus endemic areas. Unfortunately, 
tests with high specificity are also difficult to generate for flaviviruses, making flavivirus 
serology complex on both fronts.  
5.3 My contributions to understanding the effect of ZIKV on transplacental 
antibody transfer.  
To determine if ZIKV infection during pregnancy results in similar impairment of 
placental antibody transfer as Plasmodium and HIV, I collaborated with Tulika Singh 
and Dr. Sallie Permar at Duke University to study a paired cohort of 26 neonates and 
their gestational parents with febrile illness and rash from which 20 paired blood 
samples were obtained from each at delivery. I differentiated the ZIKV and DENV 
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exposure history of the gestational parents by neutralization assay, because ZIKV and 
DENV exposure were not distinguishable by ELISA due to the antigenic cross-reactivity 
of these viruses. The algorithm I created to differentiate ZIKV and DENV exposure 
presumes that ZIKV neutralization titers are higher than DENV neutralization titers by 
having a more stringent cut-off for ZIKV neutralization than DENV neutralization. This 
assumption was sufficient for this study because if ZIKV exposure happened during 
gestation, it would have been very recent. Additionally, by sexual maturity, nearly 
everyone in DENV-endemic regions has already been exposed to DENV, so DENV 
infections may not have been as recent as the febrile illness during pregnancy43.  
 Differentiating these samples by exposure history was necessary in order to 
compare pregnancies in ZIKV-naïve individuals to those with gestational ZIKV infection, 
because ZIKV viremia is brief and may have not been detected381. I determined that 
DENV neutralization titers were highly correlated between gestational parents and 
infants, regardless of gestational ZIKV infection and the slope of the correlations were 
significantly overlapping. This suggests that gestational ZIKV infection did not affect 
neutralizing antibody transfer across the placenta. Roughly half of the placentas had 
evidence of inflammation despite the lack of evidence for placental infection. 
Additionally, there was no decrease in transplacental transfer of vaccine-induced 
antibodies as determined by a similar assessment of correlation between cord blood 
and gestational parent plasma.  
 My work in this study has since been corroborated by two other cohort studies of 
gestational ZIKV infection269,305. Though each study suffers independently from small 
sample size, together they suggest that antibody transfer is maintained despite 
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gestational ZIKV infection even in the presence of placental inflammation. Intact 
antibody transfer during gestational ZIKV infection may prove beneficial for protection of 
the fetus from congenital Zika syndrome and the infant from ZIKV infection. Likewise, 
transplacental antibody transfer is beneficial for health in early life. However, the cross-
reactive non-neutralizing DENV-binding antibodies may pose a risk in early life, leading 
to more severe disease in infants as maternal antibody titers wane53,257. 
 The potently ZIKV-neutralizing IgM isolated from the individual with prolonged 
viremia during pregnancy, once characterized, will provide fascinating insight into the 
development of neutralizing IgG when their epitopes are compared. This IgM could 
provide evidence that highly neutralizing flavivirus antibodies can be generated before 
entering convalescence after continued affinity maturation. This IgM could also serve as 
a prophylactic against ZIKV infection during gestation as it will neither be transferred 
across the placenta nor induce ADE, properties which would require additional Fc 
modifications to achieve with an IgG. Finally, because this IgM can protect against ZIKV 
viremia in mice and IgM are not thought to be secreted into the female reproductive 
tract146, it potentially could be a useful laboratory reagent to restrict viral infection in 
mice to the female reproductive tract by allowing Ifnar1-/- mice to serve as a model for 
ascending ZIKV infection distinct from systemic spread; ongoing studies in the Lazear 
Laboratory are investigating this application.  
5.4 My contributions to understanding hormonal regulation of ZIKV infection in 
the vagina  
 To determine whether IgG-mucin interactions in the vagina can contribute to 
protection against ZIKV even in the absence of neutralizing antibodies, I vaginally 
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inoculated Ifnar1-/- mice with ZIKV bound to either neutralizing or non-neutralizing 
antibodies. Although we had hypothesized that non-neutralizing antibodies would 
provide protection based on analogous studies with HSV, I found that ZIKV infection 
was only prevented by a neutralizing monoclonal antibody. These results suggest that 
cross-reactive non-neutralizing antibodies (such as those elicited by prior DENV 
infection) are unlikely to contribute to protection against ZIKV vaginal infection 
I subsequently performed the same experiment in WT mice, which we expected 
to be less susceptible to ZIKV infection, but again found that the non-neutralizing 
monoclonal antibody tested did not provide protection against ZIKV infection. Rather 
than pursuing additional experiments evaluating antibody-mucin effects, I instead opted 
to follow up on the unexpected ability of ZIKV to infect WT mice intravaginally despite its 
inability to replicate systemically in these mice.  
In addition to type I IFNs restricting ZIKV from replicating systemically in 
mice141,329, type III IFNs are thought to play special roles at barrier sites including the 
vagina160. Caine et al found that in the absence of type III IFN signaling, ZIKV was able 
to replicate to higher levels in the vagina. However, when I tested this in mice lacking 
the IFN-λ receptor, I found no difference in viral loads between WT and Ifnlr1-/- mice. I 
did not investigate whether ZIKV is able to ascend the FRT in Ifnlr1-/- mice, but in WT 
mice ZIKV infection was restricted to the vagina and cervix with no evidence of 
replication in the uterus. In humans sexually-acquired ZIKV results in viremia but in 
these mice the infection is restricted to the vagina so this model is not suited to study 
systemic dissemination of ZIKV from the vagina. However, the IFN-αβ impaired mice in 
which ZIKV dissemination is observed die of neuroinvasion134, and are thus not 
144 
necessarily suited to study pathogenesis as it occurs in adult humans which does not 
result in neuroinvasion. Infection models need to therefore be selected with a clear 
purpose to most closely match physiologic relevance in humans. I conclude that WT 
mice should be the model of choice for studies specifically of ZIKV infection within the 
vagina itself, rather than mouse models with impaired innate immune signaling.  
 In order to determine the parameters around which ZIKV is able to replicate in 
the vagina, I inoculated WT and Ifnar1-/- mice with ZIKV both with and without prior 
DMPA treatment. I found that progesterone is required for consistent vaginal infection, 
even in Ifnar1-/- mice. Thus progesterone rather than IFNs regulate ZIKV susceptibility in 
the vagina. I even found that pregnant WT mice are susceptible to vaginal ZIKV 
infection. Pregnancy is a high progesterone state, providing further evidence that 
progesterone regulates ZIKV susceptibility in the vagina 
To understand progesterone-induced susceptibility to ZIKV infection, I 
investigated three potential mechanisms: epithelial barrier integrity, changes in the 
leukocytes populations, and decreased innate immune antiviral signaling128,183. Vaginal 
abrasion did not sensitize WT mice to ZIKV infection, indicating that disruption of 
epithelial barrier integrity is insufficient for ZIKV infection. I also did not find any DMPA-
induced changes in vaginal leukocyte populations. Finally, I did not find a DMPA-
mediated difference in Ifit1 expression either at baseline or in response to p:IC, arguing 
against dampened antiviral signaling as the mechanism of DMPA-induced susceptibility. 
Though Khan et al. found decreased expression of viral RNA sensing PRRs in the 
vagina relative to other tissues, I did not find relative expression of Ifit1 in the vagina to 
be lower than in the spleen183.  Measurement of expression of the sensors themselves 
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as Khan et al performed may be misleading if not coupled with measurements of 
downstream signaling or effector functions. 
I found ZIKV infection predominantly in cells along the vaginal lumen (e.g. 
epithelial cells), rather than in leukocytes or other cell types in the vaginal stroma. In 
particular, this infection was localized to small sporadic foci of infected cells. I did not 
find an influx of leukocytes around these infected cells even though I found ZIKV was 
cleared from the vagina by 10 days after infection, consistent with a protective adaptive 
immune response. By flow cytometry, I did find an increase in the number of dendritic 
cells in vaginal tissue at 6 days post-infection, coinciding with the peak of viral load as 
measured by qRT-PCR of vaginal wash.  Concurrently, there was an increase in the 
number of B cells and T cells in secondary lymphoid tissues (spleen and iLN), which 
may be the result of expansion indicative of a germinal center reaction and development 
of an adaptive immune response from dendritic cells sampling antigen at the site of 
infection. To date no studies have compared immunity resulting from ZIKV vaginal 
infection or mosquito-borne infection, but vaginal infection may also result in a germinal 
center reaction even in these mice with a strictly localized infection to the vaginal 
epithelium. A systemic vaccine response is also likely to protect against vaginal 
infection, as passively transferred plasma in mice provides potent protection against 
vaginal ZIKV infection159. 
Despite the prior suggestion that sensing of viral RNA is deficient in the vagina, I 
did not find a broad ability of other RNA viruses to replicate in the vagina of WT mice. 
Instead, I observed that some but not all flaviviruses replicated in the vagina even 
though they do not replicate well in WT mice (SPOV and USUV), though DENV was 
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unable to. My data suggest that a subset of flaviviruses are capable of replication in the 
vagina and should be evaluated for their potential to be sexually transmitted in the case 
of their broader emergence.  
5.5 My contributions to understanding SARS-CoV-2 seroprevalence in central 
North Carolina 
To determine to what extent SARS-CoV-2 has been spreading locally and 
identify the communities bearing the burden of infection, I worked with Dr. Alena 
Markmann to assay hospital remnant samples by a SARS-CoV-2 RBD-binding ELISA. 
Though hospital remnant samples are not representative of the general population228, 
this is still more representative of the population in central NC than another study by 
Barzin et al. in the same population center and time frame that prioritized asymptomatic 
individuals and undersampled by race and ethnicity226. Additionally, to avoid common 
pitfalls of other seroprevalence studies including Barzin et al., I decided the best 
statistical techniques to employ for this study would require Bayesian inference and 
recruited the team that developed a state-of-the-art model that estimates assay 
sensitivity and specificity and simultaneously incorporates that uncertainty into 
prevalence estimates and credible intervals. Finally and possibly most importantly, this 
study uses an RBD-binding ELISA that likely has better sensitivity for asymptomatic 
SARS-CoV-2 infections and therefore can better assess population seroprevalence 
rather than only seroprevalence among individuals with respiratory infection 
symptoms219,220,382. Prevalence in this cohort of individuals accessing healthcare in 
central NC rose from 3.9% (1.7, 4.3) to 9.1% (7.2, 11.1) from April to October 2020. 
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I also decided to analyze seroprevalence by different demographic factors. I 
collapsed both race and ethnicity into a single ethnoracial variable as an imperfect 
measure of racism198 and found that non-Latinx individuals were the group at highest 
risk of infection over this time frame compared to non-Latinx white individuals. I also 
included insurance type as a variable in the analysis and decided how to categorize 
insurance types. Behind Latinx individuals, individuals with undefined health insurance 
and those self-paying for healthcare were the next most likely to be SARS-CoV-2 
seropositive compared to those with private health insurance. Black individuals were at 
the next greatest risk when compared to non-Latinx white individuals. Interestingly, 
there was no difference in risk of exposure by age or sex that persisted beyond the first 
two months despite schools being closed. In general, the increased odds for all of these 
groups decreased, trending towards baseline risk suggesting that the observed risk is 
the result of SARS-CoV-2 first spreading among individuals with high exposure risk and 
later to the rest of the population. The high odds of seropositivity in Latinx and Black 
populations are indicative of the systemic racism that has been driving the burden of 
SARS-CoV-2 to largely fall on these communities198,236,238,239. 
Finally, I defined ICD-10 codes that overlap with SARS-CoV-2 respiratory signs, 
symptoms, and disease. I determined that individuals with documented COVID-19 or 
symptomatic respiratory disease had increased odds of developing neutralizing 
antibody titers, consistent with the hypothesis that asymptomatic individuals develop 
lower titers of neutralizing antibodies to SARS-CoV-2373. It is impossible to conclude 
from neutralization titers the extent to which neutralizing antibodies are necessary to 
protect against severe disease. 
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My work on this study allowed for an estimation of SARS-CoV-2 seroprevalence 
that is more representative and accurate than previous efforts and is one of few 
seroprevalence studies outside of a major metropolitan region. I further found that there 
was exceptionally high SARS-CoV-2 exposure risk in Latinx individuals as well as in 
potentially underinsured individuals in central North Carolina. The driving risk factors for 
exposure of this infection are both racism and socioeconomic access to infection 
prevention, not race as a biological factor (race is an imperfect measure of racism and 
underinsurance is an imperfect measure of socioeconomic discrimination)358. 
Additionally, individuals without SARS-CoV-2 symptoms but who tested positive had 
lower neutralization titers, consistent with the ideas that asymptomatic infections result 
in lower neutralization titers.  
5.6 Future directions for the study of vector-independent flavivirus infections 
 The results detailed here demonstrate that even though ZIKV can produce 
placental damage, it may not necessarily do so via high levels of infection directly within 
the placenta. Instead, the placental pathology observed may be the result of 
inflammation. Although this placental damage may resemble that induced in 
Plasmodium infection, it might not result in the same clinical consequences after 
delivery because transplacental IgG transfer is maintained after gestational ZIKV 
infection. Other infections such as HIV and SARS-CoV-2 can also cause decreased IgG 
transfer without necessarily inducing the same degree of placental insufficiency, so 
much remains to be determined about how some infections can decrease transplacental 
IgG transfer independent of inflammatory pathology111,266,376,377.  
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 Intact antibody transfer during gestational ZIKV infection may prove beneficial for 
protection of the fetus from congenital Zika syndrome and the infant from ZIKV infection. 
Likewise, transplacental antibody transfer is beneficial for health in infancy. However, 
we need to remain alert to the possibility that ZIKV antibodies transferred during 
gestation can negatively impact health in the first year of life because they may enhance 
DENV infection as is observed in infants born to DENV-immune mothers257.  
 Much remains to be learned about ZIKV in the vagina. In particular, we do not yet 
understand why ZIKV is capable of sexual transmission when other common 
flaviviruses are not. There is increasing evidence that a subset of other flaviviruses are 
also capable of either infecting either vaginal tissue or prostate tissues. If any of these 
were to cause a large outbreak, surveillance of individuals returning from those 
locations and their sexual partners will help clarify if ZIKV is not so unique after all.  
 We also do not understand why progesterone has such a strong effect of ZIKV 
infection in mice, or whether this impacts human health. Sex hormones can affect rates 
of transmission of other viruses in humans. However, this is no reason to cease sex 
hormone-based contraceptives if the goal is to prevent CZS. It is possible that increased 
ZIKV sexual transmission could result a greater number of infectious hosts for 
mosquitoes to feed on, but the benefits of contraception likely still outweigh this 
theoretical risk. Potential mechanisms to explore include progesterone-induced innate 
immune signaling changes or changes to cellular metabolism specifically in epithelial 
cells , which appear to be the target cells of ZIKV in the vagina. Additionally, we still 
need to determine whether local ZIKV replication in the vagina is sufficient to induce 
protective immunity against subsequent vaginal or systemic infection. We also will need 
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to determine to what extent these observations carry over in sexually mature animals 
rather than the 5 week old mice I studied.  
It also remains to be seen how well the model for vaginal infection in mice I’ve 
characterized correlates with vaginal infection in humans. I observe limited replication 
beyond the superficial layer of epithelial cells in the LFRT without ascension to the 
uterus. Pregnant non-human primates similarly have replication within epithelial cells in 
the LFRT with inconsistent ascension to the uterus, though in that model ZIKV is 
capable of causing viremia133. Other non-human primate models demonstrate that the 
viremia that results from vaginal inoculation is delayed relative to subcutaneous 
infection132. Also, non-human primates inconsistently seroconvert after vaginal ZIKV 
infection133,383. 
5.7 Future directions for the prevalence of immunity to SARS-CoV-2 and other 
emerging pathogens 
 SARS-CoV-2 is likely to become an endemic human pathogen. It is likely we will 
continue to see emerging β-coronaviruses, so we need to prepare to best estimate the 
prevalence of novel coronaviruses before the next outbreak. SARS-CoV-2 
asymptomatic infections are not accurately detected by the existing nucleocapsid assay 
in clinical use, and these assays will not detect antibodies to S-based vaccines. 
However, the limitation to RBD-based assays is that they cannot differentiate between 
natural infection-induced and vaccine-induced immunity. This is an important distinction 
for many reasons, including if vaccination proves to provide a different degree of 
protection from disease than natural infection, as well as defining if some populations 
are not being reached for vaccination. When combined in the same study, these assays 
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can therefore have complementary roles to discern infection-vs-vaccine-induced 
immunity. 
 Disparities in vaccination unfortunately appear to be along the same ethnoracial 
groupings that placed Black and Latinx individuals at greater risk of infection. 
Eliminating the racism that places these groups at risk requires societal change as well 
as economic investments. Mass incarceration must be eliminated, paid protected sick 
leave needs to be provided including for essential work positions, and financial 
inequality leading to overcrowded housing needs to be addressed. Many of the worst 
impacted areas during the ZIKV epidemic had such a high force of infection as a result 
of poverty and a lack of infrastructure leading to high numbers of Aedes aegypti 
mosquitoes384. The most severe ZIKV outcome, congenital disease, results in high 
healthcare costs and requires substantial care during and after pregnancy, and 
pregnant individuals already face difficulties in healthcare access. We must also correct 
inequities in access to health insurance, care, testing, vaccination, and treatments. 
Many of the worst impacted areas during the ZIKV epidemic had such a high force of 
infection as a result of poverty and a lack of infrastructure leading to high numbers of 
Aedes aegypti mosquitoes384. Whether global or local, hoarding of supplies drives the 
burden of disease and disability. These are important considerations for Zika and 
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